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The content of  this thesis is based on research that was conducted at the travel and 
vaccination clinic at Leiden University Medical Centre (LUMC). This clinic provides 
pre-travel care to the general population, and to special groups of  travellers, such as 
patients who use immunosuppressants or who have chronic diseases. The clinic is closely 
connected to the department of  Infectious Diseases at LUMC. A team of  specialized 
nurses provides pre-travel care. The setting of  a travel clinic within an academic medical 
hospital, provides unique circumstances for medical research, like an experienced 
team of  nurses, expertise regarding immunization, a constant flux of  travellers and the 
knowledge and infrastructure that is required for research into microbiology, virology 
and parasitology. Examples of  research that stem from this clinic are projects on 
immunization against malaria,1,2 yellow fever,3-6 travellers’ diarrhea,7,8 poliomyelitis9 and 
hepatitis B,10 vaccination of  immunocompromised patients,11-14 and projects on travel 
related acquisition of  extended spectrum ß-lactamase producing Enterobacteriacae15 and 
on the utility of  post-travel screening of  asymptomatic travellers for parasites.16 We hope 
that the research that is conducted at our travel clinic, will be of  benefit to travellers and 





In 2014 more than one billion tourists travelled abroad, according to the World Tourism 
Barometer.17 Over 500 million people travelled to an emerging economy.1 The number is 
expected to grow between 3 and 4% in 2015, with the strongest growth in the Americas 
and in Asia and the Pacific. It is estimated that annually, two million Dutch tourists 
travel to low and middle income countries, one million to Turkey (800.000) and Egypt 
(200.000), 400.000 to countries in Asia, 400.000 to Latin America and 90.000 to 
Sub-Saharan Africa.18,19 Travellers face specific health risks. Travel-related disease can be 
defined as diseases for which the chance of  acquisition is increased due to increased exposure 
or increased susceptibility associated with temporary translocation.20 Various measures 
can be used to numerically express the frequency of  disease occurrence in a population, 
as is summarized in Box 1. In 1987 and in 2008 Steffen et al. have summarized the 
available data on the incidence proportions of  travel-related morbidity (figure 1 u page 14).21,22 
 Cobelens has summarized the data for travel-related infectious diseases (figure 2 u page 15).20 
The GeoSentinel Surveillance Network provides data on regional differences in 
proportionate morbidity, which is the number of  travellers diagnosed with a certain 
disease divided by the total number of  ill travellers reported.23,24 GeoSentinel data cannot 
estimate travel-related incidences and are limited in estimating risk of  disease, because 
only ill patients with a presumed travel-related illness are captured.25 Diarrhoea is the 
main cause of  travel-related morbidity.22,26 Accidents are the main cause of  mortality.26-28 
Over time, the incidence of  travel-related morbidity  has changed. The risk of  diarrhoea 
has decreased. This is mainly due to improved levels of  sanitation at many destinations, 
seeing that hygiene, is the main determinant of  infections that are transmitted via the 
faecal-oral route.19,29-31 The association between a determinant of  disease and disease 
frequency can be numerically expressed, either as an absolute difference between groups 
that are being compared (e.g., exposed versus unexposed) or as relative differences.32 
An example of  a determinant of  travel-related morbidity is the difference in the risk of  
illnesses between tourists and those who travel  to visit friends and relatives.33,34
 
1 Classification based on the International Monetary Fund (IMF), see the Statistical Annex of the IMF 
World Economic Outlook of April 2012, page 177, at www.imf.org/external/pubs/ft/weo/2012/01.
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figure 1  
Cumulative incidence of health 
problems for a stay of one month 
in a developing country - 2008.22 
(Reproduced by permission from 
Journal of Travel Medicine 2008. 
Copyright International Society 
of Travel Medicine.)
figure 2 (right) 
Summary of risk estimates for 
selected travel-related infectious 
diseases by their preventability 
by vaccination.20  
(Reproduced by permission of 
F.G.J. Cobelens).
box 1
Various measures can be used to numerically express the frequency of  disease 
occurrence in a population. The incidence rate is defined as the number of  new cases 
of  disease in a specific population, divided by the person-time over the period.35 
This quantity is sometimes also called the incidence density.35,36 If  the incidence rate 
varies over time, this time-dependency can be traced by dividing time into small 
periods and calculating an incidence rate per time-period, as was demonstrated 
by William Far in 1838.37-39 Alternatively, one can measure the incidence proportion 
per specified time period.34 This quantity is sometimes also called the cumulative 
incidence or the attack rate and is defined as the proportion of  a specified at-risk 
population that experiences an outcome over a given time period.35,36
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Travellers are often categorized according to travel-purpose, such as: visiting family and 
friends, business, study or leisure. The last category, ‘leisure’ is a poorly defined category, 
that encompasses various reasons for people to travel. Although we do not routinely 
stop to reflect upon these reasons, philosophers have contemplated the act of  travel. In 
his famous letters, the Greek philosopher Seneca writes: “You need a change of  soul rather 
than a change of  climate. Though you may cross vast spaces of  sea, and though, as our Vergil 
remarks you leave lands and cities behind you, your faults will follow you whithersoever you 
travel. Socrates made the same remark; to one who complained he said: ‘Why do you wonder 
that travelling does not help you, seeing that you always take yourself  with you? The reason 
which set you wandering is ever at your heels.”40, 2,  These words echo the modern day 
philosopher Alain de Botton: “The pleasure we derive from journeys is perhaps dependent 
more on the mindset with which we travel than on the destination we travel to.”41 However, 
in contrast to Seneca, de Botton argues that travel may be conducive to a change of  
soul: “It is not necessarily at home that we best encounter our true selves. The furniture insists 
that we cannot change because it does not; the domestic setting keeps us tethered to the person 
we are in ordinary life, who may not be who we essentially are.” To paraphrase his words; 
a different surrounding with different people, and an encounter with new physical or 
mental challenges may provide circumstances that are more conducive to a change of  
soul and to personal growth than those at home. 
Seeing that personal growth may be one of  many benefits of  working abroad, students 
are encouraged to pursue electives in other countries. Therefore it is deemed a positive 
development that more and more Dutch (bio)medical students venture abroad for 
study and work. Universities have a certain degree of  responsibility for the health and 
well-being of  students and a responsibility towards the medical staff  and the hospitals 
abroad who facilitate the electives. Therefore students are made aware of  the degree of  
responsibility that they can and may shoulder. For example, it should be clear beforehand 
whether a student is sufficiently experienced to participate in certain procedures, such 
as suturing or assisting in the operating theatre or delivery room. If  new skills are to be 
acquired abroad, it should be specified beforehand whether the medical staff  abroad has 
the time and facilities to supervise and teach new skills. Awareness of  ethical aspects is 
also required. In clinics where resources and medical staff  may be scare, it is important 
that students do not feel obliged to take on responsibility beyond their means and that 
they do not use scarce resources in an inefficient manner. The first chapter of  this 
thesis describes a study which was designed to improve the quality of  medical electives. 
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2 Animum debes mutare, non caelum. Licet vastum traieceris mare, licet, ut ait Vergilius noster, terraeque 
urbesque recedant, sequentur te quocumque perveneris vitia. Hoc idem querenti cuidam Sokrates ait, ‘quid 
miraris nihil tibi peregrinationes prodesse, cum te circumferas? premit te eadem causa quae expulit’.
It describes the health risks and the quality and comprehensiveness of  pre- and post-
travel care for this group of  travelers.42 A second multi-centre study with a wider scope 
is under way.
For students on electives, as for most travellers to the tropics, diarrhoea is the most common 
health hazard. It can be a major nuisance but it is very seldom fatal. Although the world-
wide incidence of  travellers’ diarrhoea has been well documented, there is limited data 
on the degree of  inconvenience that travellers experience. The second chapter deals with 
this subject.8 The data from this study provides an estimate of  the burden of  illness and 
of  the size of  the target population for preventive and curative measures. 
Over the years, many pathogens that cause travellers’ diarrhoea have been identified. 
This has led to dietary advice such as “boil it, cook it, peel it or forget it”, and to 
algorithms for self-treatment with antidiarrhetic and antimicrobial agents. Some experts 
in the United States go so far as to advocate the use of  a non-absorbable antimicrobial 
agent to prevent diarrhoea when traveling.43 One of  the arguments that is used to 
promote such practice, is that travellers’ diarrhoea leads to a chronic condition known as 
post-infectious irritable bowel syndrome in a sizeable proportion of  travelers.44-49 Post-
infectious IBS is characterized by relapsing and fluctuating gastrointestinal symptoms, 
including abdominal pain, discomfort, and changed bowel habits.50 Until recently the 
incidence of  post-infectious IBS in travellers remained obscure. A recent large and 
well-conducted questionnaire study by Pitzurra et al. shows that the incidence of  new-
onset IBS, as defined by the Rome III criteria, is 1.0% six months after travel.51,52 The 
incidence is higher in those who had an episode of  travellers’ diarrhoea (3.0%) than 
in those who did not (0.7%). Of  those who fulfilled the criteria for IBS, based on the 
answers to the questionnaire, one in three were diagnosed with a condition other than 
IBS by their physician. Pathogens, that are not detected with routine faecal culture, 
such as Enteroaggregative Escherichia coli (EAEC), can cause long-lasting diarrhea.53,54 
This reflects some of  the difficulties in finding the cause and treating post-travel chronic 
gastro-intestinal complaints. Nowhere is this more challenging than in patients with 
inflammatory bowel disease (IBD), i.e. Crohn’s disease and ulcerative colitis. An enteric 
infection is hard to distinguish from an exacerbation of  IBD. Moreover, there are many 
anecdotal reports of  exacerbations of  inflammatory bowel disease after enteric infections 
and observational studies that found an association between enteric infection and the 
onset of  IBD.55 The third chapter describes a retrospective web-based questionnaire 
study on past travel experiences in which we investigated pre-travel preparation of  
Dutch IBD patients and the quality of  pre-travel advice. We also surveyed health 
problems encountered during travel and investigated whether travel increased the risk of  
an exacerbation of  IBD.42
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One of  the common causes of  prolonged gastro-intestinal complaints after travel is 
infection with protozoa, in particular Giardia lamblia. However, up to a third of  those 
who are infected with G. lamblia have no complaints at all. Although asymptomatic 
infection with  G. lamblia is not known to have any long term sequelae, there are a number 
of  protozoa and helminths that can cause morbidity long after a primary asymptomatic 
infection. Early detection and eradication would be beneficial. Chapter four describes 
a study in which we aimed to determine the utility of  routine post-travel screening of  
asymptomatic long-term travellers to the (sub)tropics for intestinal parasites using 
molecular diagnostics and for schistosomiasis using serology.16 Chapter five describes 
the long-term immune response to former Schistosoma infection in a group of  travelers.56 
Research on travellers’ diarrhoea also has implications for people in low-income countries, 
where diarrhoea in infants is caused by many of  the same pathogens as travellers’ 
diarrhoea. It is well known that hygiene and better living conditions constitute the most 
important factors in reducing infant mortality due to communicable (enteric) diseases. 
This is illustrated by an elegant study in Indonesia, which shows that the presence of  
a bar of  soap in the bathroom is an independent factor that protects against infection 
with Salmonella typhi.57 The importance of  hygiene is also illustrated by the fact that my 
grandfather, who was the chief  medical officer in Bombay, dedicated a whole section of  
his book on preventive medicine, to environmental hygiene, going into considerable detail 
on purification and distribution of  water, and collection and handling of  sewage.58 In 
low-income countries, infants carry the largest burden of  diarrheal illness, because they 
are more vulnerable to dehydration and because early in life they lack immunity.59 With 
time, and repeated exposure to enteric pathogens, a degree of  (short-term) immunity 
develops.60 This is also true for expatriates who reside in the tropics. Figure 3 shows 
how the incidence of  diarrhoea decreases over time in expatriates living in Nepal.61 The 
fact that people can acquire immunity to diarrheal illness offers potential for developing 
vaccines against enteric infection. Successful vaccines have been developed for preventing 
infection with Vibrio cholerae,62,63 and Rotavirus.64-68 Dukoral, which protects against 
cholera, offers a degree of  cross protection against the most common cause of  travellers’ 
diarrhoea, enterotoxigenic Escherichia coli (ETEC), because ETEC produces heat-labile 
toxins that are antigenically similar to the toxin produced by Vibrio cholerae. However, 
its efficacy to prevent all-cause travellers’ diarrhoea is limited. This is due to i) the 
multitude of  different causative pathogens of  diarrhoea (i.e. different bacteria, viruses 
and protozoa); ii) simultaneous infection with more than one pathogen; and iii) the 
antigenic differences within groups of  bacteria, such as diarrheagenic E. coli. Chapter six 
describes a randomized trial on the efficacy of  a live attenuated oral cholera vaccine to 
prevent all-cause travellers’ diarrhea.7
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Innate and acquired mucosal immunity form the first line of  defence against pathogens that 
invade the body through the respiratory- or intestinal mucosa. Some of  these pathogens, 
such as enteropathogenic Escherichia coli, cause disease by invading and/or damaging the 
mucosa. Others, such as poliovirus cross the mucosa and cause disease at a distant site 
in the body. Poliovirus is transmitted through the oral-oral and fecal-oral route. Infection 
with wild type poliovirus induces mucosal and systemic immunity.69 Live attenuated oral 
poliovirus vaccine (OPV) mimics infection with wild-type virus and induces a similar 
immune response.70 Intramuscular immunization with inactivated poliovirus vaccine 
(IPV) however, does not induce a mucosal immune response.70,71 Nevertheless, it is a 
very effective vaccine because it induces a reliable and robust systemic immune response 
and prevents poliovirus from travelling up the nervous system and causing morbidity. In 
general it is fair to state that eliciting a mucosal immune response is not always necessary 
to prevent illness from pathogens that are acquired through the mucosa but that eliciting 
a mucosal immune response is of  paramount importance if  the aim is to prevent diarrheal 
illness and reduce faecal shedding. In an indirect way this is exemplified by a study in 
which OPV is shown to be better than IPV in protecting people against re-infection with 
wild-type poliovirus and in which OPV is shown to shorten the time during which an 
infected person sheds poliovirus.72,73 In this respect it is interesting that intradermal as 
opposed to intramuscular delivery of  a vaccine may elicit both mucosal and systemic 
immunity.74,75 Intradermal immunization may also have other advantages. It is thought 
to enhance the immunogenicity because of  the abundance of  antigen presenting cells 
in the papillary dermis.76,77 This is relevant to the Global Polio Eradication Initiative 
of  the World Health Organization. At some point in time, the use of  OPV has to be 
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figure 3
Incidence of diarrhoea decreases 
over time in expatriates living in 
Nepal. (Courtesy of Dr. David .R. 
Shlim, CIWEC Clinic Travel Medicine 
Centre, Kathmandu, Nepal).61
discontinued to prevent outbreaks due to circulating vaccine derived poliovirus, because 
OPV can sporadically mutate back to wild type virus.78-80 IPV is a factor 20 more expensive 
than OPV. Therefore, one of  the prerequisites for cessation of  the use of  OPV is to make 
IPV affordable and suitable for use in developing countries.81 Using fractional-doses 
(reduced-doses) may impact affordability and optimize the utilization of  the production 
capacity for IPV. Intradermal administration has the potential to lower the dose without 
reducing immunogenicity. A needle-free jet injector may be a reliable way to administer 
vaccines intradermally. Chapter seven describes a randomized controlled trial in which 
we compared the immunogenicity and tolerability of  fractional-dose intradermal IPV 
booster vaccination administered with a jet injector to full-dose and fractional-dose 
intramuscular vaccination with a needle and syringe in healthy adult volunteers.9
Intradermal injection is best known for its application in the tuberculin skin test (TST). 
The TST is used to diagnose (latent) infection with Mycobacterium tuberculosis (MTb). 
Tuberculin is an extract from a culture of  strains of  MTb. Infection with MTb induces an 
immune response that is characterized by a T-helper 1 (Th1) cellular immune response, 
with secretion of  IFN-γ, which activates bactericidal effector mechanisms in the 
macrophage.82 In the majority of  infected people, MTb remains dormant in macrophages, 
where it is kept in check by the immune system. If  an individual’s immunity is weakened 
due to poor nourishment, age, hypovitaminosis D, comorbidity such as Human 
Immunodeficiency Virus (HIV), or immunosuppressant medication, reactivation of  
latent MTb infection may occur. It is estimated that in 2012, 8.6 million people fell ill 
with tuberculosis and that 1.3 million died from tuberculosis.83 About one-third of  the 
world’s population has latent infection with MTb.83 Unfortunately, there is no vaccine 
that effectively protects against active tuberculosis, or against latent infection. The only 
available vaccine, BCG, which is a live attenuated vaccine derived from Mycobacterium 
bovis by Calmette and Guérin, offers limited protection.84 Eliciting a stronger Th1 immune 
response to MTb may protect against infection and reactivation of  MTb. Statens Serum 
Institute (SSI) has cloned and screened 250 antigens from Mycobacterium tuberculosis. 
Among these are the Early Secretory Antigenic Target (ESAT-6) and Antigen 85 
(Ag85B). These antigens are strongly recognized by T-cells in the first phase of  infection 
and they offer protective efficacy in animal models.85,86 As compared to conventional 
vaccines, recombinant subunit vaccines are poorly immunogenic when administered 
alone, due to the high degree of  purification. In order to improve their immunogenicity, 
these antigens must be administered with an adjuvant. Aluminum salts, which are used 
as adjuvants in conventional vaccines, promote the ‘wrong’ type of  immune response, a 
Th2 antibody mediated response.87 Therefore new adjuvants are needed, that promote a 
Th1 type response. Chapter eight describes the results of  a clinical trials on the safety 
and immunogenicity of  a recombinant subunit vaccine composed of  the fusion protein 
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Ag85B-ESAT-6, combined with the novel adjuvant IC31(®), in subjects with a positive 
tuberculin skin test.88 Chapter nine describes a phase I clinical trial on the safety and 
immunogenicity of  the Ag85B-ESAT-6 subunit vaccine, combined with a new liposomal 
adjuvant system CAF01, in healthy adults.89
Reactivation of  Mycobacterium tuberculosis is a peculiar phenomenon. Decades after the 
primary infection, age-related changes in the immune system may cause reactivation of  
latent tuberculosis. This is related to the process of  immunosenescence. Immunosenescence 
can be studied in many ways, one of  which is to compare the immune response to 
a standardized  infection between the young and the elderly. Vaccination with a live 
attenuated vaccine offers an ideal opportunity to study such differences. Yellow fever 
vaccine is a well studied highly effective live-attenuated vaccine that replicates in the 
naïve host. In rare instances it may cause serious illness; either yellow fever-associated 
neurotropic disease, which manifests as encephalitis, or the viscerotropic variant, which 
mimics wild type infection.90,91 Neurotropic disease occurs mainly in young infants and 
in the elderly. The risk of  viscerotropic disease increases with age, with an estimated risk 
ratio of  4 for vaccinees who are 60-69 years of  age and a risk ratio of  13 for vaccinees 
older than 70 when compared with young adults.92 Therefore advanced age is regarded to 
be a relative contra-indication for vaccination against yellow fever. Chapter 10 describes 
the results of  a controlled study on age-related differences in the immune response, after 
administering yellow fever vaccine.6
Live-attenuated vaccines are contra-indicated for immunocompromised patients, such as 
those who are infected with HIV and who have low CD4+ T-cell counts. These patients 
are more likely to develop vaccine-derived disease, due to their decreased ability to mount 
an adequate immune response and inhibit viral replication. This is less so for memory 
immune responses and more so for responses to antigens that have never been encountered 
before, so called neo-antigens. In 2009 an antigenically distinct influenza virus emerged, 
to which most people lacked immunity, namely 2009 pandemic influenza A(H1N1) 
(pH1N1). It spread rapidly over all parts of  the world and was deemed a major health 
risk, particularly for immunocompromised patients. This led to the swift development and 
use of  vaccines, to prevent severe morbidity. Although immune responses to influenza 
vaccines in HIV-infected patients has been studied quite extensively, the circumstances 
of  the 2009 vaccination campaign were unique for a number of  reasons: i) the antigen 
(hemagglutinin of  strain A/California/7/2009) was considered to be a neo-antigen; ii) 
the vaccine was administered twice instead of  once; and iii) most people had received 
standard trivalent inactivated influenza vaccine (TIV) the month before. In 2009 we 
quickly initiated an observational controlled study in which we measured the humoral 
immune response to pH1N1 vaccine in HIV-infected patients and in healthy controls. 
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In addition we tested whether recent vaccination with seasonal trivalent inactivated vaccine 
(TIV) induced cross-reactive antibodies to pH1N1 and whether a second vaccination 
induced a typical booster immune response. Chapter 11 describes the results of  this study. 
We were surprised to find that seasonal TIV, induced cross-reactive antibodies to pH1N1 
in a sizeable proportion of  volunteers.14 The specificity of  these antibodies for pH1N1 
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Abstract
Background: Clinical and research electives abroad offer medical students many unique experiences. However,
participating in an unfamiliar health-care setting combined with limited medical experience may place students at
risk of illness. To improve pre-and post-travel care, we assessed the health risks and the quality and
comprehensiveness of pre-and post-travel care in a cohort of Dutch medical students returning form an elective
abroad.
Methods: All medical students who had performed an elective in the tropics between July 2006 and December
2008 were sent an informative email asking them to complete a web-based questionnaire.
Results: 180 of 242 (74%) students completed the questionnaire. Regarding the risk of bloodborne viral infection:
67% of all students and 32% of junior students engaged in procedures that constitute a risk of exposure to
bloodborne viral infection, often in countries with high HIV prevalence rates. None of nine students who
experienced possible or certain mucosal or percutaneous exposure to potentially infectious body fluids reported
the exposure at the time it occurred and none used PEP. Regarding other health risks: 8 of 40 (20%) students
stopped using mefloquine due to adverse effects. This left a sizeable proportion unprotected in countries that are
hyperendemic for malaria. Post-travel screening for schistosomiasis, tuberculosis (tuberculin skin test) and carriage
of methicillin-resistant Staphylococcus aureus (MRSA) encompassed approximately half of all students who should
have been screened.
Conclusions: Based on the results of this study we have adopted an integral set of measures to reduce the health
risks associated with an elective abroad. The pre and post-travel consult has been centralized and standardized as
well as the distribution of PEP. In addition we have developed a mandatory module on Global Health for all
medical students planning an elective abroad.
Background
Clinical and research electives abroad offer medical stu-
dents many unique experiences. Shouldering responsibil-
ity in a different health care system and working with
underserved patients broadens the personal and medical
horizon. This may even influence future career choice as
international medical experience is associated with an
increase in the choice for a primary care specialty [1].
A number of studies have surveyed the health risks
facing students during an elective abroad and the pre-
travel advice [2-9]. Particular regard has been given to
the risk of bloodborne viral infection. For example, it is
worrying that 75% of students fail to report exposures
to potentially infectious body fluids [4].
Each year approximately 300 students enroll in the
medical program at Leiden University Medical Center
(LUMC) in The Netherlands. Approximately half of
them perform one or more electives abroad. Unlike
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other medical schools, ours allows students to go on
electives in countries where infection with Human
Immunodeficiency Virus (HIV) is endemic and does not
restrict senior students who have completed the fourth
college year from performing surgical or obstetric prac-
tice in such countries. To receive study credits it is
mandatory that the students obtain permission from the
student registrar before departure. If study credits are
obtained, it is also mandatory for students to seek a
Dutch supervisor who assesses the quality of the
planned elective and who judges the students’ written
report at the end of the elective. The registrar’s office
provides general information on preparation for an elec-
tive abroad and advises students to obtain pre-travel
counseling and immunization. Although the university
occupational health department provides such counsel-
ing and immunizations, the students are free to visit any
other travel clinic including the LUMC in-hospital travel
clinic or their general practitioner. As part of the travel
advice, and depending on the destination and intended
elective, the health department or travel clinic may refer
the student to an infectious disease consultant for coun-
seling on the need of carrying post-exposure prophylaxis
for HIV (PEP) with them and on its use. Upon return
home, no standard post-travel counseling is offered.
To improve pre-and post-travel care, we performed a
questionnaire study of students returning from an elec-
tive abroad. We assessed the health risks and the quality
and comprehensiveness of pre-and post-travel care. This
led to improvements that are described in the discussion.
Methods
All medical students who had performed an elective
abroad between July 2006 and December 2008, who had
visited countries where hepatitis A is endemic, and who
had notified the student registrar to obtain study credits,
were sent an informative email asking them to complete
a web-based questionnaire. This study was designed in
2008. Students who had returned home prior to Decem-
ber 2007 were sent an email in May 2008. Students who
returned between December 2007 and November 2008,
which is during the conduct of this study, were sent an
email in November 2008. Non-responders were sent a
reminder two weeks after the first email. The question-
naire was designed to seek information on pre-travel
preparation including vaccinations, on characteristics of
the elective, on health risks (in particular the exposure
to and protection against bloodborne viruses), on adher-
ence to advice regarding anti-malarial measures and on
illness while abroad and upon returning home. In addi-
tion the rate of routine screening for tuberculosis using
one pre-and one post travel Tuberculin Skin Test (TST)
was surveyed. We also surveyed the rate and result of
screening for methicillin-resistant Staphylococcus aureus
(MRSA) as students visiting foreign hospitals may
import MRSA to Dutch hospitals. Finally we surveyed
the rate and result of screening for schistosomiasis. The
questionnaire was piloted among acquaintances and
among staff of the department of Clinical Epidemiology
at the Leiden University Medical Center. The protocol
of this study (protocol 08/37B) was studied by the Medi-
cal Ethics Committee of Leiden University Medical Cen-
ter in The Netherlands. The Medical Ethics Committee
did not object to the conduct of this study.
Results
The mean number of days between having completed
the elective and completing the questionnaire was 235
days (interquartile range 121 to 325 days, range 2 to 638
days). The characteristics of the responders and of the
electives are described in Table 1; 242 students were
sent a questionnaire. Of the 180 (74%) who completed it
the majority (78%) was female; 77% had planned a holi-
day before or after the elective, and the mean duration
of the time spent abroad was 74 days (median 69 days,
range 10 to 224 days). The majority went for the pur-
pose of a clinical (47%) or pre-clinical elective (16%) as
opposed to research or volunteer work (37%). Surinam
was visited by 31%, making it the most popular destina-
tion. Obstetrics and gynecology (42%) was the most
popular rotation. Before departure 90% consulted a cen-
ter specialized in travel medicine; 4% sought advice
from their general practitioner and 6% did not obtain
advice from a qualified source.
Risk of infection with bloodborne viruses
All 180 students had been vaccinated against hepatitis B.
The vaccine response is checked by the university occupa-
tional health department. For privacy reasons we did not
have access to the response data; 120 students (67%) per-
formed at least one type of procedure that is associated
with an increased risk of exposure to bloodborne viral
infection (i.e. surgical or obstetric practice, suturing, phle-
botomy) (Table 2). In general, before completing the
fourth college year, students have not yet been trained to
perform many of these procedures. Therefore it is surpris-
ing that of the 58 junior students, 18 (32%) did take part
in such activities. Procedures associated with an increased
risk of exposure to bloodborne viral infection were also
performed in countries with high HIV prevalence rates
(Table 3). Some students received medical care while on
elective which increases the risk of exposure to blood-
borne viruses. Two students received dental care and ten
received an intramuscular or intravenous injection.
Depending on type of elective, the destination and the
on-site availability of antiretroviral drugs students were
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advised to take post-exposure prophylaxis with them; 31
students (17%) carried their own supply of PEP but 12
of these students need not have done so as they did not
perform procedures that put them at risk of exposure to
HIV. Of the 120 students who did perform such proce-
dures, 66 (55%) either had onsite access to PEP or car-
ried a personal supply; 51 (43%) did not know whether
the hospital where they performed their elective had
PEP and three students (2%) knew that they did not
have onsite access to PEP.
Four students experienced mucosal or percutaneous
exposure to potentially infectious body fluids while on
elective (two in Surinam, one in South Africa and one in
Malawi). Five students were unsure whether the event
they had experienced qualified as such. None of the stu-
dents had reported the exposure at the time it occurred
and none had used PEP even though all except one either
had onsite access to PEP or carried a personal supply. As a
result of their response to the questionnaire these nine
students were offered screening for HIV and hepatitis C.
For reasons of confidentiality we could not find out
whether these students opted to be screened.
Other health risks
Nearly all students (98%) filled out the optional ques-
tions regarding sexual contact during the time abroad.
Eight female students (6%) and three male students (8%)
reported having had sex with a new partner; in seven
instances with a partner native to the country where the
elective was performed. We did not ask whether a con-
dom was used.
Schistosomiasis may be acquired through fresh water
contact; 76 students had swum or waded in fresh water
in countries where schistosomiasis is prevalent. Of these
students 22 had swum in highly endemic countries in
sub-Saharan Africa. Eleven of these 22 students had
consulted a physician upon return and had mentioned
the fresh water contact, 10 were screened of which two
showed seroconversion for antischistosomal antibodies.
One student reported a bite by an unidentified animal
in the forest in Surinam. He was not vaccinated for
rabies. Overall 28 students had been vaccinated against
rabies prior to departure.
Table 1 Baseline characteristics of 180 Dutch medical
students returning from an elective abroad.
Parameter
Mean age years (range) 23 (19-38)
Female (%) 141 (78)






Type of elective n (%)
Pre-clinical elective 29 (16)
Clinical elective 85 (47)
Research elective 60 (33)
Volunteer work 6 (3)
Mean duration of stay days (range) 74 (10-224)




















Eastern Europe 1 (1)
Holiday at the end of the elective n (%) 139 (77)
Table 2 Number and percentage of 180 Dutch medical students who performed procedures associated with an
increased risk of exposure to bloodborne viral infection during an elective abroad.
College year completed 2nd (n = 18) 3rd (n = 39) 4th (n = 25) 5th (n = 27) 6th (n = 71) All (n = 180)
Activity n (%)
Obstetric practice 2 (11) 6 (15) 6 (24) 6 (22) 50 (70) 70 (39)
Surgical practice 1 (6) 13 (33) 10 (40) 16 (59) 58 (82) 98 (54)
Suturing 0 5 (13) 2 (8) 8 (30) 50 (70) 65 (36)
Phlebotomy 1 (6) 1 (3) 6 (24) 8 (30) 38 (53) 54 (30)
Any of the above 3 (17) 15 (39) 15 (60) 19 (70) 68 (96) 120 (67)
None of the above 15 (83) 24 (62) 10 (40) 8 (30) 3 (4) 60 (33)
Results stratified by college year.
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Malaria chemoprophylaxis
The majority of students (83%) who visited areas that are
endemic for malaria used a bed net. Of the 129 students
who visited such areas nearly all were prescribed an ade-
quate chemoprophylaxis (75 atovaquone-proguanil,
43 mefloquine, two proguanil, one primaquine and one
doxycycline). One student had been prescribed chloro-
quine by a relative and six students did not remember
which prophylaxis had been prescribed. Many students
visited countries where malaria prophylaxis is only indi-
cated for selective parts of the country. Of this group 17
did not start prophylaxis. In total 112 students started
malaria chemoprophylaxis.
Of the 40 students who used mefloquine 18 (33%)
reported an adverse effect: mainly sleep or mood disor-
der. One student returned prematurely due to neuropsy-
chological adverse effects. Of the 62 students on
atovaquone-proguanil 12 (19%) experienced an adverse
effect: mainly gastro-intestinal complaints. Eight students
who used mefloquine (20%) stopped the drug prema-
turely as did ten students on atovaquone-proguanil (16%)
and the student on doxycycline. Only two of these stu-
dents switched to another prophylaxis. One did so after
having had malaria. All students who stopped using
mefloquine did so due to adverse effects. Shortage of
tablets or simply forgetting to take the prophylaxis con-
stituted the main reasons for stopping the use of atova-
quone/proguanil. Premature stopping of prophylaxis left
eight students (15%) unprotected during part of their
elective in hyperendemic regions in sub-Saharan Africa.
One student in Benin and one in Kenia were diag-
nosed with malaria. Both had used mefloquine, but the
latter was one of those who had stopped the use due to
side effects.
Health problems
Diarrhea was the most common illness and was
reported by 117 of 180 students (65%). The incidence
was even higher (93%) among 40 students who did not
have running water at their lodgings. Most cases were
self-limiting and did not last beyond a week. However,
25 of 117 students (21%) had diarrhea accompanied by
either bloody stools or fever, and in 29 of 117 students
(25%) diarrheal illness caused a temporary interruption
of the elective for a mean duration of 2.5 days (median
2 days, range 1 to 7 days). Thirteen of 117 students
(11%) consulted a physician for diarrheal illness, three
were admitted to hospital, and five received intramuscu-
lar or intravenous treatment.
Other common health problems were: constipation
(33%), skin infections and wounds (29%) and upper
respiratory tract infection (11%). Two students were
involved in a traffic accident.
Twenty eight students used an antimicrobial agent;
thirteen for enteritis, seven for a urinary tract infection
and four each to treat a skin infection and respiratory
tract infection.
Post-travel
Seven students (4%) reported having had a fever shortly
after returning home. Two of these students consulted a
physician and one was diagnosed with Dengue. Travel-
related illness after having returned home caused five of
180 students to interrupt their medical course for a per-
iod of 7 to 28 days; one due to Dengue, one due to neu-
ropsychological problems attributed to the use of
mefloquine, one due to an upper respiratory tract infec-
tion and two because they were identified as carriers of
MRSA. Dutch hospitals have a low MRSA infection rate
and adopt a strict policy to prevent spread of this bac-
terium [10]. Screening for MRSA using pharyngeal and
nasal swabs is mandatory for hospital employees with
recent employment abroad. Upon return, 79 of 180 stu-
dents (44%) were screened of which two were found to
be MRSA carriers (3%). The main focus of screening
should be aimed at senior year students involved in clin-
ical work; 70 of 121 senior year students (58%) had been
screened for MRSA. Screening was mainly done at the
instigation of hospital occupational health departments.
Depending on the destination and the duration of the
elective, students are advised to have themselves tested
for tuberculosis before departure and 8 weeks after
returning home; 84 of 173 students (49%) had a TST
performed after returning home. Two students (2%) had
a positive reaction which had been negative before the
elective abroad. Both had been on a clinical elective; one
in Benin and one in Nepal. Both were referred to the
municipal health service for counseling.
Discussion
We assessed the health risks that face medical students
on an elective abroad to improve the quality and
Table 3 Number and percentage of 180 Dutch medical
students who performed procedures associated with an
increased risk of exposure to bloodborne viral infection
during an elective abroad.







Obstetric practice 48 (62) 11 (48) 3 (12)
Surgical practice 57 (74) 9 (39) 8 (32)
Suturing 42 (55) 5 (22) 9 (36)
Phlebotomy 33 (43) 5 (22) 11 (44)
Any of the above 66 (86) 14 (61) 15 (60)
None of the above 11 (14) 9 (39) 10 (40)
Results stratified by adult HIV prevalence rates in the country where the
elective was carried out.
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comprehensiveness of pre-and post-travel care. A num-
ber of results are related to the risk of bloodborne viral
infection. Firstly, we found that regardless of the study
year the students were in, none took action following
mucosal or percutaneous exposure to potentially infec-
tious body fluids. This result is similar to that of a sur-
vey among British medical students [4]. Secondly, junior
students on pre-clinical electives often took part in pro-
cedures that pose a risk for bloodborne viral infection.
We were not informed about the individual capabilities
of the students. Junior students may have had extra-cur-
ricular training to perform certain procedures before
starting the elective, or they may have been supervised
adequately during the elective while learning new proce-
dures. Nevertheless, junior students have not yet
received the standard curricular training and in general
have limited clinical experience. This puts them at a
greater risk of mucosal or percutaneous exposure to
potentially infectious body fluids while performing pro-
cedures. They may also be less well informed how to act
in case of such exposure. Thirdly, we found that alloca-
tion of PEP starter kits was inadequate. Kits were com-
monly handed out to students who turned out not to be
at risk of coming in contact with potentially infected
body fluids and were not handed out to a sizeable group
of students who may have been at risk of such exposure.
Due to the difficulty in predicting what students will do
while on the elective, improving the pre-travel assess-
ment of who should carry a PEP starter kit is not
straightforward. Lastly, systematic education on safe sex
should be stressed, as 6% of the students reported that
they had sex with a new partner while abroad.
This survey also detected other health risks. One in
five students stopped using mefloquine due to adverse
effects, which means that a sizeable proportion was left
unprotected against malaria. Diarrheal illness was very
common as is to be expected. Importantly, a small pro-
portion needed to be hospitalized or required intramus-
cular or intravenous treatment for diarrheal illness. We
also found that medical care following return from the
elective can be improved upon. Screening for schistoso-
miasis, tuberculosis and MRSA did not encompass all
who should have been screened.
This study has a number of strengths and limitations.
It was restricted to students who had applied for study
credits, and we expect this group to constitute the
majority of students who perform an elective abroad.
For a web-based questionnaire, the response rate
was relatively high and none of the questionnaires
was incomplete. There are two limitations. The survey
was not completely anonymous as we asked the age,
gender, study year and e-mail address of the partici-
pants. This may have prompted socially desirable
answers. The time between having completed the
elective and filling out the questionnaire was not stan-
dardized and was sometimes quite long which may
have reinforced recall bias. To reduce the chance of
such bias, we mainly surveyed events that are unlikely
to be forgotten, such as needle-stick injury, malaria
and diarrheal illness.
Measures that are intended to limit the health risks
associated with an elective abroad
Based on the results of this study a number of measures
have been adopted to reduce the health risks associated
with an elective abroad. Firstly, it has been made manda-
tory that all medical students planning an elective abroad
follow a module on Global Health prior to departure
[11-13]. The aim of this module is to enhance student
safety and student learning, and to highlight the ethical
dimension of an elective abroad. Secondly, at the visit to
the administrative department all students are now
strongly advised to visit the university occupational
health department instead of opting to visit another
travel clinic or the general practitioner. By centralizing
pre-travel advice, as has been suggested by Tilzey and
Banatvala [14] we expect to achieve a number of
improvements. The risk of bloodborne viral infection and
the on-site availability of PEP are systematically assessed.
This assessment has been standardized. We now ask stu-
dents to fill out a form describing which procedures they
plan to perform. This form is signed by the Dutch super-
visor, who judges whether the student is competent to
perform the planned procedures and who judges whether
the student will be adequately supervised during the elec-
tive in case he/she is to learn a new procedure. Based on
this signed form, an assessment can be made during the
pre-travel consult whether PEP needs to be provided.
Whereas students first had to pay for their PEP kit, it is
now provided at no cost by the university. To reduce the
threshold for reporting and acting on an exposure to
potentially infectious body fluids, the written information
has been adapted. It now contains a checklist that speci-
fies which steps to take in case of exposure.
If a traveler is to experience adverse effects when
using mefloquine, such effects often manifest in the first
few weeks of usage. Therefore it is common policy to
prescribe mefloquine on trial prior to departure. By cen-
tralizing pre-travel advice we aim to increase the pro-
portion of students that receive mefloquine on trial. We
have also adapted the written information. In case of
adverse effects which seem attributable to mefloquine,
students are advised to use half the dosage twice weekly
instead of the standard full dosage once a week in order
to lower the peak plasma concentration [15]. Further-
more, students are urged to contact the on call infec-
tious disease consultant in our hospital if they are
considering stopping chemoprophylaxis.
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To improve post-travel care, upon return all students
must now fill out a standard short web-based checklist
which assesses certain health risks (exposure to poten-
tially infected body fluids, the risk of schistosomiasis
and the need for screening for tuberculosis and MRSA).
This results in a computer generated recommendation
which states whether the student needs to contact the
occupational health department or another care provider
for a post-travel consult.
Conclusion
Many of the health risks that were detected in this sur-
vey are probably not unique to Dutch medical students.
We believe that adopting a standardized pre-and post-
travel consult will reduce these health risks by reinfor-
cing knowledge regarding prevention of bloodborne
viral infection, by maintaining a clear-cut policy on pro-
vision of PEP, by addressing the problem of treatment
limiting adverse events with regard to malaria prophy-
laxis, by reducing the chance of (latent) tuberculosis and
chronic schistosomiasis and by preventing spread of
MRSA. In a future survey we intend to see whether the
new policy is indeed effective in protecting our medical
students by limiting health risks.
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Inconvenience due to travelers’ diarrhea:
a prospective follow-up study
Darius Soonawala*, Jessica A Vlot and Leo G Visser
Abstract
Background: Limited data exist documenting the degree to which travelers are inconvenienced by travelers’
diarrhea (TD). We performed a prospective follow-up study at the travel clinic of Leiden University Medical Center
in The Netherlands to determine the degree of inconvenience and to determine how experiencing TD affects
travelers’ perception.
Methods: Healthy adults who intended to travel to the (sub)tropics for less than two months were invited to take
part. Participants filled out a web-based questionnaire before departure and after returning home. TD was defined
as three or more unformed stools during a 24-hour period.
Results: 390 of 776 Eligible travelers completed both questionnaires. Participants’ median age was 31 years and
mean travel duration 23 days. Of 160 travelers who contracted TD (incidence proportion 41%, median duration of
TD episode 2.5 days) the majority (107/160, 67%) could conduct their activity program as planned despite having
diarrhea. However, 21% (33/160) were forced to alter their program and an additional 13% (20/160) were confined
to their accommodation for one or more daylight days; 53 travelers (33%) used loperamide and 14 (9%) an
antibiotic. Eight travelers (5%) consulted a physician for the diarrheal illness. When asked about the degree of
inconvenience brought on by the diarrheal illness, 39% categorized it as minor or none at all, 34% as moderate
and 27% as large or severe. In those who regarded the episode of TD a major inconvenience, severity of
symptoms was greater and use of treatment and necessity to alter the activity program were more common.
Travelers who contracted travelers’ diarrhea considered it less of a problem in retrospect than they had thought it
would be before departure.
Conclusion: Conventional definitions of TD encompass many mild cases of TD (in our study at least a third of all
cases) for which treatment is unlikely to provide a significant health benefit. By measuring the degree of
inconvenience brought on by TD, researchers and policy makers may be able to better distinguish ‘significant TD’
from mild TD, thus allowing for a more precise estimation of the size of the target population for vaccination or
stand-by antibiotic prescription and of the benefit of such measures.
Background
Travelers’ diarrhea (TD) affects 20-50% of travelers from
industrialized regions to developing countries [1-3]. Many
travel medicine experts recommend loperamide for mild
TD and self-administered antibiotic treatment in case of
moderate or severe TD [4-6]. Compared with placebo,
antibiotics shorten the duration of diarrhea by 0.7-1.5 days
and reduce the number of unformed stools per 24 hour
time interval by 1.6 on the first day of treatment, 2.1 on
the second day, and 1.4 on the third day [7]. No studies
exist that have assessed to what extent early antibiotic
treatment significantly impacts the subjective and objective
(i.e. incapacitation) degree of inconvenience due to TD.
The benefit of prescribing all travelers with antibiotics for
self-treatment in case of TD should be weighed against
the drawbacks. Although side-effects are seldom serious,
use of an antibiotic makes a person more susceptible to
colonization by drug resistant Enterobacteriaceae [8,9].
Furthermore, large-scale use and disposal of antibiotics in
the environment induces resistance among pathogens. For
these reasons, there are pro- and opponents regarding
routine pre-travel prescription of stand-by antibiotics for
travelers [10]. An argument favoring routine prescription
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is that there is an increasing concern about purchasing
antibiotics abroad, many being false. A central argument
for those who advocate wide-spread use of antibiotics for
TD is that it can cause considerable inconvenience, ruin
holidays and cause financial loss and that it may cause
chronic gastro-intestinal complaints [6,11,12]. A number
of studies describe the impact of TD on quality of life and
incapacitation [2,3,13-15]. Of those with TD, 20-45% is
unable to pursue planned activities for 1 day and the qual-
ity of life is affected, mostly with regard to the ability to
participate in leisure activities, sexual activity, and the feel-
ing of general well-being [13]. The present prospective fol-
low-up study was designed to determine the degree of
subjective and objective inconvenience that Dutch trave-
lers experience when they contract diarrhea during travel
to the (sub)tropics. In addition we determined how an epi-
sode of TD affects travelers’ perception of TD and we
explored risk factors.
Methods
Design and study population
This was a single-center prospective cohort study at the
travel clinic of Leiden University Medical Center in The
Netherlands. It was conducted from March until Novem-
ber 2010. Healthy adults who visited the travel clinic and
intended to travel to the (sub)tropics were invited to take
part by way of an informative letter. The letter was
attached to a standard intake form that clients fill out
before their appointment at the travel clinic. All who read
the letter were asked to fill out an accompanying answer
card that provided three options: (i) “yes, I want to partici-
pate”, (ii) “no, I do not want to participate”, (iii) “I am not
eligible to participate”. Exclusion criteria were: travel dura-
tion of more than two months, use of systemic immuno-
suppressive medication, history of inflammatory bowel
disease or insulin-dependent diabetes mellitus. Partici-
pants were sent two web-based questionnaires via e-mail,
the first before departure, and the second a week after
returning home. In The Netherlands no formal approval
by a medical ethics committee is required for this kind of
questionnaire study.
The pre-travel consult was not different for participants
than for other travelers. All received a brochure about pre-
ventive measures and self-treatment with loperamide and
oral rehydration solution in case of TD. In The Nether-
lands, pre-travel supply of antibiotics for self-treatment in
case of TD is restricted to high-risk travelers who are at
increased risk of severe infection or dehydration, and to
those who travel to remote areas with limited access to
health care facilities [16].
Definition of travelers’ diarrhea
In order to avoid misinterpretation we used a straight-
forward definition of TD. In the questionnaires TD was
defined as: the passage of three or more unformed
stools during a 24-hour period with or without addi-
tional symptoms [14,17]. In the analyses, ‘classic TD’
was defined separately as: the passage of three or more
unformed stools during a 24-hour period with one or
more symptoms of enteric disease such as nausea,
abdominal cramps, vomiting, fever or fecal urgency
[18,19].
Questionnaires
The first questionnaire (Q1) consisted of questions on past
travel to the tropics, past experience with TD and past
inconvenience due to TD. In addition, we surveyed the
incidence of diarrhea among participants during a two-
month period in The Netherlands and during past travel
to the tropics. The second questionnaire (Q2) was sent
within a week after returning home and dealt with travel
characteristics, the incidence of TD and accompanying
symptoms, the use of anti- diarrheal medication, the inci-
dence of other health problems, the incidence of TD
among travel companions, health-care use for TD and
subjective and objective inconvenience due to TD. The
objective degree to which TD inconvenienced travelers
was measured by asking: “To what extent were you incon-
venienced by your episode of diarrhea?”. Participants
could choose one of the following answers: (i) “I inter-
rupted my journey and returned home due to the diarrhea
and abdominal complaints”, (ii) “I was ill, I altered my
activity program and stayed indoors for one or more days
due to the diarrhea and abdominal complaints”, (iii) “I
altered my activity program due to the diarrhea and
abdominal complaints”, or (iv) “despite the episode of diar-
rhea, I could take part in all planned activities”. Some tra-
velers may have had more than one episode of TD. All
questions concerning symptoms of TD and the degree of
inconvenience due to TD pertained to the most severe
episode. The subjective degree of inconvenience due to
TD was measured by asking: “To what degree did you
experience inconvenience due to the episode of diarrhea?”.
Participants could choose from the following answers: (i)
“no inconvenience”, (ii) “a minor degree of inconvenience”,
(iii) “a moderate degree of inconvenience”, (iv) “a large
degree of inconvenience”, or (v) “a severe degree of incon-
venience”. In addition, we explored how an episode of TD
during travel changed travelers’ own perception of TD.
This was done as follows. Before departure we asked: “If
you were to contract travelers’ diarrhea with fecal urgency
and abdominal cramps for three days, how large a problem
would you consider this to be?”. (i) “no problem”, (ii) “a
small problem”, (iii) “neither a small nor a large problem”,
(iv) “a large problem”, (v) “a very large problem”. After
returning home all travelers were presented a similar sce-
nario pertaining to a hypothetical future travel. We
thought that the answer to this question would change in
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travelers who had contracted TD and would remain the
same in those who had not. The overall direction in which
the answer changes, reflects how experiencing an episode
of TD influences the perception of TD. We piloted the
questionnaire among travelers, acquaintances and staff of
the department of Clinical Epidemiology at Leiden Univer-
sity Medical Center.
Data editing
Travel destination was categorized according to the United
Nations (UN) International Migrant Stock [20]. Travel
destination was also categorized according to the UN
Human Development Index (HDI) value (0 to 1) and UN
HDI category (high, medium, low) [21]. The HDI is based
upon indicators of life expectancy, education and living
standards. If a participant visited more than one country,
the HDI value of the country with the lowest HDI was
used. In regression analyses, continuous variables that
were not linearly associated with the dependent variable
were categorized based on exploratory analyses of the con-
tinuous data in small categories to see at which values of
the continuous variable the regression coefficient changed.
Sample size
The sample size was based on the rule of thumb that 10
cases are needed for each covariate that is introduced in a
logistic regression model [22]. Based on an assumed inci-
dence proportion (i.e. the incident number of cases in rela-
tion to the size of the population) for TD of 25% we
estimated that 400 travelers were needed to be able to
introduce a maximum of 10 separate covariates in a logis-
tic regression analysis.
Regression analyses
In a prediction model we explored which variables signif-
icantly increased the odds of contracting classic TD.
Categorical variables were analyzed with c2-tests and
continuous variables with t-tests. Variables with p < 0.2
were entered in a multiple logistic regression model
based on maximum likelihood estimation. Interaction
terms were not entered in the model to prevent overfit-
ting and because interaction was deemed unlikely. Cook’s
distance values, leverage values and standardized resi-
duals were examined to detect cases that might be influ-
encing the model disproportionately. Variance inflation
factors were examined to test whether any covariates
were highly collinear. The relative strength of each cov-
ariate in the final regression model was determined by
computing the delta in Nagelkerke R2 when one covariate
was deleted and by dividing delta by the final model’s
Nagelkerke R2. In another logistic regression analysis
restricted to travelers who had TD, we explored which
person- and travel characteristics predicted incapacita-
tion due to TD. In a third model we explored which
symptoms predicted incapacitation due to TD. All ana-
lyses were done using PASW Statistics, version 18.0,
IBM®. Statistical significance was defined as a p-value <
0.05.
Results
Study population and travel characteristics
At our travel clinic 776 of 1,000 travelers fulfilled the
inclusion criteria of which 406 provided informed consent
(response rate 52%). Of the 224 people who were not eligi-
ble to participate, travel duration in excess of two months
was the most common exclusion criterion. Three hundred
and ninety travelers completed both the pre- and post-
travel questionnaire (follow-up rate 96%) (Figure 1). The
median age was 31 years (IQR 24-50 years). The majority
was female (65%), and had completed higher education
(62%) (i.e. a Bachelor degree). Person- and travel charac-
teristics are described in Table 1 and 2. Tourism was the
main reason for travel and South-eastern Asia was visited
most frequently (31%). The mean travel duration was
23 days (range 4-57 days). At the pre-travel consult, 27 tra-
velers (7%) received a stand-by antibiotic prescription
(ciprofloxacin or azitromycin). In total 335 travelers (86%)
carried treatment for TD in their travel-kit, mainly lopera-
mide (282/390, 72%), oral rehydration solution (229/390,
59%) or activated carbon (83/390, 21%).
Travelers’ diarrhea: incidence, symptoms, treatment and
risk factors
One hundred and sixty travelers (160/390, 41%) (26% per
any two weeks of stay) contracted TD. Of these 160 trave-
lers with TD, 16 did not have any accompanying symptom
of enteric disease such as nausea, abdominal cramps,
vomiting, fever or fecal urgency, making the incidence
proportion of classic TD 37% (144/390). The overall TD
Incidence Rate (IR) was 1.78 cases per 100 person days of
travel (pdt). IRs were highest for travelers to Northern-
Africa (3.95/100 pdt) and South-central Asia (2.55/100
pdt) (Table 2). Most affected travelers had typical symp-
toms: watery stools (138/160, 86%), fecal urgency (114/
160, 71%) and abdominal discomfort (123/160, 77%)
(Table 3). The diarrheal episode lasted a median of 2.5
days (IQR 1-2.5 days). Sixty-five of 160 travelers with TD
(41%) started treatment with an anti-motility agent or an
antibiotic: 26% (41/160) used loperamide only, 4% (6/160)
activated carbon only, 3% (4/160) used both loperamide
and activated carbon and 9% (14/160) used an antibiotic,
of whom most (9/14, 64%) used the antibiotic in combina-
tion with an anti-motility agent. Five travelers who used
an antibiotic (5/14, 36%) had been prescribed the antibio-
tic at the pre-travel consult. Loperamide was started a
median of 1 day (IQR 0-2 days) after onset of symptoms.
Antibiotics were started later (median 3 days after onset of
symptoms; IQR 2-5 days). In total eight travelers (8/160,
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5%) consulted a physician for the diarrheal illness of whom
two (2/160; 1%) were admitted to hospital in Africa with
fever, diarrhea, vomiting and dehydration. One hundred
and two travelers (102/390, 26%) reported non-travelers’
diarrhea related health problems: 13 vomiting without
diarrhea, 11 abdominal discomfort or loose stools that did
not fit the definition of TD, 6 constipation, 24 a respira-
tory tract infection, 19 a skin or eye infection, 3 a urinary
tract infections, 2 fever (1 unknown cause, 1 malaria), 12
headache or tiredness, and 12 some other health problem.
The following variables independently increased the
odds of contracting TD: younger age, use of an antacid,
longer travel duration, lower Human Development
Index of the country that was visited, backpacking as
type of travel and staying in luxury hotels. Travelers
whose main travel purpose was to visit friends/relatives
or who traveled for business/professional reasons had
reduced odds for contracting TD. Nagelkerke’s R2 was
0.22, which means that the model accounted for 22% of
the variance in TD (Table 1).
Inconvenience due to travelers’ diarrhea
Although most travelers (107/160; 67%) could conduct
their activity program as planned despite having diarrhea,
21% (33/160) were forced to alter their program and an
additional 13% (20/160) were confined to their accom-
modation for one or more daylight days (median 1 day;
IQR 1-2 days). When asked about the degree of inconve-
nience brought on by the diarrheal illness, 39% (63/160)
categorized it as minor or none at all, 34% (54/160) as
moderate and 27% (43/160) as large or severe. Severity of
symptoms was greater and use of treatment and necessity
to alter the activity program were more common in those
who were incapacitated due to TD (Table 3). In a logistic
regression model, restricted to travelers who contracted
TD, none of the person- or travel-characteristics were
significantly (p < 0.05) associated with incapacitation due
to TD. The following symptoms independently increased
the odds of incapacitation due to TD: stool frequency,
nausea and fever (Table 4).
Before departure, we surveyed the incidence of diar-
rhea among participants during a two-month period in
The Netherlands; 22% answered that they had an epi-
sode of diarrhea according to our definition of (trave-
lers’) diarrhea. The normal stool pattern of these
participants may come close to fulfilling the definition
of TD, making these participants more likely to report
TD during travel without significant inconvenience.
Therefore, we performed a sensitivity analysis in which
we excluded these participants. This did not cause a
major change in the results. In the remaining subset
62% could conduct their activity program as planned,
27% were forced to alter their program and 10% were
confined to their accommodation. In another sensitivity
analysis restricted to 144 participants with classic TD,
65% could conduct their activity program as planned,
22% were forced to alter their program and 14% were
confined to their accommodation.
Not included 
 Did not want to participate n = 370 
 Did not meet inclusion criteria n = 224 
Completed second questionnaire         n = 390 
Did not complete second questionnaire 
 Lost to follow-up  n = 16 
Invited to participate  n = 1000 
Completed first questionnaire n = 406 
Figure 1 Flowchart of participants in the study of inconvenience due to travelers’ diarrhea.
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Table 2 Travelers’ diarrhea, incidence proportions and incidence rates for 390 Dutch travelers.




TD incidence proportion - %
(SE)
Mean travel duration -
days
TD Incidence rate - per 100
pdt (SE)
Northern Africa 17 7 41 (12.3) 10.4 3.95 (1.47)
South-central Asia 31 16 52 (9.1) 20.2 2.55 (0.63)
Central America and
Caribbean
24 11 46 (10.4) 18.9 2.42 (0.72)
South-eastern Asia 121 61 50 (4.6) 22.5 2.25 (0.28)
Eastern Africa 57 25 44 (6.6) 23.4 1.88 (0.37)
Central Africa 7 3 43 (20.2) 23.4 1.83 (1.05)
Central and Western Asia 32 8 25 (7.8) 14.3 1.75 (0.61)
Western Africa 15 7 47 (13.3) 28.6 1.63 (0.61)
Southern Africa 15 4 27 (11.8) 23.1 1.16 (0.58)
Eastern Asia 36 11 31 (7.8) 29.4 1.04 (0.31)
South America 46 7 15 (5.4) 26.4 0.58 (0.22)
All travelers 401† 160 41 (2.4) 22.4 1.78 (0.14)
pdt: person days of travel; SE: standard error. †11 participants travelled to more than one destination. NOTE: Incidence rates were not corrected for the time to
first episode of TD or for the number of episodes of TD.
Table 3 Characteristics of the episode of travelers’ diarrhea for 160 Dutch travelers, stratified by the objective degree
of inconvenience.
Objective degree of
inconvenience - n (%)
Conducted program as planned
107/160 (67%)






Stool frequency - n (%)
3 stools/day 64 (60) 11 (33) 1 (5) 76 (48)
4-5 stools/day 35 (33) 15 (46) 8 (40) 58 (36)
6-10 stools/day 7 (7) 6 (18) 9 (45) 22 (14)
> 10 stools/day 1 (1) 1 (3) 2 (10) 4 (3)
Watery stools, duration - n
(%)
No watery stools 20 (19) 1 (3) 1 (5) 22 (14)
1 day 37 (35) 11 (33) 4 (20) 52 (32)
2-3 days 31 (29) 14 (42) 8 (40) 53 (33)
4-7 days 10 (9) 5 (15) 5 (25) 20 (13)
> 7 days 9 (8) 2 (6) 2 (10) 13 (8)
Fecal urgency, duration - n
(%)
No fecal urgency 38 (36) 8 (24) - 46 (29)
1 day 30 (28) 10 (30) 7 (35) 47 (29)
2-3 days 22 (21) 10 (30) 6 (30) 38 (24)
4-7 days 11 (10) 3 (9) 1 (5) 15 (9)
> 7 days 6 (6) 2 (6) 6 (30) 14 (9)
Abdominal cramps, duration -
n (%)†
No abdominal cramps 32 (30) 3 (9) 2 (10) 37 (23)
1 day 32 (30) 11 (33) 4 (20) 47 (29)
2-3 days 30 (28) 12 (36) 6 (30) 48 (30)
4-7 days 9 (8) 5 (15) 4 (20) 18 (11)
> 7 days 4 (4) 2 (6) 4 (20) 10 (6)
Nausea, duration - n (%)
No nausea 82 (77) 13 (39) 4 (20) 99 (62)
1 day 17 (16) 9 (27) 6 (30) 32 (20)
2-3 days 6 (6) 8 (24) 6 (30) 20 (13)
4-7 days 1 (1) 2 (6) 3 (15) 6 (4)
> 7 days 1 (1) 1 (3) 1 (5) 3 (2)
Soonawala et al. BMC Infectious Diseases 2011, 11:322
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Before departure all travelers were asked the following
question: “If you were to contract travelers’ diarrhea with
fecal urgency and abdominal cramps for three days, how
large a problem would you consider this to be?”. After
returning home all travelers were presented a similar sce-
nario. Table 5 shows that the distribution of participants’
answers did not shift in those who did not contract TD
(p = 0.6, Wilcoxon signed rank test for two-related sam-
ples, comparison of the distribution of two variables).
However, those who did contract TD tended to consider
TD a smaller problem when asked the question upon
return than they had thought it would be prior to depar-
ture (p < 0.001). Surprisingly, even the participants who
were forced to alter their planned activities (p = 0.01)
and the participants who were forced to stay indoors (p =
0.03) tended to consider TD less of a problem when
asked the question upon return than they had thought it
would be before departure.
Discussion
This study was specifically designed to measure the degree
of inconvenience brought on by TD. We found that
approximately one-third of travelers who contracted TD
were forced to change their activity program or stay
indoors, which is in line with other reports [2,3,13-15].
Two travelers were even admitted to hospital. Two-thirds
did not need to change their activity program and a size-
able proportion (39%) said that the episode of TD caused
only minor inconvenience. Those who reported minor
inconvenience seldom used an anti-diarrheic agent mean-
ing that the reported degree of inconvenience in this sub-
group was not significantly influenced by treatment. As it
Table 3 Characteristics of the episode of travelers?’? diarrhea for 160 Dutch travelers, stratified by the objective
degree of inconvenience. (Continued)
Vomiting - n (%)* 13 (12) 12 (36) 7 (35) 32 (20)
Fever - n (%) 6 (6) 8 (7) 11 (55) 17 (11)
Treatment - n (%)
Loperamide 29 (27) 11 (33) 14 (70) 54 (34)
Activated carbon 3 (3) 6 (18) 2 (10) 11 (7)
Antimicrobial agent 3 (3) 6 (18) 5 (25) 14 (9)
Subjective degree of
inconvenience - n (%)
None/Minor 58 (54) 5 (15) - 63 (39)
Moderate 33 (31) 13 (39) 8 (40) 54 (34)
Large/Severe 16 (15) 15 (46) 12 (60) 43 (27)
*13 additional travelers who did not have diarrhea reported vomiting; †10 additional travelers who did not have travelers’ diarrhea according to the definition,
reported abdominal cramps.
Table 4 Logistic regression model evaluating which symptoms best predicted incapacitation due to travelers’ diarrhea.
Characteristic All with TD n =
160












3 stools/day 76 (48) 64 (60) 12 (23) 1.0 1.0
4-5 stools/day 58 (36) 35 (33) 23 (43) 3.51 [1.56-7.88] 2.05 [0.77-5.43]




37 (23) 32 (30) 5 (9) 1.0 1.0
1 -3 days 95 (59) 62 (58) 33 (62) 3.41 [1.21-9.57] 1.86 [0.55-6.34]
> 3 days 28 (18) 13 (12) 15 (28) 7.39 [2.22-24.5] 2.64 [0.62-11.3]
Fecal urgency1 114 (71) 69 (65) 45 (85) 3.10 [1.32-7.25] 0.009 0.93 [0.32-2.70]
Nausea2 61 (38) 25 (23) 36 (68) 6.95 [3.35-14.4] <
0.001
4.38 [1.70-11.3]
Vomiting3 32 (20) 13 (12) 19 (36) 4.04 [1.80-9.06] 0.001 0.96 [0.32-2.91]
Fever4 25 (16) 6 (6) 19 (36) 9.41 [3.47-25.5] <
0.001
5.65 [1.80-17.7]
TD: travelers’ diarrhea; OR: odds ratio; CI: confidence interval. P-values based on c2-tests for categorical variables. Variables with p < 0.2 were included in the
multivariate logistic regression model. Reference category: 1no fecal urgency, 2no nausea, 3no vomiting, 4no fever. Model: constant = 0.06, Nagelkerke’s R2 = 0.42,
Hosmer and Lemeshow test for goodness of fit p = 0.7.
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is to be expected, the severity of symptoms was greater in
those who regarded the episode of TD a major inconveni-
ence. The travelers’ perception of TD changed based on
the current experience. Travelers who contracted TD con-
sidered it less of a problem in retrospect than they had
thought it would be before departure. Surprisingly, this
was even true for those who were forced to change their
plans and for those who had to stay indoors. Although
this finding may simply mean that travelers are less appre-
hensive about problems they have faced before, it suggests
that TD is less of a nuisance than travelers expect
beforehand.
Most risk factors for contracting TD were in line with
recent reports. Unexpectedly, we found that staying in lux-
ury hotels increased the odds for contracting TD. Travel
duration for participants who stayed in luxury hotels was
shorter and they were more likely to have traveled to high
risk destinations, such as Indonesia and Egypt (data not
shown). Residual confounding due to incomplete adjust-
ment for destination and for the time to the first episode
of TD may account for (part of) the unexpected associa-
tion between accommodation in luxury hotels and TD.
Alternatively, staying in luxury hotels may be associated
with consumption of more elaborate food which bears
more risks [13].
This study has a number of strengths. First, participants
were recruited before departure. This way we aimed to
limit the chance of preferentially selecting travelers with
more severe TD who may be more inclined to respond to
a questionnaire taken after the facts. Secondly, surveying
travelers both before- and after travel, enabled analysis of
how travelers’ perception of TD changed depending on
whether or not TD was contracted during travel. Thirdly,
nearly all participants completed both questionnaires,
further limiting the chance of bias. Lastly, we measured
both the objective and subjective degree of inconvenience.
Participants’ reporting of both kinds of inconvenience was
consistent, which shows that the data are robust. The
study also has limitations. First, although we piloted the
questionnaire among travelers, acquaintances and
epidemiologists, questions could have been misinterpreted.
To limit the chance of misinterpretation, participants
could contact us by e-mail in case of any ambiguity. We
also provided ample opportunity for participants to further
specify answers. For example, those who reported that
they had to change their activity program or remain
indoors due to TD were requested to describe which activ-
ities were cancelled. Secondly, the normal stool pattern of
some participants may come close to fulfilling the defini-
tion of TD, making these participants more likely to report
TD without significant inconvenience. This may have led
to an underestimation of the inconvenience associated
with ‘real TD’. However, two sensitivity analyses in which
such participants were excluded did not yield different
results. Therefore it is unlikely that we underestimated the
inconvenience associated with TD during the stay abroad.
Thirdly, many travelers used an anti-motility agent or an
antibiotic to treat TD. It stands to reason that the degree
of inconvenience would have been larger if nobody had
used treatment and would have been smaller if all had
used treatment. Lastly, TD incidence rates were not cor-
rected for the time to the first episode of TD or for the
number of episodes. This may have inflated incidence
rates for destinations for which travel duration was longer
than average and deflated incidence rates for destinations
for which it was shorter than average.
Most cases of TD in this study fitted the classic defini-
tion of TD. Overall incidence rates and risk factors were
in line with recent reports [1,3,13,14,23]. These aspects
increase the generalizability of this study. Some aspects
limit the generalizability. Firstly, the study population
consisted mainly of Dutch born nationals. Dutch people
may be more inclined to await the natural course of a
self-limiting illness than travelers from other countries
[24]. This could influence the way in which they perceive
TD as a problem. However, such cultural differences
would probably not impact the objective degree of incon-
venience. Secondly, participants were recruited at our
travel clinic. The results may not be representative of tra-
velers who do not seek health-related travel advice before
Table 5 How did an episode of travelers’ diarrhea (TD) influence travelers’ perception of TD? The expected amount of
subjective inconvenience due to travelers’’ diarrhea before and after travel is stratified by whether travelers had TD.*
Travelers who had TD n = 160 Travelers who did not have TD n = 230
Before departure After returning Before departure After returning
No problem - n (%) 1 (1) 11 (7) 1 (0.4) 3 (1)
A small problem - n (%) 22 (14) 42 (26) 50 (22) 53 (23)
Neither a small nor a large problem - n (%) 51 (32) 56 (35) 61 (27) 57 (25)
A large problem - n (%) 69 (43) 49 (31) 99 (43) 99 (43)
A very large problem - n (%) 17 (11) 2 (1) 19 (8) 18 (8)
*Participants were presented the following scenarios: Before departure: If you were to contract travelers’ diarrhea during the coming journey, with a duration of
three days accompanied by urgency and abdominal cramps, how large a problem do you think this would be for you? After returning: If you were to make the
exact same journey in the future and you were to contract travelers’ diarrhea with a duration of three days accompanied by urgency and abdominal cramps,
how large a problem do you think this would be for you?.
Soonawala et al. BMC Infectious Diseases 2011, 11:322
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travel. Furthermore, the response rate was 50%. The
demographic features of those who refused to participate
may be different. Lastly, although the majority of visitors
to our hospital based travel clinic can be classified as
‘general travelers’, relatively more hospital employees and
(bio)medical students visit our travel clinic compared
with other out-of-hospital based travel clinics.
Conclusion
This study shows that conventional definitions of TD
encompass many cases of mild TD (in our study at least
a third of all cases) for which vaccination or antibiotic
treatment is unlikely to provide a significant health ben-
efit. By measuring the degree of inconvenience brought
on by TD, researchers and policy makers may be able to
better distinguish ‘significant TD’ from mild TD, thus
allowing for a more precise estimation of the size of the
target population for vaccination or stand-by antibiotic
prescription and of the benefit of such measures. We
suggest that a future study should investigate to what
extent routine stand-by antibiotic prescription impacts
on the subjective and objective degree of inconvenience
due to TD as well as the incidence of chronic gastro-
intestinal complaints. This could be done by randomiz-
ing a similar group of travelers at the pre-travel consult,
either to receive a stand-by antibiotic prescription or
not.
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ORIGINAL ARTICLE
Pretravel Preparation and Travel-related Morbidity in Patients
with Inflammatory Bowel Disease
Darius Soonawala, MD,* Anna M. van Eggermond, MSc,* Herma Fidder, MD, PhD,†
and Leo G. Visser, MD, PhD*
Background: There are no published data on health preparation and travel-related morbidity in patients with inflammatory bowel disease (IBD).
Methods: A retrospective web-based questionnaire study on past travel experiences with more detailed questions concerning the most recent
journey. Participants were recruited from the IBD outpatient clinic and via the website of the Dutch patient organization.
Results: In all, 277 patients who had traveled abroad during the past 5 years (172 Crohn’s disease, 105 ulcerative colitis) filled out the question-
naire. The majority (62%) answered that IBD limited their choice of travel destinations. Forty-three percent traveled to resource-limited destina-
tions and 76% thereof obtained pretravel advice. Only 48% were prescribed an antibiotic for self-treatment in case of infectious diarrhea, and
23% were not protected against hepatitis A. Fecal urgency and incontinence were the main IBD-related inconveniences. Thirty-two percent
reported a new episode of diarrhea and 28% thereof attributed it to an enteric infection. In total, 15/277 (5%) consulted a foreign physician, of
whom five were admitted to hospital. Fifty-four (19%) had a self-reported exacerbation of IBD within 2 months following travel and 24% thereof
attributed it to the recent travel. The Mantel–Haenszel odds ratio for an exacerbation within a 2-month period after travel was 1.1 (95% confi-
dence interval [CI] 0.7–1.8) when the number of self-reported exacerbations in a 5-year period was used as reference and 1.5 (95% CI 0.9–2.6)
when the year 2008 was used as reference.
Conclusions: Pretravel advice for IBD patients was often deficient. There was a considerable amount of travel-related morbidity and inconvenience.
(Inflamm Bowel Dis 2012;000:000–000)
Key Words: inflammatory bowel disease, travel, vaccination
T ravelers with inflammatory bowel disease (IBD) are ata greater risk of travel-related morbidity. First, use of
immunosuppressive therapy increases susceptibility to and
severity of infections,1–6 attenuates the immune response to
vaccination,4,7,8 and increases the chance of morbidity after
vaccination with live attenuated vaccines such as yellow
fever vaccine.9,10 Second, in long-standing IBD functional
asplenia may occur, which increases the chance of fulminant
infections with polysaccharide encapsulated bacteria and
Plasmodium falciparum.11,12 Third, an episode of gastroen-
teritis, which is the most common travel-related illness, is
regarded as a risk factor for an exacerbation of IBD and
may influence drug absorption and elimination.4,13 Use of
inactivated carbon to treat diarrhea also influences drug
absorption.14 It stands to reason that pretravel preparation
reduces the risk of morbidity.15 The European Crohn’s and
Colitis Organization and the Dutch national guideline for
pretravel advice offer specific recommendations for (immu-
nocompromised) travelers with IBD4,16: 1) An antibiotic
should be prescribed for self use in case of gastroenteritis
(Evidence Level (EL) 5, Recommendation Grade (RG) D).17
2) Acquisition of immunity should be monitored after
administering certain vaccines (EL 2a, RG B). 3) Travel to
areas where yellow fever is endemic is discouraged if vacci-
nation with live attenuated vaccines is contraindicated (EL
5, RG D). Of note, an inactivated yellow fever vaccine is
being developed.27 4) Individuals with functional asplenia
should be informed of the extra risk associated with malaria
and should be vaccinated for Streptococcus pneumoniae,
Haemophilus influenzae, and Neisseria meningitides and
should carry an antibiotic for self use in case of fever (EL
5, RG D). 5) As immunosuppressants and in particular tu-
mor necrosis factor alpha (TNF-a) inhibitors increase the
risk of tuberculosis, certain high-risk travelers should be
screened for tuberculosis before and after travel (EL5, RG
D). The rate of Mycobacterium tuberculosis infection is of
similar magnitude to that of the local population.18
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No prior studies have reported on health preparation
and travel-related morbidity in patients with IBD. In order
to evaluate and improve the quality of pretravel advice we
performed a web-based questionnaire study on past travel
experience and investigated pretravel preparation of Dutch
IBD patients and the quality of pretravel advice. We also
surveyed health problems encountered during travel and
investigated whether travel increased the risk of an exacer-
bation of IBD.
MATERIALS AND METHODS
Design and Study Population
Between April 2009 and April 2010 we performed a ret-
rospective web-based questionnaire study on travel experiences
in the past 5 years with more detailed questions regarding the
most recent journey abroad. Dutch-speaking IBD patients at the
outpatient clinic of the Leiden University Medical Center
(LUMC) in the Netherlands received an informative letter in
the waiting room inviting them to participate in a survey.
Patients who provided informed consent were sent a web-based
questionnaire via e-mail. LUMC is a tertiary referral center for
IBD. To obtain a representative sample of IBD patients’ travel
experiences we also recruited participants by posting informa-
tion and a link to the questionnaire on the website of the Dutch
IBD patient organization.19 The study protocol was approved
by the Medical Ethics Committee at LUMC.
Definitions
Travel destination was categorized into two groups: 1)
countries where hepatitis A is endemic, meaning that vaccina-
tion is recommended according to the national guideline
(VACþ countries), and 2) countries where hepatitis A is not
endemic (VAC countries).16 Drug use was divided into four
categories: i) none, or loperamide or mebeverine only; ii) 5-
aminosalicylate or topical steroids only; iii) glucocorticoids or
immunomodulators (azathioprine, 6-mercaptopurine, metho-
trexate); iv) TNF-a inhibitors. As specified in the guideline,16
we defined those who should have been screened for tubercu-
losis as those who had traveled to high-risk countries for at
least 8 weeks, and those who traveled to high-risk countries
for less than 8 weeks, but more than 2 weeks and whose travel
was characterized by at least two of the following factors:
very frequent use of public transportation in resource-limited
countries, lodging with local population under resource-limited
circumstances or intense (medical) professional contact with
the local population.
Questionnaire
All participants filled out questions on disease character-
istics. Those who had only traveled to VAC countries in the
past 5 years reported the number of journeys abroad in the
past 5 years and answered questions regarding the most recent
travel: questions regarding the bowel disease, pretravel prepa-
ration, health-related issues while abroad, and travel-related
illness upon return. Participants who had traveled to a VACþ
country in the past 5 years answered additional questions on
pretravel vaccination for hepatitis A and yellow fever and
questions designed to estimate the risk of latent tuberculosis.
We piloted the questionnaire among IBD patients and staff of
the department of Clinical Epidemiology at our center. A
question on the nature of inconvenience due to IBD during
travel was added at a later stage and was completed by half of
all respondents.
Statistical Analysis
We investigated whether travel abroad was associated
with an increased risk of an exacerbation of IBD. For each trav-
eler the expected risk of an exacerbation within any 2-month pe-
riod was compared with the observed risk of an exacerbation
within the first 2 months after returning home from travel. The
expected risk of an exacerbation within any 2-month period was
calculated by dividing the number of self-reported exacerbations
in the past 5 years by 30 (5 years multiplied by 12 months, di-
vided by 2 months). If this fraction exceeded 1, the risk was
defined as 1. The observed risk of an exacerbation within 2
months following travel was either 1 or 0, depending on whether
such an exacerbation had or had not occurred. Using the
observed and expected risk of an exacerbation per traveler we
calculated the Mantel–Haenszel overall odds ratio (MH-OR) for
the risk of an exacerbation within a 2-month period after travel.
Because the number of self-reported exacerbations in the past 5
years may not reflect the current rate of exacerbations per year,
a sensitivity analysis was performed which was limited to those
who had traveled after 2008 and in which the number of exacer-
bations in 2008 was used as reference.
All participants were asked whether IBD did or did not
influence their choice of travel destinations. In a prediction
model we explored which factors influenced respondents’
answers to this question. The following variables were analyzed
with v2-tests for categorical variables and t-tests for continuous
variables: ‘‘gender,’’ ‘‘age,’’ ‘‘type of bowel disease (Crohn’s
disease or ulcerative colitis),’’ ‘‘Montreal classification of dis-
ease activity and extent,’’20 ‘‘time since diagnosis,’’ ‘‘past bowel
surgery,’’ ‘‘type of medication,’’ ‘‘work disability due to IBD,’’
and ‘‘the average number of exacerbations of IBD over the past
5 years in categories (0 exacerbations per year, up to 1 exacer-
bation per year, 1 to 2 exacerbations per year, more than 2
exacerbations per year).’’ Variables with P-values < 0.2 were
entered in a multiple logistic regression model based on maxi-
mum likelihood estimation. Interaction terms were not entered
in the model to prevent overfitting. Variables with P-values <
0.2 in the final model were reported. Cook’s distance values,
leverage values, and standardized residuals were examined to
detect cases that might be influencing the model disproportion-
ately. Variance inflation factors were examined to test whether
any covariates were highly collinear.
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RESULTS
Study Population
In all, 277 IBD patients who had traveled abroad dur-
ing the past 5 years (172 Crohn’s disease, 105 ulcerative co-
litis) filled out the questionnaire. The response rate at the
outpatient clinic was 70%. Respondents’ mean age was 43
years, median duration of IBD 13 years, and 40% underwent
bowel surgery in the past. At the time of the survey 44%
used a glucocorticoid or an immunomodulator, mostly aza-
thioprine, and 26% a TNF-a inhibitor (10% infliximab, 16%
adalimumab) (Table 1). None of the participants had been
diagnosed with functional asplenia. Fifty-five percent (153/
277) had been recruited at the outpatient clinic at LUMC.
Use of glucocorticoids or an immunomodulator (73/153,
48%) and of a TNF-a inhibitor (49/153, 32%) was more
common in this group than in participants who had been
recruited via the website of the IBD patient organization
(48/124, 39%, and 24/124, 19%, respectively), reflecting the
fact that LUMC is a tertiary referral center for IBD.
Factors Influencing the Choice of Travel
Destinations
The majority (171/277, 62%) answered that IBD lim-
ited their choice of a travel destination. This was signifi-
cantly more so for those on a TNF-a inhibitor (odds ratio
[OR] 2.2, 95% confidence interval [CI] 1.2–4.3), for those
TABLE 1. Demographic and Disease Characteristics of 277 Dutch Patients with Inflammatory Bowel Disease (IBD) Who








Mean age, years (SE) 42 (1.0) 43 (1.2) 43 (0.8)
Gender, female n (%) 127 (74) 71 (68) 198 (71)
Median time since diagnosis, years (IQR) 13 (8–20) 12 (6–17) 13 (7–19)
Location of disease activity n (%)a
Ileum only 45 (26) — —
Colon only 48 (28) — —
Ileocolon 69 (40)
Any localization and jejunum or stomach 10 (6) — —
Fistulas 66 (38) — —
Strictures 74 (43) — —
No strictures or fistulas 53 (31) — —
Proctitis only — 11 (10) —
Left hemicolon only — 24 (23) —
Pancolonic — 60 (57) —
Unknown — 10 (10) —
Past bowel surgery n (%)b 90 (52) 22 (21) 112 (40)
Colostoma 6 (4) 1 (1) 7 (3)
Ileostoma 14 (8) 8 (8) 22 (8)
Ileorectal anastomosis 4 (2) 1 (1) 5 (2)
Pouch 2 (1) 10 (10) 12 (4)
Current medication for IBD n (%)
None / loperamide / mebeverine only 28 (16) 17 (16) 45 (16)
5-aminosalicylate / topical steroid only 31 (18) 41 (39) 72 (26)
Systemic immunosuppressant 78 (45) 43 (41) 121 (44)
TNF-a inhibitor 60 (35) 13 (12) 73 (26)
Work-disabled (complete or in part) n (%) 65 (38) 31 (30) 96 (35)
Comorbidity requiring medication n (%)c 33/87 (38) 22/60 (37) 55/147 (37)
Admitted to hospital for an exacerbation of
IBD in the past 5 years n (%)
76 (44) 35 (33) 111 (40)
SE: standard error of the mean; IQR: interquartile range.
aMontreal classification of IBD.20
bi.e., part of the bowel was removed.
cDenominator is different due to missing data.
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who underwent bowel surgery in the past (OR 1.5, 95% CI
0.9–2.6), for those who were work-disabled due to IBD
(OR 2.2, 95% CI 1.2–3.9), and for those who reported a
larger average number of exacerbations of IBD over the
past 5 years (reference category 0 exacerbations OR 1.0,
up to 1 exacerbation per year OR 2.9 (95% CI 1.3–6.4), 1
to 2 exacerbations per year OR 2.2 (95% CI 0.8–5.6), more
than 2 exacerbations per year OR 4.8 (95% CI 1.7–13).
Pretravel Advice and Vaccination
Forty-three percent (120/277) had traveled to coun-
tries where hepatitis A is endemic (VACþ), often while on
a glucocorticoid or an immunomodulator (58/120, 48%) or
a TNF-a inhibitor (20/120, 17%) (Table 2). Of those who
traveled to VACþ countries 76% (91/120) obtained pretra-
vel advice from a qualified source. Fewer men (22/37,
59%) than women (69/83, 83%) obtained pretravel advice.
Forty-eight percent (44/91) received a prescription for an
antibiotic for self-treatment in case of infectious diarrhea.
Travelers to VACþ countries who underwent bowel sur-
gery in the past may be at a greater risk of dehydration.
Therefore, this group in particular should carry an antibi-
otic to treat infectious diarrhea. Only 53% (17/32) were
advised to do so. At the time of travel 23% (27/120) were
not protected against hepatitis A (i.e., they had never been
vaccinated for hepatitis A and had never been infected
with hepatitis A). Guidelines stipulate that the antibody
response to inactivated hepatitis A vaccine should be
checked in vaccinees on immunosuppressant drugs and that
nonresponders should receive passive immunization. Anti-
body titers were checked in less than half (10/26; 38%) of
those in whom the response should have been checked.
Regarding vaccination for yellow fever, three of 11 partici-
pants (27%) who received the live attenuated vaccine
should not have been vaccinated, as two used azathioprine
and one a TNF-a inhibitor. All three were vaccinated at
specialized travel clinics. Three travelers who visited coun-
tries for which yellow fever vaccination is required had
never been vaccinated. Two of these travelers visited coun-
tries where no cases of yellow fever have been reported in
recent years (Kenya and Tanzania), and for which travelers
with a contraindication for vaccination are routinely
exempted. The other traveled to Uganda and used predniso-
lone and azathioprine.
Travel-related Morbidity
Fecal urgency and incontinence were mentioned most
frequently as the main IBD-related inconveniences during
travel (36%). Abdominal discomfort (10%) and fatigue or
joint or muscle pain (9%) were also common hindrances.
Onset of a new episode of diarrhea was reported by 32%
(90/277) and more so by those with Crohn’s disease than
by those with ulcerative colitis. Past bowel surgery, Mon-
treal Classification of disease activity, and extent and type
of medication were not associated with the onset of a new
episode of diarrhea (data not shown). Twenty-eight percent
(25/90) thought that the diarrheal episode was due to an
enteric infection, of which 56% (14/25) used an antimicro-
bial agent. In total 15/277 (5%) consulted a foreign physi-
cian, of whom five were admitted to hospital. Three of
those who were admitted had undergone bowel surgery in
the past, one of whom had a pouch. Details are specified in
Table 3.
Posttravel Screening and Posttravel Morbidity
According to the national guideline, 11 travelers
should have been screened for tuberculosis after travel by
way of a Tuberculin Skin Test (TST). The guideline is
based on travel destination, duration, and intensity of con-
tact with the local population. Nine of these 11 travelers
used an immunosuppressant at the time of travel, but none
used a TNF-a inhibitor. Three travelers were actually
TABLE 2. Travel Characteristics of 277 Dutch Patients
with Inflammatory Bowel Disease Regarding the Most
Recent Travel Abroad
Characteristic All n ¼ 277
Destination, n (%)
Countries not endemic for hepatitis A, n (%)* 157/277 (57)








Central and Eastern Asia 14
Indian subcontinent 2
South-East Asia 24
Median travel duration, weeks (IQR) 2 (1–3)
Main travel purpose, n (%)
Tourism 216/277 (78)
Visit friends/relatives 39/277 (14)
Business/professional/study/volunteer work 22/277 (8)
Medication for IBD at the time of travel, n (%)
None / loperamide / mebeverine only 38/277 (14)
5-aminosalicylate / topical steroid only 97/277 (35)
Systemic immunosuppressant 123/277 (44)
TNF-a inhibitor 45/277 (16)
IQR: interquartile range;
*Defined as countries for which vaccination against hepatitis A is recom-
mended according to the national guideline for travel medicine.
Inflamm Bowel DisSoonawala et al
4
chapter 3 | 55
screened before and 8 weeks after travel (3/11, 27%); eight
were not, of whom six used an immunosuppressant.
Nineteen percent (54/277) reported an exacerbation
of IBD within 2 months following travel; 24% (13/54)
attributed the onset to the recent travel. The OR for an
exacerbation within a 2-month period after travel, using the
number of self-reported exacerbations in a 5-year period as
reference, was not increased (MH-OR 1.1, 95% CI 0.7–
1.8). Using 2008 as reference, the MH-OR was higher (1.5,
95% CI 0.9–2.6).
DISCUSSION
In this study on past travel experiences among 277
Dutch patients with IBD, we found that more than half of
the patients traveled while using systemic immunosuppres-
sive therapy, that 40% traveled to resource-limited destina-
tions, and that one in four failed to obtain pretravel advice
and vaccinations for these medically more hazardous desti-
nations. The pretravel consult was deficient in some
respects. There was considerable travel-related morbidity
and IBD caused much inconvenience and limited the
choice of travel destinations. The risk of an exacerbation of
IBD after travel was increased, but the increase was not
statistically significant.
This is the first survey on pretravel preparation and
travel-related morbidity in patients with IBD. Apart from a
number of useful websites with advice for travelers with
IBD21–23 and apart from guidelines, review articles, and
expert opinion,4,11,16,24,25 we know of only one cohort
study that examined morbidity in travelers with IBD. In
TABLE 3. Travel-related Morbidity For 277 Dutch Patients with Inflammatory Bowel Disease












Any illness while abroad, n (%) 55/99 (56) 39/73 (53) 22/58 (38) 18/47 (38) 134 (48)
Onset of a new episode of diarrhea, n (%) 37/99 (37) 31/73 (43) 7/58 (13) 14/47 (30) 89 (32)
Duration, n (%)
1-3 days 20/37 (54) 17/31 (55) 5/7 (71) 7/14 (50) 49/89 (55)
3-7 days 12/37 (32) 8/31 (26) 1/7 (14) 4/14 (29) 25/89 (28)
1-3 weeks 2/37 (5) 2/31 (6) — 2/14 (14) 6/89 (7)
More than 3 weeks 3/37 (8) 2/31 (6) 1/7 (14) 1/14 (7) 7/89 (8)
Does not remember — 2/31 (6) — — 2/89 (1)
Symptoms, n (%)
Vomiting 1/37 (3) — 1/7 (14) 3/14 (21) 5/89 (6)
Fever 3/37 (8) — 1/7 (14) 2/14 (14) 6/89 (7)
Treatment, n (%)
None 20/37 (54) 10/31 (32) 5/7 (71) 4/14 (29) 39/89 (44)
Loperamide / activated carbon 13/37 (35) 12/31(39) 1/7 (14) 6/14 (43) 32/89 (13)
Antimicrobial agent 1/37 (3) 7/31 (23) 2/7 (29) 4/14 (29) 14/89 (16)
Oral rehydration solution — 4/31 (13) 1/7 (14) 2/14 (14) 7/89 (8)
Extra prednisolone 2/37 (5) 1/31 (3) 1/7 (14) — 4/89 (1)
5-aminosalicylate 1/37 (3) — — — 1/89 (1)
Cause of diarrheal episode (participants’ opinion), n (%)
IBD 32/37 (86) 11/31 (35) 3/7 (43) 6/14 (43) 52/89 (58)
Infection 3/37 (8) 12/31 (39) 3/7 (43) 7/14 (50) 25/89 (28)
Does not know 2/37 (5) 8/31 (26) 1/7 (14) 1/14 (7) 12/89 (13)
Consulted a physician while abroad, n (%) 5/99 (5) 6/73 (8) 3/58 (5) 1/47 (2) 15 (5)a
Admitted to hospital 1/99 (1) 2/73 (3) 1/58 (2) 1/47 (2) 5 (2)b
Journey interrupted, returned home 1/99 (1) — — — 1 (0.4)
VAC-: traveled to countries that are not endemic for hepatitis A; VACþ: traveled to countries that are endemic for hepatitis A.
aReasons for consulting a physician while abroad: gastrointestinal complaints/dehydration (n ¼ 6, of whom 4 had a history of bowel surgery), joint/muscle
pain or trauma (n ¼ 3), upper airway tract infection (n ¼ 2), uveitis (n ¼ 1), altitude sickness (n ¼ 1), itch (n ¼ 1), hot flushes (n ¼ 1).
bDetails for those who were admitted to hospital: cholangitis/dehydration, South Africa; gastro-enteritis with dehydration due to Salmonella enteritidis,
admitted in The Netherlands upon return from Tunesia; vomiting/dehydration, Europe; infectious diarrhea/exacerbation colitis ulcerosa, Europe; enteritis,
central Asia.
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that study few of the 71 IBD patients used systemic immu-
nosuppressive therapy and travel-related morbidity was not
significantly higher in patients than in controls.26 In another
study among Dutch renal transplant recipients, a compara-
ble proportion of transplant recipients failed to obtain pre-
travel advice and a comparable proportion was not pro-
tected against hepatitis A. Hospitalization for travel-related
morbidity was higher in transplant patients.13
Regarding the deficiencies in the pretravel consult,
one should take into account that guidelines on travel med-
icine are based on consensus and that there may be valid
reasons not to follow a guideline. First, although IBD
patients with a shorter bowel are at increased risk of dehy-
dration and although immunosuppressive drugs increase the
risk of severe salmonellosis6 there are no compelling rea-
sons for all travelers with IBD to carry an antibiotic for
self-treatment in case of diarrhea. Opponents may argue
that distinguishing infectious diarrhea from IBD activity is
very difficult and that unnecessary use of antibiotics may
aggravate IBD. Second, our finding that many travelers
were not screened for latent tuberculosis can be com-
mented upon. We did not have detailed information on the
circumstances under which respondents came in contact
with the local population. Therefore, based on our defini-
tion, we may have over- or underestimated the ‘‘true’’ pro-
portion that should have been screened for tuberculosis.
Furthermore, a TST has reduced sensitivity in IBD patients
in general and in those on systemic immunosuppressive
therapy in particular.28,29 An interferon gamma release
assay (IGRA) increases sensitivity of screening for tubercu-
losis. Because IGRA is costly, TST is still used in most
travel clinics.
Although we did not find that travel increased the
risk of an exacerbation of IBD within a 2-month period af-
ter travel, one should realize that there may be inaccuracies
in patients’ self-reported number of exacerbations and that
patients may be more inclined to travel when their disease
is in a stable phase. Therefore, the individual’s self-
reported number of exacerbations over the past 5 years
may not be a valid marker for the expected incidence of an
exacerbation following travel. In this respect it is interest-
ing that the MH-OR was higher in the sensitivity analysis
in which the number of exacerbations in 2008 was used as
reference, which may be a better estimate of the expected
incidence of an exacerbation after travel. It should be noted
that we inquired about exacerbations of IBD within a 2-
month period after travel and did not account for the incu-
bation period of travel-related infectious diarrhea. There-
fore, it is possible that some self-reported exacerbations
were actually episodes of travel-related infectious diarrhea.
Such bias may have increased the MH-OR.
This study has a number of limitations. First, it was
designed as a questionnaire study taken after the fact. This
allowed us to survey a larger number of patients in a
shorter time-frame than a study in which participants are
recruited before travel. The downside is an increase in the
chance of recall bias among respondents and an increase in
the chance of preferentially selecting travelers with more
severe travel-related morbidity who may be more inclined
to respond to a questionnaire taken after the fact. Second,
we could not determine the response rate for those who
were recruited via the website of the IBD patient organiza-
tion. Third, besides enteric symptoms the survey only con-
tained a general question on any additional travel-related
morbidity. Morbidity that travelers deemed less relevant
may not have been mentioned. Last, although we piloted
the questionnaire among patients and epidemiologists,
questions could have been misinterpreted.
Based on our study, we make the following recom-
mendations: 1) The physician caring for patients with IBD
is best positioned to raise awareness of the risks associated
with travel and to refer patients to a travel medicine clinic.
2) Travel clinics should check serology after hepatitis A
vaccination in those who use systemic immunosuppres-
sants. Even if seroprotection is not attained after one dose,
a second dose is often effective, as has been shown in
organ transplant recipients.30 3) Continued vigilance is
needed when prescribing live attenuated vaccines such as
yellow fever vaccine. 4) Fecal urgency and incontinence
are major sources of inconvenience and should be
addressed by IBD physicians and healthcare workers at
travel clinics.
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Post-Travel Screening of Asymptomatic Long-Term Travelers to the Tropics
for Intestinal Parasites Using Molecular Diagnostics
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Abstract. The incidence of asymptomatic travel-related parasitic infection is uncertain. Previous studies did not
distinguish new incident infections, from past infections. Regardless of symptoms, we performed multiplex real-time
polymerase chain reaction on pre- and post-travel stool samples of Dutch long-term travelers to the (sub)tropics.
Serological screening for Schistosoma spp. was only performed in travelers to sub-Saharan Africa. In total, 679 travelers
were included in the study. The follow-up rate was 82% (556 of 679). Participants’ median travel duration was 12 weeks.
There was one incident infection with Strongyloides stercoralis; there were none with Entamoeba histolytica, 4 with
Cryptosporidium spp. (1%), and 22 with Giardia lamblia (4%). Nine of 146 travelers (6%) seroconverted for
Schistosoma spp. Routine screening of stool samples for parasitic infection is not indicated for asymptomatic people,
who travel to the (sub)tropics for up to 3 months. Screening for Schistosoma spp. should be offered to travelers with
fresh-water contact in endemic regions.
INTRODUCTION
Asymptomatic infection with protozoa or helminths can
cause morbidity long after the primary infection. Travelers to
the tropics are at risk of such infections. Asymptomatic infec-
tion, in particular with parasites such as Entamoeba
histolytica, Strongyloides stercoralis, or Schistosoma spp. can
cause devastating morbidity later on in life. Early detection
and eradication is beneficial. Some travel clinics offer post-
travel screening, which includes screening for parasites. How-
ever, the prevalence of asymptomatic parasitic infections after
travel remains uncertain. Two sizeable studies have been per-
formed, in which people from highly industrialized countries
were screened for parasitic infections, after having stayed in
the tropics. Whitty and others1 determined the use of post-
travel screening in the United Kingdom. They studied two
cohorts, totaling over 1,000 symptomatic and asymptomatic
travelers and expatriates who stayed in the tropics or subtrop-
ics for at least 3 months. The majority had lived in the tropics
for well over a year. A stool specimen was screened with stool
concentrate microscopy. Gut helminths were detected in 3%
of samples, as was Giardia lamblia. The study did not distin-
guish between E. histolytica and Entamoeba dispar cysts,
which were detected in 9% of samples. Schistosomal serology
was positive in 13% and was limited to those who had stayed
in Africa. These results are not generalizable to most long-
term non-expatriate travelers, whose travel duration is con-
siderably shorter than 1 year. Furthermore, the sensitivity of
traditional microscopic methods to detect parasitic infections
is limited, even in experienced well-equipped laboratories. In
addition, the available serological tests for S. stercoralis either
have a limited sensitivity during the early stage of infection, or
have a low specificity, and therefore are less useful for screen-
ing travelers.2 A study by Ten Hove and others3 screened
over 2,500 samples from symptomatic and asymptomatic peo-
ple who visited a large travel clinic in Belgium for a variety of
reasons. The majority was born in Europe. The multiplex real-
time polymerase chain reaction (PCR) analysis that they used
was clearly more sensitive to detect infection with E. histolytica
(prevalence 0.5%), S. stercoralis (0.8%),G. lamblia (6%), and
Cryptosporidium spp. (1.3%) than the more traditional
methods. This cross-sectional study could not distinguish
recently contracted incident infections from infections that
may have been contracted earlier, during past travel or during
residency in the tropics.
We aimed to determine the use of routine post-travel screen-
ing for asymptomatic parasitic infections. The screening was
restricted to parasites that may cause asymptomatic infection
and late-onset morbidity. Therefore, we studied the incidence
of infection with E. histolytica, G. lamblia, Cryptosporidium
spp., S. stercorali, and Schistosoma spp. in a cohort of Dutch
long-term travelers who visited the tropics.
MATERIALS AND METHODS
Design and study population. This prospective cohort study
was conducted in The Netherlands from July 2007 until
November 2009. Healthy adults who visited the travel clinics at
Leiden University Medical Center (LUMC) and Wageningen
University and Research center (WUR) and who intended to
travel to the (sub)tropics for more than 1 month were invited to
take part. The majority of those who visit the travel clinic at
LUMC are “general travelers.” However, relatively more hos-
pital employees and (bio)medical students visit the travel clinic
at LUMC compared with other out-of-hospital based travel
clinics. The WUR focuses on the field of agriculture and the
living environment and only university students and staff visit
the travel clinic at WUR. All participants submitted stool sam-
ples and filled out web-based questionnaires before departure
and 2 and 12 weeks after returning home. Pre- and post-travel
serum samples were only obtained from those who visited sub-
Saharan Africa. Stool specimens were sent by regular mail.
Pre-travel samples were stored and analyzed later in case of a
positive post-travel sample. Post-travel samples (i.e., the sam-
ples that were collected 2 weeks and 12 weeks after returning
*Address correspondence to Darius Soonawala, Department of Infec-
tious Diseases and Tropical Medicine C5-P, Leiden University Medical
Center, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail:
d.soonawala@lumc.nl
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home) were processed directly upon arrival. Participants were
notified of their result. In case of an infection, the participants’
general practitioner was also notified. The study protocol was
approved by the Medical Ethics Committee at LUMC and
participants provided written informed consent.
Questionnaires. The first questionnaire (Q1) was sent
before participants’ departure and consisted of questions on
past travel to the tropics, current illness, past and current
bowel complaints, use of medication, and past infection or
treatment of enteric parasites. The second questionnaire
(Q2) was sent 2 weeks after participants had returned home
and consisted of questions on travel characteristics and (treat-
ment of) intestinal infection during travel. The third question-
naire (Q3) was sent 12 weeks after participants had returned
home and dealt with persisting complaints and use of medica-
tion after travel. Travelers’ diarrhea was defined as the pas-
sage of three or more unformed stools during a 24-hour
period with or without additional symptoms.4
Laboratory methods. Stool samples. Participants were
asked to fill an empty tube with stool and send it by regular
mail to the diagnostic laboratory of LUMC. The DNA isola-
tion and multiplex real-time PCR amplification were per-
formed upon arrival of each post-travel sample. Pre-travel
samples were stored at −20°C and analyzed later in case of a
positive post-travel sample. The DNA isolation and multiplex
real-time PCR were performed as described previously.3,5,6 For
DNA isolation, 200 mL of feces suspension (~0.5 g/mL feces in
phosphate buffered saline [PBS] containing 2% polyvinylpo-
lypyrrole [PVPP; Sigma, Steinheim, Germany]) was heated for
10 min at 100°C. After sodium-dodecyl-sulphate-proteinase K
treatment (overnight at 55°C), DNA was isolated with the
MagNA Pure LC 2.0 instrument using the MagNA Pure LC
DNA isolation kit III (Roche, Almere, Nederland). In each
sample, a fixed amount of phocin herpes virus 1 (PhHV-1) was
added within the isolation lysis buffer, to serve as an internal
control for the isolation procedure and to monitor inhibition of
the multiplex real-time PCR assays. Entamoeba histolytica, G.
lamblia, and C. hominis/C. parvum DNA amplification was
performed in a multiplex real-time PCR including the PhHV
internal control (HGC PCR).5 Strongyloides stercoralis DNA
amplification was performed in a separate assay, also including
PhHV-1 as an internal control.6 Amplification, detection and
data analysis was performed on the CFX96 real-time detection
system (BioRad, Veenendaal, The Netherlands).
Serum samples. Before travel and 12 weeks after travel a
serum sample was collected from participants who had visited
sub-Saharan Africa. Pre-travel samples were stored at −20°C
and analyzed later in case of a positive post-travel sample.
Antibodies to Schistosoma mansoni-derived somatic antigens
(Adult Worm Antigen, AWA) were assessed by an indirect
immunofluorescence assay for the detection of immunoglobu-
lin G (IgM) antibodies, using paraffin sections of adult male
S. mansoni with Rossmann fixative. The IgG antibodies to egg
antigens (Soluble Egg Antigens, SEA) were assessed by
Figure 1. Flowchart of participants in the study of post-travel screening for intestinal parasites.
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enzyme-linked immunosorbent assay.7,8 Stool samples of trav-
elers who seroconverted were analyzed for Schistosoma spp.
using PCR as has been described previously.9 No urine samples
were collected.
Data editing. Travel destination was categorized according
to the United Nations (UN) International Migrant Stock.10
Sample size. This was a descriptive study. We deemed an
incidence rate of at least 1% for each separate parasitic infec-
tion to be a significant finding. Based on this assumption, we
chose to screen 500 travelers.
RESULTS
Study population, travel characteristics, and travelers’
diarrhea. Six hundred and seventy-nine travelers (84%LUMC,
16% WUR) provided informed consent of who 123 were
excluded from the analyses because they submitted less than
two stool samples (follow-up rate 556 of 679, 82%) (Figure 1);
200 participants visited sub-Saharan Africa of whom 54 did not
submit a post-travel serum sample (follow-up rate 146 of 200,
73%). Participants’ median age was 25 years (interquartile
range [IQR] 23–30) and the median travel duration was
12 weeks (IQR 6–20 weeks). Among the participants from
Leiden, South-Eastern Asia was the most popular travel desti-
nation. Among the participants fromWageningen, Western and
Eastern Africa were the most popular destinations. The main
travel purpose was study (55%) and the main mode of travel
was qualified as backpacking (47%) (Table 1). The incidence
proportion of travelers’ diarrhea was very high (74%). The
majority reported more than one episode, although it needs to
be mentioned that a formal definition of what constituted an
episode was not included in the questionnaire (Table 2).
Post-travel screening results: fecal parasites. The results of
real-time PCR for all fecal parasites are summarized in Table 3.
None of the 542 stool samples obtained 2 weeks after partici-
pants’ return was positive for E. histolytica. Twelve weeks
after travel only 1 of 437 samples (0.2%) was positive for
S. stercoralis (Ct-value 27.5). This participant was asymptom-
atic and had traveled to Indonesia for 14 weeks of field work
involving water management. No rhabditiform larvae were
detected with microscopy of a direct smear of the same sam-
ple, possibly because the sample was no longer fresh.
Strongyloides serology was positive. His pre-travel stool sam-
ple was negative, as was his sample taken 2 weeks after return
(i.e., no specific amplification). He was treated with ivermec-
tin. Cryptosporidium spp.-specific amplification was detected
in four samples (1%). The pre-travel samples of these partic-
ipants were negative for Cryptosporidium. With microscopy
Table 1








Median age, years (IQR) 25 (23–32) 25 (23–26) 25 (23–30)
Gender, female, n (%) 323 (69) 52 (58) 375 (67)
Median travel duration,
weeks (IQR)
13 (7–20) 17 (13–22) 12 (6–20)
Travel destination, n (%)†
Latin America 111 (24) 23 (26) 134 (24)
Central America
and Caribbean
38 (8) 6 (7) 44 (8)
South America 85 (18) 19 (21) 104 (19)
Africa 160 (34) 46 (52) 206 (37)
Northern Africa 4 (1) 1 (1) 5 (1)
Western Africa 39 (8) 17 (19) 56 (10)
Middle Africa 14 (3) 3 (3) 17 (3)
Eastern Africa 82 (18) 24 (27) 106 (19)
Southern Africa 42 (9) 4 (5) 46 (8)
Asia 184 (39) 18 (20) 202 (36)
Central
and Western Asia
11 (2) 1 (1) 12 (2)
Eastern Asia 34 (7) 2 (2) 36 (7)
South-Eastern Asia 108 (23) 12 (14) 120 (22)
Southern Asia 67 (14) 6 (7) 73 (13)
Unknown 16 (3) 2 (2) 18 (3)
Main travel purpose, n (%)
Study 170 (36) 75 (84) 307 (55)
Tourism 197 (42) 5 (6) 202 (36)
Volunteer work 58 (12) 4 (5) 62 (11)
Professional 15 (3) 2 (2) 17 (3)
Visit friends/relatives 5 (1) 1 (1) 6 (1)
Unknown 22 (5) 2 (2) 24 (4)
Type of travel, n (%)
Backpacking 204 (44) 48 (54) 252 (45)
Self-arranged,
not backpacking
184 (39) 37 (42) 221 (40)





309 (66) 43 (48) 352 (63)
With locals in rural area 43 (9) 23 (26) 66 (12)
With locals in city 43 (9) 19 (21) 62 (11)
Large hotel 32 (7) − 32 (6)
Camping/boat 17 (4) 3 (3) 20 (4)
Unknown 22 (5) 2 (2) 24 (4)
*IQR = interquartile range.
†Four participants traveled to more than one continent.
Table 2








Travelers’ diarrhea, n (%)* 309/416 (74) 59/80 (74) 368/496 (74)
1 Episode 84/309 (27) 15/59 (25) 99/368 (27)
2 Episodes 82/309 (27) 20/59 (34) 102/368 (28)
More than 2 episodes 143/309 (46) 24/59 (41) 167/368 (45)
Accompanying symptoms,
n (%)
Abdominal cramps 178/309 (58) 26/59 (44) 204/368 (55)
Nausea 89/309 (29) 14/59 (24) 103/368 (28)
Vomiting 78/309 (25) 10/59 (17) 88/368 (24)
Fever 54/309 (17) 9/59 (15) 63/368 (17)
Blood in stool 10/309 (3) 3/59 (5) 13/368 (4)
Travelers’ diarrhea
by continent, n (%)
Latin America 73/111 (66) 15/23 (65) 88/134 (66)
Africa 116/160 (73) 32/46 (70) 148/206 (72)
Asia 122/184 (66) 12/18 (67) 134/202 (66)
*Data is missing for 60 travelers who did not return the questionnaire after travel. Diarrhea
was defined as the passage of three or more unformed stools during a 24-hour period.
Table 3
Results of routine post-travel screening of stool samples of long-term
travelers to the tropics using multiplex real-time PCR and
serological screening*
Characteristic Leiden Wageningen All
Entamoeba histolytica, n (%) 0/456 (0) 0/86 (0) 0/542 (0)
Giardia lamblia, n (%) 19/456 (4) 10/86 (12) 29/542 (5)*
Cryptosporidium spp., n (%) 3/456 (1) 1/86 (1) 4/542 (1)
Strongyloides stercoralis, n (%) 0/369 (0) 1/78 (1) 1/437 (0.2)
Schistosoma spp.
Seroconversion, n (%)
7/113 (6) 2/33 (6) 9/146 (6)
*Twenty-three of 542 (4%) were newly infected with G. lamblia after travel and 6 of 29
were already infected, but asymptomatic, before departure. Half of the travelers who were
infected with G. lamblia after travel reported gastrointestinal complaints (i.e. abdominal
discomfort and/or diarrhea), for which the majority did not consult a physician.
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using carbol-fuchsine-staining Cryptosporidium oocysts were
seen in 3 of 4 PCR-positive samples (75%). Giardia lamblia-
specific amplification was detected in 29 individuals (5%). Six
of these participants were also positive for G. lamblia before
departure. These six participants did not have abdominal com-
plaints before departure, nor did they develop complaints after
returning home. With microscopy, G. lamblia cysts and/or tro-
phozoites were seen in 23 of 26 (88%) PCR-positive samples.
In the PCR, Ct-values ranged from 20.2 to 35.3 (median 26.7).
As expected, negative microscopy was associated with higher
Ct values (P value 0.002, Kruskal-Wallis test).
Giardia lamblia and Cryptosporidium spp., symptoms,
risk factors, and treatment. The four cases of cryptosporidium
infection were detected in travelers returning from Western
Africa (two cases) and Eastern Africa or Southern Asia (one
case each) (Table 4). All four had experienced travelers’ diar-
rhea and three had abdominal complaints in the first 2 weeks
after having returned home. None were treated. Twelve weeks
after travel Cryptosporidium spp. were no longer detected. The
incidence proportion of travelers’ diarrhea and travel duration
was not higher in those who were newly infected with
G. lamblia, compared with all other travelers. Half of all trav-
elers infected withG. lamblia were asymptomatic at the time of
diagnosis. Ct values forG. lambliawere not higher in symptom-
atic compared with asymptomatic participants. Gastrointestinal
complaints (i.e., abdominal discomfort and/or diarrhea) were
more common in those infected with G. lamblia (48%) than in
their non-infected counterparts (31%) (relative risk [RR] 1.6,
95% confidence interval [CI] 1.0–2.4). Of note, two symptom-
atic participants who had contracted G. lamblia in Ghana did
not respond to treatment with metronidazole.
Giardia lamblia and Cryptosporidium spp., household
contacts. We screened 27 household contacts of 11 G. lamblia
infected travelers and eight household contacts of two Cryp-
tosporidium-infected travelers. Giardia lamblia was detected
in one household contact of a traveler who had contracted
G. lamblia during travel, and in one household contact of a
traveler whose pre- and post-travel sample was positive for
G. lamblia. Cryptosporidium spp. was not detected.
Post-travel screening results: schistosomiasis. Twelve weeks
after travel, nine of 146 travelers (6%) seroconverted for
Schistosoma spp. All had been swimming in Lake Malawi or
Lake Victoria. Seven were asymptomatic and two had
Katayama syndrome. Three had antibodies to both SEA and
AWA. Six only had antibodies to AWA. The stool samples
of these nine travelers were analyzed for Schistosoma spp.
using PCR. Two, both with antibodies to AWA only, were
positive. Treatment and follow-up was done by the travelers’
general practitioners.
DISCUSSION
The incidence of asymptomatic infection with E. histolytica
and S. stercoralis after travel was low. Only one infection with
S. stercoralis was found in over 400 travelers and no infection
with E. histolytica in over 500 travelers. Therefore, routine
screening of asymptomatic travelers is not indicated for those
who travel to the (sub)tropics for up to 3 months. The inci-
dence of infection with Schistosoma spp. was higher. However,
each case was associated with exposure to highly endemic lakes
in Malawi and Tanzania. Therefore, screening for Schistosoma
spp. can be limited to travelers with a history of exposure to
fresh water exposure in endemic regions. In the study by
Whitty and others,1 freshwater exposure did not correlate with
schistosomiasis. However, their result may be influenced by a
considerable amount of recall bias, considering the fact that
most participants had lived in the tropics for well over a year.
Infection with G. lamblia was seen in 5% and was associ-
ated with gastrointestinal complaints in 48%, meaning that
half of the infected participants were asymptomatic. Partici-
pants, who already hadG. lamblia in their stool before depar-
ture, did not have abdominal complaints. Infection is usually
self-limiting and does not have long-term repercussions. Fur-
thermore, the prevalence of asymptomatic G. lamblia infec-
tion in The Netherlands is comparable to the post-travel
incidence in this study11; therefore, routine screening of
asymptomatic travelers for G. lamblia is not warranted.
This study has a number of strengths. First, the participants
were recruited prospectively and samples were collected
before and after travel. This allowed us to differentiate post-
travel incident cases from pre-existent infections. Second, we
used a well-validated multiplex real-time PCR to screen stool
samples. This method is more sensitive than traditional
methods to detect infection.3,12,13 Furthermore, it can differ-
entiate pathogenic E. histolytica from apathogenic E. dispar.
Finally, although 18% were lost to follow-up, there is no
reason to assume that these participants had higher rates of
symptomatic or asymptomatic infection. This study also has
limitations. The results may not be representative of all trav-
elers. First, the results pertain to travelers who seek health-
related travel advice before travel and who traveled for
~3 months. Post-travel screening of specific groups of asymp-
tomatic travelers, such as migrants, expatriates, or aid
workers may yield higher infection rates. Second, half of the
participants in this study were students. Although most stu-
dents combined their stay abroad with travel for touristic
purposes, this may limit the generalizability of this study.
To conclude, based on the low incidence of infection, rou-
tine screening for E. histolytica, S. stercoralis, Cryptosporid-
ium spp., and G. lamblia is not indicated for asymptomatic
people, who travel to the (sub)tropics for up to 3 months.
Received October 14, 2013. Accepted for publication January 23,
2014.
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Table 4
Incidence proportion of infection with Giardia lamblia and






Latin America* 7/133 (5) −
Central America and Caribbean 2/44 (5) −
South America 6/104 (6) −
Africa 10/205 (5) 9/146 (6)
Northern Africa 0/5 (0) −
Western Africa 7/56 (13) 0/37 (0)
Middle Africa 1/17 (6) 0/11 (0)
Eastern Africa 2/106 (2) 9/78 (12)
Southern Africa 0/46 (0) 0/27 (0)
Asia* 12/202 (6) −
Central and Western Asia 1/12 (8) −
Eastern Asia 2/36 (6) −
South-Eastern Asia 3/120 (3) −
Southern Asia 9/73 (12) −
*A few participants traveled to more than one region or continent.
838 SOONAWALA AND OTHERS
62 | i. travel-related morbidity
Acknowledgments: We thank the nurses of the travel clinic at LUMC
and WUR for their valuable assistance in recruiting participants and
the technicians at the laboratory of Medical Microbiology and Para-
sitology at LUMC for handling and analyzing the samples.
Financial support: Support for this work was provided by the Depart-
ment of Medical Microbiology at LUMC.
Authors’ addresses: Darius Soonawala, Department of Nephrology,
Leiden University Medical Center, Leiden, The Netherlands, E-mail:
d.soonawala@lumc.nl. Lisette van Lieshout, Department of Parasitol-
ogy, Leiden University Medical Center, Leiden, The Netherlands,
E-mail: e.a.van_lieshout@lumc.nl. Marion A. M. den Boer and Leo G.
Visser, Department of Infectious Diseases and Tropical Medicine,
Leiden, The Netherlands, Emails: a.m.den_boer@lumc.nl and l.g.visser@
lumc.nl. Eric C. J. Claas, Department of Medical Microbiology, Leiden
University Medical Center, Leiden, The Netherlands, E-mail: e.c.j
.claas@lumc.nl. Jaco J. Verweij, Laboratory for Medical Microbiology
and Immunology, St. Elisabeth Hospital, Tilburg, The Netherlands,
E-mail: j.verweij@elisabeth.nl. André Godkewitsch and Marchel
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 INTRODUCTION 
 Most of the information on the immunopathology of schis-
tosomiasis is derived from murine models. 1– 6 Studies in humans 
have mainly focused on chronic infections seen in endemic 
areas. 7 The acute response known as Katayama syndrome is 
thought to occur in non-immune hosts only. 8 Prior exposure to 
antigens  in utero 9– 12 or infection early as opposed to late in life 
is believed to account for this difference in symptoms between 
persons living in an endemic area and non-immune hosts. 
 Several studies have analyzed the acute response after a 
primary  Schistosoma infection. 13– 16 The symptoms in non-
immune hosts vary widely. 17, 18 Some non-immune subjects 
develop Katayama syndrome, whereas others remain (vir-
tually) asymptomatic The reason for this difference remains 
unknown. 19– 21 Immunologically, eosinophilia and circulating 
immune complexes have been associated with acute schis-
tosomiasis, 14, 17, 19 and it has been suggested that the cause of 
Katayama syndrome is a systemic hyperreactive immune 
response to migrating schistosomula. 21 
 Schistosomiasis in travelers can be considered an experi-
ment of nature with a defined exposure in time, a non-immune 
host, low infection intensity, and lack of coinfection or reinfec-
tion. The aim of the present study was to investigate the type 
and strength of the cellular immune response to schistosome 
antigens in a defined group of previously treated travelers. The 
secondary aim was to analyze the difference in the immune 
response between those who had and those who had not expe-
rienced Katayama syndrome. 
 MATERIALS AND METHODS 
 Subjects.  Subjects were recruited from an single episode of 
schistosomiasis that occurred among 28 Dutch travelers who 
had been infected during a swim in fresh water pools in the 
Dogon area in Mali in 1991. 17 At the time, 15 had developed 
Katayama syndrome, which was defined as occurrence of two 
or more of the following symptoms: fever, sweating, abdominal 
pain, myalgia, arthralgia, diarrhea, dry cough, weight loss, 
hepatomegaly, splenomegaly, urticaria, or swollen eyelids. 
 Treatment with praziquantel had resulted in parasitologi-
cal cure in all travelers. In 1999, when this current study was 
performed, 21 of the initial 28 subjects could be contacted for 
collection of venous blood. To exclude actual  Schistosoma 
infection, stool and urine samples of all 21 subjects were 
screened for schistosome eggs by sedimentation selective fil-
tration methods. 22 In short, washed stool samples were sifted 
first through a sieve with 106-µm pores and then through a 
sieve with 53-µm pores. Five wet smears of each sample were 
searched for schistosome eggs. Urine samples were centri-
fuged for 10 minutes at 2,500 rpm, and the entire sediment 
was examined. Stool and urine tests were performed two 
times on separate occasions before considered negative. As 
controls, eight Dutch individuals who had never traveled to 
 Schistosoma -endemic regions provided venous blood. 
 Serology.  Antibodies to  S. mansoni -derived somatic 
antigens (adult worm antigen [AWA]) were assessed by an 
indirect immunofluorescence assay (IFA) for the detection of 
immunoglobulin M (IgM) antibodies using paraffin sections 
of adult male  Schistosoma mansoni with Rossmann fixative. 
IgG antibodies to egg antigens (soluble egg antigens [SEA]) 
were assessed by enzyme-linked immunosorbent assay 
(ELISA). 23, 24 
 Antigens.  AWA and SEA were prepared from 1.5 to 2 g 
 S. mansoni adult worms and eggs, respectively. After homoge-
nizing in an all-glass homogenizer in a 0.035 M phosphate 
buffered saline (PBS), pH 7.8, at 0°C, the homogenate was 
transferred to a glass tube and sonicated for 3 minutes at level 7 
in a sonicator (Branson Sonic Power Company, Sonicator B-12 
power supply and converter, Danbury CT ) at 0°C. Next, the 
homogenate was centrifuged for 20 minutes at 25,000 rpm at 
4°C, and the supernatant was collected. The pellet was 
homogenized again, and the supernatant was collected for 
a second time. The first and second collected supernatants 
were pooled together and dialyzed against distilled water at 
4°C. During this procedure, the water was changed two times. 
The dialyzed supernatant was lyophilized and stored at 4°C. 
The protein content of the antigen fractions in the dialyzed 
supernatants was determined by a bichronic acid method (BCA; 
Pierce III, Rockford, IL) against standard series from solution 
of bovine serum albumin. Finally, the antigens were dissolved in 
Iscoves medium at a protein concentration of 20 µg/mL. 
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 Purified protein derivative (PPD) of  Mycobacterium tuber-
culosis (Statens Serum Institute, Copenhagen, Denmark) was 
diluted in Iscoves medium (Gibco, Pailsey, Scotland) to a con-
centration of 20 µL derivative per 1 mL. Tetanus toxoid (TT; 
RIVM, Bilthoven, The Netherlands) was diluted to a con-
centration of 1.5 Lf (flocculation units) per 1 mL of Iscoves 
medium. Phytohaemaglutine (PHA; Murex Biotech Ltd., 
United Kingdom) was diluted to a concentration of 4 µg per 
1 mL of Iscoves medium. 
 Cellular stimulation assay.  Peripheral blood mononuclear 
cells (PBMC) were isolated from heparinized venous blood 
by Ficoll-Hypaque density gradient centrifugation. Cells 
were frozen in Roswell Park Memorial Institute medium 
(RPMI; Gibco) supplemented with 2 mM/L glutamine, 
1 mM/L pyruvate, 20% (vol/vol) pooled human serum, and 
10% (vol/vol) dimethyl sulfoxide (DMSO; Merck, Darmstadt, 
Germany). Viability after thawing was determined by trypan 
blue dye exclusion. Only cell suspensions with at least 90% 
viability were used. For the proliferation assay, PBMC (10 5 
cells per well) were incubated in flat-bottomed microtiter wells 
(NUNC maxisorb; Life Technologies, Breda, The Netherlands) 
in 100 µL of Iscoves medium (Gibco) supplemented with 10% 
(vol/vol) pooled human serum, 2 mM/L glutamine, 1 mM/L 
pyruvate, 100 U/mL penicillin, and 100 µg/mL streptomycin in 
triplicate at 37°C in humidified air containing 7.5% C0 2 in the 
presence or absence of antigen. 
 For the determination of cytokine production, PBMC (10 6 
cells per well) were incubated in round-bottomed microtiter 
wells (NUNC maxisorb) in the presence or absence of antigen 
in 100 µL of Iscoves medium (Gibco) supplemented with 5% 
(vol/vol) fetal calf serum, 2 mM/L glutamine, 1 mM/L pyru-
vate, 100 U/mL penicillin, and 100 µg/mL streptomycin in trip-
licate at 37°C in humidified air containing 7.5% C0 2 . After the 
indicated time, the supernatants were collected, and they were 
immediately frozen and stored at −20°C for subsequent deter-
mination of cytokine production. The final concentrations of 
antigens used were: AWA, 10 µg/mL; SEA, 10 µg/mL; PHA, 
2 µg/mL; PPD, 10 µg/mL; TT, 0.75 Lf. 
 Proliferation assay.  The lymphoproliferative responses to 
antigen stimulation (AWA and SEA) and stimulation with the 
mitogenic stimulus PHA were determined by adding 1 µCu 
of [ 3 H]-thymidine at day 5. After 15 hours of incubation with 
[ 3 H]-thymidine, uptake was measured by a scintillation counter. 
Values were expressed as stimulation index (SI). SI equals 
the geometric mean of (mean counts per minute [cpm] of the 
stimulated culture)/(mean cpm of the unstimulated cultures ). 
 Cytokine production.  Supernatants were collected for 
determination of interleukin 10 (IL-10) and IL-13 on day 3 and 
interferon (IFN-γ) and IL-5 responses on day 5. Cytokines were 
measured by use of ELISA using specific capture and detection 
monoclonal antibodies (IFN-γ, IL-13, and IL-10, Pelikine 
Compact ELISA kit; Central Laboratory of Bloodtransfusion, 
Leiden, The Netherlands and IL-5; BD; Pharmingen; Franklin 
Lakes, NJ). The detection limits of the assays were 3 pg of IFN-γ/
mL, 3 pg of IL-10/mL, 3 pg of IL-5/mL, and 3 pg of IL-13/mL. The 
upper limit was 30.000 pg/mL, and any value above was defined 
as 30.000 pg/mL. Detectable values in unstimulated cultures 
were subtracted from the value in stimulated cultures. When this 
difference was negative, the value of produced cytokine after 
stimulation was defined as 1.5 pg/mL. Cytokine responses could 
not be determined in all subjects because of technical problems 
with the assay and the limited amount of blood. 
 Statistical analysis.  Differences between responses were 
tested with the non-parametric Mann–Whitney test. Statistical 
significance was defined as a  P value < 0.05. No correction was 
made for multiple testing. 
 RESULTS 
 Study subjects’ infection and clinical status.  Twenty-one 
subjects who had been treated for schistosomiasis in 1991 
volunteered to participate in the current study. At the time of 
diagnosis in 1991, all subjects had positive schistosome serology, 
and 15 subjects (71%) had eggs in the feces and/or urine. In 
1999, renewed microscopic examination of stool and urine 
was performed two times on separate occasions in all subjects. 
Schistosome eggs were found in the stool of only 1 traveler. 
This patient was treated with praziquantel and excluded from 
further analysis. Twenty travelers were included in the present 
analysis, 9 who had suffered Katayama syndrome in 1991 and 
11 who were asymptomatic. Of these 20 subjects, 14 (70%) had 
eggs in the feces and/or urine in 1991. Twelve of these subjects 
(12/14; 86%) had been infected with  S. mansoni , often as part 
of a mixed infection with  S. haematobium ( Table 1 ). 
 Serologic response to AWA and SEA.  Serum antibodies to 
AWA and SEA were determined in all travelers at 12.6 (±2.5) 
weeks after fresh water exposure in 1991 and 55.7 (±15) weeks 
and 8 years after treatment. Eight years after treatment, none 
of the travelers had reverted to negative serology for both 
AWA and SEA, although IgM anti-AWA titers had decreased. 
Median IgM anti-AWA titers were: 1:1,024 (IQR = 1:1,024–
1:2,048) at 12.6 weeks, 1:1,024 (IQR = 1:512–1:1,024) at 55.7 
weeks, and 1:362 (IQR = 1:128–1:861) at 8 years. Median 
IgG anti-SEA titers were 1:128 (IQR = 1:64–1:256) at 12.6 
weeks, 1:256 (IQR = 1:76–1:256) at 55.7 weeks, and 1:128 
(IQR = 1:76–1:256) at 8 years. At all three time points, median 
antibody levels did not differ significantly between the group 
with Katayama syndrome and the group that had remained 
asymptomatic. 
 Lymphocyte proliferative response.  The lymphoproliferative 
response could be determined for 18 of 20 travelers. A 
lymphoproliferative response was seen to both AWA and SEA 
in the 18 formerly infected travelers but not in 8 non-infected 
controls: the median SI in travelers in response to AWA was 
 Table 1 
 Patient characteristics 
Katayama 
syndrome 
( N = 9)
No Katayama 
syndrome 
( N = 11)
Controls 
(no infection; 
 N = 8)
Male/female 4/5 4/7 5/3
Mean age in years 52.0 52.1 22
Number of subjects positive for 
 Schistosoma spp . eggs in stool 
or urine in 1991 7 (78%) 7 (64%) –
 S. mansoni 3 (33%) 1 (9%) –
 S. intercalatum 1 (11%) 0 –
 S. haematobium 0 1 (9%) –
 S. mansoni and  S. intercalatum 2 (22%) 2 (18%) –
 S. mansoni and  S. haematobium 0 2 (18%) –
 S. mansoni ,  S. intercalatum , and
 S. haematobium 1 (11%) 1 (9%) –
No eggs found 2 (22%) 4 (36%) –
Number of subjects positive for 
 Schistosoma spp. eggs in stool 
or urine in 1999 0 0 –
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15 (mean = 25, standard error = 6 ) and in response to SEA was 
10 (mean = 12, standard error = 3); the median SI in controls 
in response to both AWA and SEA was 1 (mean = 1, standard 
error = 1). Although the median responses were stronger in 
those who had experi enced Katayama syndrome in the past (SI 
for AWA = 30, SI for SEA = 15) compared with those who had 
remained asymptomatic (SI for AWA = 9, SI for SEA = 7), 
these differences did not reach statistical significance ( P values 
for the differences = 0.17 and 0.08, respectively) ( Table 2 ). 
 Cytokine responses.  In comparison to non-infected controls, 
travelers had higher levels of IL-5, IL-10, and IL-13 in response 
to AWA. In response to SEA, travelers showed higher 
production of IFN-γ, IL-10, and IL-13 ( Figure 1 ). Travelers 
who had experienced Katayama syndrome in the past showed 
higher production of IL-13 ( P = 0.03) in response to AWA 
and higher production of IL-13 ( P = 0.009), IFN-γ ( P = 0.004), 
and IL-5 ( P = 0.06) in response to SEA compared with those 
who had been infected but remained asymptomatic ( Figure 1 ). 
The IL-10 responses were similar in those with and without 
Katayama syndrome. Ten samples were taken at random and 
stimulated with TT and PPD. No differences in production 
of IL-5, IL-10, IL-13, and IFN-γ were seen between four 
travelers who had Katayama syndrome and six travelers who 
did not. 
 DISCUSSION 
 Eight years after treatment of schistosomiasis, positive 
serology persisted in all 20 travelers. There was also a specific 
lymphoproliferative response to schistosome antigens, which 
indicates that an acute schistosome infection in a naïve sub-
ject induces a memory response that lasts for at least 8 years. 
Long-lasting positive serology after treatment of schistosomi-
asis is consistent with previous reports. 25, 26 This may be caused 
by persisting egg antigens, providing a stimulus to the immune 
system even after worms are eliminated. However, worms 
have been known to survive in the human host for up to 31 
years, 27 and treatment has been known to fail. Egg secretion 
was the only method to establish whether an active infection 
was still present. Although we performed microscopic analy-
sis two times, examining five wet smears per stool sample and 
the entire urine sediment on each occasion, we cannot exclude 
the possibility of persisting low-grade infection as a cause of 
long-lasting positive serology. Furthermore, the antibodies 
can be cross-reactive to antigens from other sources such as 
certain carbohydrates. 28 Therefore , even without infection, 
 Figure 1.  In vitro cytokine production in response to AWA and SEA 8 years after treatment of schistosomiasis; 20 formerly infected travelers, 
of which 9 had experienced Katayama syndrome and 11 had not, were compared with 8 non-infected controls. Cytokine responses could not be 
determined for all subjects because of technical problems with the assay and the limited amount of blood. Differences were tested using the non-
parametric Mann–Whitney test. 
 Table 2 
 Stimulation index to AWA, SEA, and PHA 8 years after treatment in 
20 Dutch travelers * 
 SEA = soluble egg antigen; AWA = adult worm antigen; PHA = phytohaemaglutinin. 
 * The stimulation index was not determined for 1 person in each group, because their sam-
ple had less than 90% viable peripheral blood mononuclear cells after thawing. 
 †  Mann–Whitney test. 
Antigen
Stimulation index median (mean ± standard error)
 P value † Katayama syndrome ( N = 8) No Katayama syndrome ( N = 10)
AWA 30 (33 ± 10) 9 (18 ± 7) 0.17
SEA 15 (13 ± 2) 7 (10 ± 5) 0.08
PHA 408 568 0.48
4 SOONAWALA AND OTHERS
stimulation of antibody production may occur from time to 
time. 
 It is surprising that AWA induced IFN-γ production in the 
controls but no lymphocyte proliferation in the controls. High 
IFN-γ levels in controls have been reported before in response 
to AWA and SEA. 16 It is possible that components of these 
antigenic mixtures bear pathogen-associated molecular pat-
terns and react with pattern recognition receptors on immune 
cells, such as monocytes, B-lymphocytes , or natural killer (NK) 
cells. The IFN-γ response to AWA in uninfected subjects might 
be produced by NK cells, which can readily release IFN-γ in 
response to stimulation by pathogen-associated molecular pat-
terns (PAMPs). 29 We do not know if these PAMPs are schisto-
some-specific or caused by endotoxin contamination. 
 The data suggest that 8 years after treatment of schistosomi-
asis, those who had Katayama syndrome in the past had stron-
ger or less well-regulated lymphoproliferative and cytokine 
responses to schistosome antigens compared with those who 
were infected but remained asymptomatic. However, most dif-
ferences did not meet conventional levels for statistical sig-
nificance. In addition, all stimulation assays were done with 
 S. mansoni -derived antigens. We can not fully rule out that 
 S. haemaobium - or  S. intercalatum -infected subjects would 
react less with  S. mansoni antigens. Studies conducted on 
Senegalese patients living in an endemic area with single 
 S. haemaobium , single  S. mansoni , or mixed  S. haemaobium 
and  S. mansoni infections indicated that the antigens are cross-
reactive when it comes to cytokine production. In other words, 
there was no consistent pattern showing that  S. haemaobium -
infected subjects respond better to  S. haemaobium antigen 
than  S. mansoni antigen or vice versa (unpublished data). 
Nevertheless, the percentage with proven  S. mansoni infection 
was slightly higher in the group with Katayama syndrome than 
in the group without Katayama syndrome, and this may have 
influenced results. 
 We studied a limited number of cytokines that we believed 
to be important in the immune response in naive subjects. It has 
been argued that it makes biological sense for IL-13, IL-5, and 
IFN-γ to have a central role in the response to infection with 
 Schistosoma spp. 16, 30 Because of IL-13’s function in signaling 
B cells to switch to IgE production and IL5’s and IL-13’s prin-
cipal role in recruiting and activating eosinophils, these cytok-
ines are important in the initial response to invading cercaria 
and later on, to schistosomula. 30 Eosinophilia is known to be 
associated with Katayama syndrome, 17, 19 and the stronger IL-5 
and IL-13 responses that we found may reflect stronger acti-
vation of eosinophils at the time of infection in the travelers 
with Katayama syndrome. The higher IFN-γ levels in response 
to SEA in travelers with Katayama syndrome may reflect a 
stronger immune response to the infection in this group. 
 This study shows that acute schistosomiasis induces a mem-
ory response that can be detected 8 years after treatment. 
Furthermore, we found that formerly infected travelers who 
had Katayama syndrome had an overall stronger action of the 
immune system to schistosome antigens compared with their 
asymptomatic counterparts. This is in line with the idea that 
Katayama syndrome is caused by a hyperreactive immune 
response to migrating schistosomula or eggs. Why some do and 
others do not mount such a hyperreactive immune response 
remains unknown. Differences in the genetic background or 
the antigen load during the acute infection offer plausible but 
unproven explanations. 
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Abstract
Enterotoxigenic Escherichia coli (ETEC), which produces heat labile toxin (LT) and/or heat stable toxin (ST), is considered to be the
most common known cause of travellers’ diarrhoea (TD). Owing to the antigenic similarity between cholera toxin and LT, immunization
with inactivated oral B-subunit/whole-cell cholera vaccine (BS–WC) offers short term (3 months) but significant (>67%) protection against
TD caused by LT-related ETEC. Since it expresses the cholera toxin B (CTB) subunit, the live attenuated oral cholera vaccine strain CVD
103-HgR, may induce similar protection. A trial was performed to determine if CVD 103-HgR live oral cholera vaccine would provide a
protective efficacy of at least 50% against TD. In addition, the protective efficacy of the vaccine against TD specifically due to LT–ETEC
and LT/ST–ETEC was determined. Volunteers (n= 134) travelling to Indonesia, India, Thailand or West-Africa were randomised to receive
either a placebo (n= 65) or the vaccine (n= 69). In the placebo group, 46% reported an episode of diarrhoea, compared to 52% in the vaccine
group. No significant group differences were found with regard to incidence, duration or severity of all caused TD or ETEC-associated TD.
However, ETEC-associated TD occurred earlier in the placebo group (median 5 days), compared to the vaccine group (median 15 days).
In conclusion, CVD 103-HgR live oral cholera vaccine failed to provide a 50% protection against TD. This study does not exclude that the
vaccine may offer a short-lived protection against ETEC-associated TD. However, the power of the study was limited by the unexpected low
incidence of LT–ETEC-associated diarrhoea (9% of all TD) compared to ST-associated TD (24% of all TD).
© 2005 Elsevier Ltd. All rights reserved.
Keywords: Travel; Diarrhoea; Cholera vaccine
1. Introduction
Travellers from industrialized countries visiting
(sub)tropical regions often develop diarrhoea. Large-scale
studies among European and North American travellers to
high-risk destinations, report an incidence rate of diarrhoea
of 20–50% per 2 weeks’ stay [1,2]. Though a self-limiting
∗ Corresponding author. Tel.: +31 71 5262613; fax: +31 71 5266758.
E-mail address: l.g.visser@lumc.nl (L.G. Visser).
illness, travellers’ diarrhoea (TD) can ruin holidays and
cause substantial financial and emotional damage, creating a
need for prophylactic and therapeutic agents. In both respects
antibiotic drug therapy has proven effective. However, the
use of antibiotics carries disadvantages when administered
to a large number of people [3]. Therefore, consensus opts
against the prophylactic use of antibiotics, and the need for
a preventive agent that is both effective and safe, persists.
Although the prevalence of etiologic agents that cause
TD differs from area to area, enterotoxigenic Escherichia
0264-410X/$ – see front matter © 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.vaccine.2005.05.022
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coli (ETEC) is deemed to be the most common cause [4].
Based on a meta-analysis, the median isolation rate of ETEC
associated TD is 42% in Latin America, 36% in Africa and
16% in Asia [3,5]. Despite the use of modern methods, in
approximately 50% of cases, no pathogen is detected [3,4,6].
A significant proportion of this pathogen-undetected TD is
probably caused by ETEC [7].
ETEC expresses a heat-labile toxin (LT), a heat-stable
toxin (ST) or both (LT/ST). Reports on the proportion of
ETEC strains producing a certain type of toxin vary. Approx-
imately 25–30% of strains express LT, 35–45% ST and
30–35% LT/ST [8,9]. LT is very similar to cholera toxin
in both structure and mode of action. It is composed of an
enzymatically active (CTA) subunit surrounded by 5 identi-
cal binding (CTB) subunits. It binds to the same ganglioside
receptors via its CTB moiety that are recognized by the
cholera toxin, and its enzymatic activity is identical to that of
cholera toxin. This explains why immunization with oral B-
subunit/whole-cell cholera vaccine (BS–WC) can induce an
increase in intestinal IgA directed against LT antigens [10].
Most likely these antibodies account for the effect found by
previous studies, that showed that BS–WC offered signifi-
cant (>67%) short-term (3 months) protection against diar-
rhoea caused by LT–ETEC and LT/ST–ETEC [11,12]. CVD
103-HgR, a live oral cholera vaccine, may induce similar
protection. It contains a genetically modified strain of Vib-
rio cholerae O1, attenuated via deletion of about 95% of the
ctxA locus encoding the toxic CTA subunit, and elicits sero-
conversion with high titres of vibriocidal antibody. Since the
strain expresses normal quantities of immunogenic CTB, it is
also known to induce a significant antitoxin immune response
in intestinal fluid [13–16]. Owing to antigenic similarity
between cholera toxin andLT, onemay expectCVD103-HgR
to induce antibodies directed against LT, offering protection
against diarrhoea caused by LT–ETEC and LT/ST–ETEC.
The use of CVD 103-HgR has some advantages over
BS–WC. Firstly, it induces a strong immune response after
only a single dose [17,18], as opposed to the multiple
doses required for immunisation with BS–WC. Secondly,
CVD 103-HgR possibly elicits higher vibriocidal titres than
BS–WC [13]. However, the antitoxin response is probably
similar to that induced by BS–WC.
We performed a randomised, double-blind, placebo con-
trolled trial to determine if CVD 103-HgR live oral cholera
vaccine would provide a protective efficacy of at least 50%
against (severe) travellers’ diarrhoea. In addition, the pro-
tective efficacy of the vaccine against travellers’ diarrhoea
specifically due to LT–ETEC and LT/ST–ETEC, was deter-
mined.
2. Materials and methods
2.1. Study design
The studywas performed at theLeidenUniversityMedical
Center (LUMC). The primary outcome was the attack rate of
TD in the placebo group compared to the vaccine group. The
difference between the two groups, regarding attack rate of
TD caused by LT–ETEC and LT/ST–ETEC was chosen as
secondary outcome. The protocol (KV 9506) was approved
by the ethical committee of the LUMC, The Netherlands.
2.2. Inclusion of subjects
Dutch volunteers were enrolled between May 1995 and
February 1996. Travellers were recruited from the travel
clinics of the LUMC (n= 131), the Municipal Health Cen-
tre at Leiden (n= 5) and the Harbour Hospital at Rotterdam
(n= 9). All adults who made an appointment at the travel
clinic between May 1995 and February 1996 and who were
intending to travel to Indonesia, Thailand, the Indian sub-
continent or West Africa (Gambia or Senegal) for a period
of 1–4 weeks were invited to take part in the trial and
were subsequently sent an informative letter concerning the
study.
2.3. Exclusion criteria
The following subjectswere excluded from the study. Peo-
ple suffering an acute or chronic inflammatory disease of
the intestinal tract; prior recipients of WC–BS cholera vac-
cine or CVD 103-HgR vaccine; subjects receiving immuno-
suppressive drugs; persons known to be immunodeficient;
anyone having received an experimental drug within the last
3 months; subjects participating in other clinical trials and
women who were either pregnant or breast-feeding. Infor-
mation on the concomitant use of medication, treatment or
vaccination was obtained by way of a standardised question-
naire.
2.4. Randomisation
After having obtained written informed consent, sub-
jects were stratified according to region, and were subse-
quently randomised (1:1) to two groups. For randomisation
a computer-generated randomisation list, was used, which
had been produced at the Berna Biotech AG (formerly Swiss
Serum andVaccine Institute), Bern, Switzerland. Sachets and
suspensions of vaccine (n= 100) and placebo (n= 100), that
were identical in appearance, were labelled by a coded num-
ber from 1 to 200. Within each stratum, for each permutation
of 20, theweighingof randomisationwas adjusted to 1:1 (vac-
cine to placebo). Participants were subsequently enrolled in
the trial. At least 2 weeks prior to departure they consumed
the appointed sachet. The key to the coded sachets was stored
at the hospital pharmacy in a sealed envelope. The envelope
was only to be opened by the investigator in case of an emer-
gency that required knowledge of the identity of the trial
medication in order to manage the participant’s condition. At
the end of the trial the coded envelope was returned to the
Berna Biotech AG and checked to ensure that the seal had
remained unbroken.
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2.5. Vaccine and placebo
The vaccine consisted of a single dose of 5× 108 colony
forming units (CFU) of lyophilised CVD 103-HgR live oral
cholera vaccine (CVD 103-HgR). CVD 103-HgR is an atten-
uated strain ofVibrio choleraeO1 derived from the wild-type
classic Inaba strain 569Bbydeleting the genes that encode for
the A subunit of cholera toxin and by inserting a marker gene
encoding for resistance toHg2+ into the hlyA locus of the bac-
terial chromosome. Genes encoding for the synthesis of the
immunogenic, non-pathogenic, B-subunit remain intact. A
placebo dose consisted of 5× 108 heat killedEscherichia coli
K-12. Both vaccine and placebo were administered in a glass
of water together with a buffer containing 2.65 g NaHCO3,
1.65 g ascorbic acid and 0.2 g lactose. A nurse supervised
administration. Volunteers were urged not to eat or drink any-
thing 1 h before and after vaccination.
2.6. Definition of travellers’ diarrhoea
TDwas defined as any episode of three or more unformed
stools per 24 h, or two such bowel movements accompanied
by vomiting, abdominal cramps or subjective fever, with an
onset during travel until 3 days after returning home. Diar-
rhoeal episodes were registered from the time of getting on
the plane. Diarrhoea was recorded as episodes, which were
considered separate when the symptom-free interval was 5
days or more.
2.7. Recording incidence of diarrhoea and collecting
stool specimens
All participants kept a diary of their defecation pattern
during their stay abroad. On return they filled out a question-
naire, concerning defecation pattern, use of medication and
information regarding travel, accommodation, and dietary
hygiene. Each participant submitted a stool specimen. Sub-
jects who had experienced an episode of diarrhoea during
travel collected a sample during the first diarrhoeal episode,
prior to having taken any medication. The remaining trav-
ellers collected and submitted a sample within 3 days after
returning home. Written instructions were given on how to
collect the stool specimen. The sample was preserved in a
plastic vial on a specific transport medium, chosen because
of its capacity to preserve ETEC for a minimum of 4 weeks
(Para-Pak Enteric Plus system, Meridian diagnostics Inc.,
Cincinnati, OH, USA) [18–20]. After returning home, the
vials were collected and sent to the laboratory for microbi-
ology at the Academic Medical Center, Amsterdam where
specimens were analysed for presence of enterotoxin pro-
ducing E. coli.
2.8. Laboratory evaluation of stool samples
All samples, submitted by subjects who had experienced
an episode of diarrhoea were examined for enterotoxigenic
E. coli. In addition the first 28 samples, taken on return home,
by people who had not suffered an episode of diarrhoea were
subjected to the same examination. Stool samples were inoc-
ulated onto Cystine Lactose Electrolyte Deficient (CLED)
agar plates. After 18 h of incubation at 37 ◦C, a sweep of the
complete bacterial growth on the agar was collected using a
sterile cotton swab, and stored in glycerol–pepton at−70 ◦C,
as described previously [21]. This frozen material was inoc-
ulated on a CLED agar plate, from which a new sweep was
taken. This material was diluted in PBS and subjected to PCR
for detection of ETEC–LT, STIa and STIb genes, as described
previously [21]. All PCR-positive samples were submitted to
repeated PCR detection from the sweeps stored at −70 ◦C.
The detection limit for ETEC is 102 CFU/g of feces [21].
2.9. Statistical analysis
The aim of this trial was to estimate the difference (δ) in
chance of acquiring travellers’ diarrhoea after having taken
the placebo (pp) compared to the vaccine (pv). The attack rate
of TD per group reflects these chances. The null hypothesis
(H0) implies that placebo and vaccine are equally effective
in preventing TD (δ= pp− pv = 0). The alternative hypothe-
sis (H1) states that δ = 0. The number of subjects required
for this trial was 100 per group (vaccine/placebo). This was
calculated on the basis of a one-sided test with a power of
the study of at least 0.9, a type I error of less than 0.025
and an expected incidence rate for travellers’ diarrhoea of
35% with an expected protection rate of the vaccine of at
least 50%. Proportions were compared using univariate anal-
ysis for numerical data and the χ2-test for categorical data.
Numerical data that were not normally distributed were anal-
ysed with Mann–Whitney U-test. The study was terminated
after an ad hoc1 interim analysis. During the interim analysis
the key to the randomisation code remained blinded from the
principal investigators.
3. Results
In total, 343 volunteers, meeting the inclusion criteria
were approached, of which 198 either refused to take part
or matched one or more of the prior mentioned exclusion
criteria. At the moment of interim analysis, 145 volunteers
had been stratified according to region and subsequently ran-
domised to receive either placebo or vaccine. Since three indi-
viduals cancelled their journey, and eight did not fill out the
questionnaire, 134 participants were evaluable. A total of 65
subjects received a placebo and 69 received CVD 103-HgR
(Fig. 1). Except for the category ’duration of stay’ and for
1 Due to changes in the law regarding the use of genetically modified
products, the study was temporarily put on halt, pending the outcome of
an investigation of the vaccine and the study design. Though the trial was
allowed to continue, the study was terminated based on the results of the
interim analysis.
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Fig. 1. Flow diagram of the progress through the phases of the randomised trial.
the subcategory ’accommodation with locals’, demographic
data and distribution of risk factors for diarrhoea did not dif-
fer significantly between the two groups (Table 1). Vaccine
tolerability was excellent, with 10% of vaccines reporting
mild abdominal discomfort compared to 17% in the placebo
group.
3.1. Primary endpoint
Of the 134 participants, 66 (49%) reported at least one
episode of diarrhoea. No significant difference was observed
between the placebo and vaccination groups with respect
to attack rate (Table 2). No significant differences existed
Table 1
Base-line characteristics of the study population consisting of 134 Dutch travellers
Parameter Placebo (n= 65) Vaccine (n= 69) All (n= 134) p-value
Average age (years)a 38.7 40.3 39.5 NS
Sex (m/f)a 26/39 36/33 62/72 NS
Interval from vaccination to departure (days)a 18.0 17.1 17.6 NS
Average duration of stay (days)a 22.5 20.1 21.3 0.01
Travel destination (n)
Indonesiab 30 28 58 NS
Indiab 12 17 29 NS
Thailandb 14 13 27 NS
Gambia + Senegalb 9 11 20 NS
Prior travel to (sub)tropics (n)b 45 48 93 NS
Antacid medication (n) 1 0
Accommodation (n)
Large hotelb 20 27 47 NS
Budget hotelb 18 13 31 NS
Guesthouseb 13 21 34 NS
Camping 0 2 2
With localsb 14 6 20 0.04
Followed advise on diet and hygiene (n)b NS
Always 27 34 61
Sometimes 38 35 73
Use of antibiotic prior to onset of TD 1 0 1
Placebo: heat-killed Escherichia coli-K1; vaccine: a single dose of CVD 103-HgR live oral cholera vaccine; mean duration of stay abroad: 20 days, range
(7–30) days; NS: not significant.
a Statistics: univariate analysis comparing placebo group to vaccine group.
b χ2-test comparing placebo group to vaccine group; p-value significant at <0.05.
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Table 2
Attack rate of travellers’ diarrhoea (TD) among 134 Dutch travellers
Parameter No. (%)
Placebo (n= 65) Vaccine (n= 69) Total (n= 134) p-value ETEC associated diarrhoea (n= 17)
Subjects with TD 30 (46) 36 (52) 66/134 (49) NS
Subjects with TD specified for
Indonesia (n= 58) 15 18 33/58 (50) NS 11/33 (33)
India (n= 29) 5 9 14/29 (48) NS 4/14 (29)
Thailand (n= 27) 6 3 9/27 (33) NS 0/9 (0)
Gambia and Senegal (n= 20) 4 6 10/20 (50) NS 2/10 (20)
Placebo: heat-killed Escherichia coli-K12; vaccine: a single dose of CVD 103-HgR live oral cholera vaccine; mean duration of stay abroad: 20 days, range
(7–30) days; statistics: χ2-test comparing placebo group to vaccine group; p-value significant at <0.05; NS: not significant.
Table 3
Detection of enterotoxigenic Escherichia coli in faeces of 134 Dutch travellers to (sub)tropical destinations
Parameter No. (% of analysed samples)
Travellers’ diarrhoea No travellers’ diarrhoea All (n= 134)
Placebo (n= 30) Vaccine (n= 36) Total (n= 66) Placebo (n= 35) Vaccine (n= 33) Total (n= 68)
Stool samples analysed 28 31 59 14 14 28 87
Sample negative for ETEC 21 (75) 21 (68) 42 (71) 13 (93) 11 (79) 24 (86) 66 (76)
Sample positive for ETEC 7 (25) 10 (32)* 17 (29) 1 (7) 3 (21) 4 (14) 21 (24)
ETEC LT only 1 0 1 0 0 0 1
ETEC LT and ST 2 3 5 1 3 4 9
ETEC ST only 4 7 11 0 0 0 11
Placebo: heat-killed Escherichia coli-K12; vaccine: a single dose of CVD 103-HgR live oral cholera vaccine; Mean duration of stay abroad: 20 days, range
(7–30) days; samples: diarrheic stool specimens taken during episodes of diarrhoea, non-diarrheic specimens taken a maximum of 3 days after return home;
statistics: χ2-test comparing placebo group to vaccine group; p-value significant at <0.05.
* p > 0.05.
regarding number of episodes, time to first onset, duration or
severity of diarrhoea (Table 4). In the placebo group 30 of
65 subjects (46%) developed diarrhoea, compared to 36 of
69 (52%) in the group of vaccines (Table 2). Comparison
of the two groups, stratified according to travel destina-
tion, did not yield significant differences either (Table 2).
The study was ended prematurely, because the primary end-
point, a vaccine efficacy of at least 50%, would not be
reached by continuing the study until 200 subjects were
included.
Table 4
Severity, number of episodes and duration of travellers’ diarrhoea (TD) in 134 Dutch travellers to (sub)tropical destinations
Parameter No.
ETEC associated diarrhoea All diarrhoea
Placebo (n= 7) Vaccine (n= 10) Toxin Placebo (n= 30) Vaccine (n= 36)
LT ST LT and ST
Severity of episode of TDa
2 stools/day 1 1 0 1 1 10 11
3–6 stools/day 6 3 1 5 3 15 16
>6 stools/day 0 6 0 5 1 5 9
Number of episodes of TDa
1 episode 6 9 23 20
2 episodes 0 1 5 12
3 episodes 1 0 2 4
Mean duration (days) [range]a 2.7 [1,11] 3.7 [1,10] 2.5 [1,14] 4.1 [1,24]
Median interval to onset of TD (days) [range]b 5 [4,17] 15 [5,23]* 9 [4,25] 9 [3,25]
Placebo: heat-killed Escherichia coli-K12; vaccine: a single dose of CVD 103-HgR live oral cholera vaccine; mean duration of stay abroad: 20 days, range
(7–30) days; a separate episode of TD is defined as an episode occurring after five consecutive days without diarrhoea.
a Statistics: χ2-test comparing placebo group to vaccine group.
b Mann–Whitney U-test comparing placebo group to vaccine group.
* p= 0.043.
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3.2. Secondary endpoint
Analysis could be performed on 59 stool samples obtained
from the 66 participants who had reported an episode of diar-
rhoea. In the placebo group ETEC was isolated from 7 of
28 samples (25%), compared to 10 of 31 samples (32%) in
the vaccine group (Table 3). The majority of sweeps (65%)
were only positive in the PCR detecting the ST-genes. In the
placebo group 4 sweeps contained only ST-, 2 LT/ST- and 1
LT-genes. For the vaccine group this was 7, 3 and 0, respec-
tively (Table 3). This means that per 100 travellers, only 4.6
experienced an episode ofLT–ETECorLT/ST–ETECassoci-
ated diarrhoea. For all travellers, the (detected) incidence rate
of ETEC associated TD was 11% in the placebo group and
15% in the group of vaccines. Travellers to Indonesia expe-
rienced the highest incidence of ETEC associated diarrhoea
(33%), followed by travellers to India (29%) andWest-Africa
(20%).NoETECdiarrhoeawas found inpeople visitingThai-
land (Table 2). The median time from departure to onset of
ETEC-associated diarrhoea was shorter in the placebo group
(5 days, range 4–17 days) compared to the vaccine group
(15 days, range 5–23 days) (p= 0.043) (Table 4). Six of 7
subjects from the placebo group developed diarrhoea within
12 days compared to 4 of 10 vaccinated travellers. However,
there was no difference in time from departure to onset of
diarrhoea when all TD were taken into account.
Of the samples obtained from travellers who had not suf-
fered an episode of diarrhoea, the first 28 were analysed for
ETEC. In the placebo group 1 of 14 contained ETEC, com-
pared to 3 of 14 in the vaccine group (Table 3).
4. Discussion
Interim analysis of 134 travellers to different tropical
destinations failed to demonstrate a 50% protective efficacy
of CVD 103-HgR live oral cholera vaccine against all-cause
travellers’ diarrhoea. In addition, no significant differences
between placebo and vaccine group were found with regard
to time of first onset, duration, severity or recurrence of TD.
A vaccine-induced protection against TD of at least 50%was
chosen as primary endpoint because we assumed that a lower
protection rate would not be relevant to clinical practice.
The study was not continued until all 200 participants were
included because a statistical significant difference would
not have been reached with an attack rate of TD of 46%
in the placebo group, even in the unlikely event that all
additionally included vaccinated travellers were protected
against diarrhoea.
Most travellers from the vaccine group developed ETEC-
associated diarrhoea after two weeks. Therefore, this study
does not exclude a short-lived protection of CVD 103-HgR
against TD specifically caused by ETEC. The duration of
protection was much shorter than observed for BS-WC (3
months) in a field trial in Bangladesh [11]. However, because
of the high incidence of LT–ETEC and LT/ST–ETEC diar-
rhoea in this country, it is likely that BS–WC had boosted
pre-existent immunity against ETEC resulting in longer pro-
tection. Further studies should confirm our observation and
evaluate whether a second oral dose of CVD 103-HgR could
boost the primary response and prolong protection.
Several potential limitations of this study require com-
ment: (1) the detected incidence of LT-associated diar-
rhoea was much lower than expected. Only 4.6 subjects
per 100 travellers experienced an episode of LT–ETEC or
LT/ST–ETEC associated TD. The vaccine’s protective effi-
cacy is based on the putative production of cross reacting
antibodies against LT. The low incidence of LT–ETEC asso-
ciated diarrhoea may have limited the power of this study
to demonstrate a protective effect of CVD 103-HgR on inci-
dence, duration and severity of LT–ETEC or LT/ST–ETEC
associated TD; (2) the preservation of the stool sample in
a faecal transport medium may have adversely affected the
recovery of ETEC. Thiswould result in an underestimation of
the true incidence of ETEC-associated diarrhoea. However,
E. coli can be recovered from the faecal transport medium
up to 49 days after inoculation in the laboratory [18–20].
The mean (±S.D.) interval between collection and micro-
biologic analysis in this study was 19 (±7.6) days (range
7–34 days). Furthermore, the attack rate of ETEC associ-
ated diarrhoea according to travel destination in the present
study was in accordance with published literature [2,4,6].
Finally, PCR detection of LT- and ST-genes in sweeps of the
complete bacterial growth is far more sensitive than the con-
ventional DNA-probe hybridisation of E. coli like colonies
[7,21]. Therefore, we do not think that the incidence of ETEC
associated diarrhoea was underestimated; (3) seroconversion
of the participants for anti-cholera toxin or anti-heat-labile
enterotoxinwas not documented in this study.No doubts exist
concerning the placebo, as it has been proven not to elicit an
antitoxin antibody response [22]. The biological activity of
the vaccine was extensively tested in the laboratory prior to
supervised administration. Dosage and method of delivery
were similar to those known to induce an anti-cholera toxin
antibody response in 72–83% of vaccinated healthy Swiss
or American volunteers 21 days after vaccination [14]. The
mean interval from vaccination to departure was 17.1 days
allowing enough time to mount an immune response; and
(4) other enteropathogens than ETEC have not been looked
for. Several studies have found mixed infections with other
pathogens along with ETEC in stools of travellers affected
by TD [6,12,24]. CVD 103-HgR may not protect against TD
caused by such mixed infections.
Remarkably 65% of all detected ETEC strains isolated
fromstool specimens of subjectswithTDwere sole producers
of ST. Furthermore, none of the asymptomatic participants,
whose specimens were analysed, carried ST–ETEC. This
suggests that ST–ETEC is more pathogenic than LT–ETEC
or LT/ST–ETEC.
In summary, a 50% protective efficacy against TD could
not be demonstrated for CVD 103-HgR live oral cholera vac-
cine. This may be due to the low incidence of LT-producing
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ETEC strains. The study does not exclude a short-lived pro-
tective effect against ETEC-associated TD. However, the
small sample size, lack of antibody-response measurements
and selective testing of faeces, limit the predictive power.
Future studies attempting to prevent TD through vacci-
nation may focus on ETEC, as it remains the most com-
mon causative pathogen [5,6,7], but should target a broader
range of strains, because ST–ETEC seems to have a higher
incidence than suggested in earlier studies [8,9,23]. Recent
studies have done just that by developing vaccines including
colonization factor antigens expressed by ETEC [24]. Fur-
thermore, it is recommended that future trials stating attack
rate of TD as a primary outcome should include large num-
bers of travellers, or limit the investigation to countries for
which detailed data concerning aetiology of TD is available.
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a b s t r a c t
For global eradication of poliomyelitis, inactivated poliovirus vaccine (IPV) needs to become available in
all countries. Using fractional-doses (reduced-doses) may impact affordability and optimize the utiliza-
tion of the production capacity. Intradermal administration has the potential to lower the dose without
reducing immunogenicity. A needle-free jet injector may be a reliable way to administer vaccines intra-
dermally. The primary objective of this randomized controlled trial was to compare the immunogenicity
and tolerability of fractional-dose intradermal IPV (Netherlands Vaccine Institute, NVI) booster vac-
cination administered with a jet injector (PharmaJet) to full-dose and fractional-dose intramuscular
vaccination with a needle and syringe. Immunogenicity was assessed by comparing the differences in
the post-vaccination log2 geometric mean concentrations of neutralizing antibodies (GMC) between the
study groups. A total of 125 Dutch adult volunteers with a well-documented vaccination history were
randomized to one of four groups: full-dose intramuscular needle (IM-NS-0.5), full-dose intramuscular
jet injector (IM-JI-0.5), 1/5th dose intramuscular needle (IM-NS-0.1), 1/5th dose intradermal jet injector
(ID-JI-0.1). Vaccination with the JI was less painful (87% no pain) than vaccination with a NS (60% no pain),
but caused more transient erythema (JI 85%, NS 24%) and swelling (JI 50%, NS 5%). Intradermal vaccination
caused less vaccination site soreness (ID 16%, IM 52%). At baseline all subjects had seroprotective antibody
concentrations. After 28 days, GMC were slightly lower in the ID-JI-0.1 group than in the reference group
(IM-NS-0.5). The differences were not statistically significant, but the stringent non-inferiority criterion
(i.e. a difference of 1 serum dilution in the microneutralization assay) was not met. After one year, dif-
ferences in GMC were no longer apparent. In contrast, intramuscular vaccination with a fractional dose
administered with a needle (IM-NS-0.1) was statistically inferior to full-dose intramuscular vaccination.
This shows that intradermal but not intramuscular delivery of fractional-dose IPV may be sufficient for
routine polio vaccination.
© 2013 Elsevier Ltd. All rights reserved.
1. Introduction
The new Global Polio Eradication Initiative has set a target for
complete interruption of the transmission of poliovirus [1]. After
eradication, cessation of oral poliovirus vaccine (OPV) is needed
to prevent outbreaks due to circulating vaccine derived poliovirus
[2,3]. Countries must then decide whether to stop all routine immu-
nization against polio or to continue immunization with inactivated
poliovirus vaccine (IPV). One of the prerequisites for cessation of the
∗ Corresponding author at: Department of Infectious Diseases, Leiden University
Medical Center, Building 1, C5-P, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Tel.: +31 71 5262613; fax: +31 71 5266758.
E-mail address: d.soonawala@lumc.nl (D. Soonawala).
use of OPV is therefore to make IPV affordable and suitable for use
in developing countries [4]. The worldwide production capacity for
IPV is limited and the current weighted-average purchase price per
dose of vaccine, when purchased by the United Nations Children’s
Fund, is $0.15 for trivalent OPV and approximately $3 for IPV [5].
Strategies to reduce this 20-fold cost increase include intradermal
(ID) delivery of a fractional (reduced) antigen dose, intramuscu-
lar (IM) delivery of a fractional dose, or delivery of fewer doses.
Administering vaccines intradermally is thought to enhance their
immunogenicity because of the high density of antigen presenting
cells in the dermis [6–9]. In a trial in the Philippines, a fractional
dose of IPV administered intradermally with a needle at 6, 10 and
14 weeks and at 15–18 months, induced similar seroprotection
rates but lower antibody titers than full-dose intramuscular IPV
[10].
0264-410X/$ – see front matter © 2013 Elsevier Ltd. All rights reserved.
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Intradermal vaccination with a needle and syringe can be diffi-
cult, particularly in small children. A needle-free jet injector may
be a reliable way to administer vaccines intradermally. It requires
little training and reduces the risk of needle-stick injuries. In a
trial in Oman, a fractional dose of IPV administered intradermally
with a needle-free jet injector (Biojector® 2000) at 2, 4 and 6
months of age induced similar seroconversion rates but lower anti-
body titers than three full intramuscular doses [5]. In a similar
trial in Cuba, in which infants were vaccinated at 6, 10 and 14
weeks after birth, which is a suboptimal immunization schedule
for IPV [11,12], both the seroconversion rates and antibody titers
were lower after fractional-dose intradermal vaccination than after
full-dose intramuscular vaccination [13]. In both trials, parents
preferred administration with a jet injector over injection with a
needle [5,13]. No data are yet available on long-term protection
and booster responses after vaccination with fractional-doses in
infants.
These studies could not distinguish whether the intradermal site
of administration or the lower antigen dosage were responsible for
the lower immunogenicity of fractional-doses, because the study
design did not include a third arm with fractional-dose IPV given
intramuscularly. In anticipation of subsequent trials in infants as
the primary target for polio eradication, this trial was designed to
compare the immunogenicity and safety in adult volunteers with a
well-documented vaccination history of a fractional booster dose of
IPV administered intradermally with PharmaJet injection system,
to both full- and fractional-dose IPV (Netherlands Vaccine Institute,
NVI) injected intramuscularly with a needle and/or jet injector. The
PharmaJet injection system is a handheld spring-powered injector
and therefore suitable for use in developing countries.
2. Methods
2.1. Ethics statement
All participants provided informed consent. The study was
approved by the Dutch ethics committee, the Central Commit-
tee on Research Involving Human Subjects (protocol number
NL29671.000.09; EU Clinical Trials Register EUDRACT 2009-
015175-27; Netherlands Trial Register 2196).
2.2. Study design
This was a single-center, randomized, controlled, non-
inferiority trial conducted at Leiden University Medical Center in
The Netherlands, between August 2010 and February 2012. Sub-
jects were vaccinated between August 2010 and January 2011. The
primary objective was to evaluate the tolerability (vaccination site
and systemic reactions) and to compare the immunogenicity 28
days after vaccination of a fractional booster dose of IPV adminis-
tered intradermally with a needle-free jet injector (ID-JI-0.1), with
standard full-dose intramuscular vaccination administered with a
needle and syringe (IM-NS-0.5). Secondary objectives were (i) to
compare the safety and immunogenicity of full-dose intramuscular
IPV booster vaccination administered with a jet injector (IM-JI-0.5),
with IM-NS-0.5, and (ii) to compare the immunogenicity of ID-
JI-0.1, with fractional-dose intramuscular IPV administered with
a needle and syringe (IM-NS-0.1). Healthy Dutch adult volunteers
who had received exactly 6 combined DTP-IPV vaccinations accord-
ing to the National Immunization Program (i.e. at age 3 months, 4
months, 5 months, 11 months, 4 years and 9 years) were eligible.
Exclusion criteria were: any IPV booster dose after 10 years of age,
any OPV dose.
Photograph 1. PharmaJet Needle-free Jet Injection System for intradermal delivery.
The ID injector used in this study was an investigational version of the FDA 510k-
cleared v1.0 SC/IM device.
2.3. Vaccine and jet injector
Per participant we used one vial of IPV (NVI, lot 814AB, 0.5 mL
per vial, expiration date: 05 Nov 2011) containing formaldehyde-
inactivated poliovirus (strains Mahoney, MEF-1 and Saukett), type
1, 2 and 3: 40:8:32 d-antigen units respectively, and formalde-
hyde: 0.025 mg in phosphate buffer. The jet injector that was used
was the PharmaJet Needle-free Jet Injection System. Separate jet
injectors and single-use needle-free syringes were used for intra-
muscular and intradermal administration. The ID injector used in
this study was an investigational version of the FDA 510k-cleared
v1.0 SC/IM device. Modifications to permit ID delivery included a
smaller main spring, a longer ejection pin to limit syringe fill vol-
ume to 100 L, and the ability to continuously vary the main spring
pressure through the use of spring preload system. With the excep-
tion of orifice diameter modifications, syringes were identical to
SC/IM syringes (Photograph 1).
2.4. Randomization and procedures
The sponsor (NVI) prepared 125 sealed envelopes indicating
allocation to one of the four treatment groups. The envelopes
were numbered in random order using a random number gen-
erator (www.random.org). The study was not blinded. A single
investigator included and vaccinated all participants (D.S.). The ref-
erence group, IM-NS-0.5, received one full-dose vaccination with
IPV (40:8:32 DU in 0.5 mL) administered intramuscularly with a 25-
gauge needle and 1.0 mL syringe. Study group IM-JI-0.5 received
one full-dose (0.5 mL) vaccination administered intramuscularly
with a jet injector. Study group IM-NS-0.1 received one fractional-
dose vaccination with IPV (8:1.6:6.4 DU in 0.1 mL) administered
intramuscularly with a 25-gauge needle and 1.0 mL syringe. Study
group ID-JI-0.1 received one fractional-dose vaccination (0.1 mL)
administered intradermally with a jet injector. Vaccinations were
injected into the deltoid muscle of the right arm, except for intra-
dermal vaccinations, which were injected in the skin overlying the
posterior deltoid (Photograph 2). In all study-groups, we measured
residual moisture, defined as vaccine remaining on, rather than in
the skin, with a quantitative filter paper. Blood samples were taken
at baseline (immediately before vaccination) and at day 7 (6–8),
day 28 (25–31) and day 365 (330–400) after vaccination. For four
days, participants filled out a diary on vaccination site and systemic
reactions and recorded use of medication. Participants measured
the size of vaccination site redness, swelling and induration using
a caliper that was designed to measure the size of skin reac-
tions. Adverse events occurring after four days were collected by
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Photograph 2. Intradermal vaccination in skin overlying the posterior deltoid.
routinely inquiring after health-complaints at the 7- and 28-day
blood collection.
2.5. Immunogenicity assay
The titer of neutralizing antibodies against poliovirus types 1,
2 and 3 was determined by microneutralization assay [14]. Sera
were diluted in 24 two-fold dilution steps and in duplicate. Dilu-
tions were incubated for three hours at 36 ◦C with 100CCID50 (cell
culture infectious dose 50%) of poliovirus type 1, 2 or 3 (strains
Mahoney, MEF-1 and Saukett) followed by an overnight incubation
at 5 ◦C. Then, 2 × 105 Vero cells/mL were added to the serum/virus
mixtures. After a seven-day incubation at 36 ◦C (5% CO2) the results
were read following fixation and staining with a crystal-violet solu-
tion with 5% formalin. The log2 titer was defined as the final serum
dilution giving protection against 100CCID50 of challenge virus in
which no CPE is present, resulting in a completely stained mono-
layer. Titers were converted to IU/mL by comparison with the
titer of an in-house reference serum (IHS) of known potency. The
potency of the IHS in IU/mL was determined by comparison with
the titer of an International Standard Serum (NIBSC code: 82/585)
as described previously [14]. To allow comparison between the
groups, a log2 transformation was performed on the antibody con-
centrations in IU/mL and the mean was calculated which is referred
to as the log2 geometric mean antibody concentration (log2 GMC).
Titers of 1:8 are considered seroprotective and this has been shown
to correspond to 0.080 IU/mL for type 1, 0.0180 IU/mL for type 2 and
0.075 IU/mL for type 3 poliovirus [15].
2.6. Statistical analysis
The primary immunogenicity endpoint was evaluated at day
28, by comparing the differences in the post-vaccination log2 GMC
between group ID-JI-0.1 (minuend) and the reference group, IM-
NS-0.5 (subtrahend). Non-inferiority was to be concluded if the
lower limit of the 95% confidence interval (95% CI) for the difference
did not exceed -1, which corresponds to a difference of 1 serum
dilution in the microneutralization assay. Only if the margin was
not crossed for any of the three poliovirus strains (PV1, PV2, PV3),
the overall verdict was ‘non-inferior’. Based on a standard devia-
tion of the log2 GMC of 2.0, a one-sided alpha of 0.025 and a beta of
0.8, the sample size for each study arm was 30. The non-inferiority
margin was based upon a combination of statistical reasoning and
clinical judgment [16]. We assumed that all participants would
already have a titer well above the level that corresponds to sero-
protection since they had received 6 previous polio vaccine doses
[17,18]. That is why the between-group difference in the log2 GMC
at day 28 was chosen as the primary endpoint for immunogenicity.
GMCs were analyzed in the per-protocol population with t-tests.
Adverse events were described in the intention-to-treat popula-
tion and analyzed with 2 tests. Statistical significance was defined
as a p-value <0.05. Analyses were done with IBM® SPSS®, Statistics,
Version 20.0.
2.7. Role of the funding source
IPV was produced and supplied by the NVI. Funding was pro-
vided by the ministry of Public Health, Welfare and Sport. The
jet injectors and related materials were provided by PharmaJet®,
which has a research and development agreement with NVI to
support clinical trials in kind.
3. Results
A total of 125 adults were randomly assigned to one of four
groups. One subject did not complete the visit at day 28 and was
excluded from immunogenicity analyses, as were four subjects
who followed a different childhood immunization program (Fig. 1).
These five subjects were included in the safety analysis but not in
the immunogenicity analysis. One year after vaccination, 79 sub-
jects submitted an additional sample. The remaining 41 subjects
were not included at this time-point; 20 had received pre-travel
DTP booster vaccinations, 20 were lost to follow-up and 1 had
received chemotherapy. Baseline characteristics are described in
Table 1.
Fig. 1. Trial profile. IM, intramuscular; ID, intradermal; IPV, inactivated poliovirus vaccine; NVI, Netherlands Vaccine Institute.
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Table 1
Demographic characteristics of volunteers assigned to full- (0.5 mL) or fractional-dose (0.1 mL) inactivated poliovirus booster vaccination, injected intramuscularly (IM) or
intradermally (ID), with a needle and syringe (NS) or a jet injector (JI).
Characteristic IM-NS-0.5 (n = 32) IM-JI-0.5 (n = 30) IM-NS-0.1 (n = 31) ID-JI-0.1 (n = 32)
Female sex – n (%) 20 (63) 18 (60) 23 (74) 21 (66)
Mean age – years (SE) 21.1 (0.5) 21.8 (0.8) 21.6 (0.7) 21.5 (0.4)
Mean body mass index (SE) 22.2 (0.4) 22.0 (0.6) 22.4 (0.4) 22.3 (0.5)
Mean skin fold measurement – mm (SE)* 17.6 (1.4) 18.2 (1.6) 19.4 (1.3) 15.0 (1.0)
Current smoker – n (%) 4 (13) 7 (23) 4 (13) 5 (16)
The skin fold was measured at the injection site. Vaccinations were injected into the deltoid muscle of the right arm, except for intradermal vaccinations which were injected
in the skin overlying the posterior deltoid. SE, standard error.
Table 2
Adverse events following administration of full- (0.5 mL) or fractional-dose (0.1 mL) inactivated poliovirus vaccine, injected intramuscularly (IM) or intradermally (ID), with
a needle and syringe (NS) or a jet injector (JI).
IM-NS-0.5 (n = 32) IM-JI-0.5 (n = 30) IM-NS-0.1 (n = 31) ID-JI-0.1 (n = 32)
Vaccine delivery
Pain – n (%) 13 (41) 6 (20) 12 (39) 2 (6)
Vagal reaction 0 0 1 (3) 0
Bleb diameter in mm – median (IQR) NA NA NA 8 (8–8)
Spillage on skin in L – median (IQR) 0 (0–17) 12 (2–45) 0 (0–2) 13 (8–40)
Systemic adverse events
Fever – n (%) 0 0 1 (3) 0
Myalgia – n (%) 2 (6) 3 (10) 4 (13) 3 (9)
Fatigue – n (%) 8 (25) 6 (20) 10 (32) 10 (31)
Headache – n (%) 6 (19) 6 (20) 9 (29) 8 (25)
Vaccination site adverse events
Erythema – n (%) 9 (28) 25 (83)c 6 (19) 28 (88)c
Maximum size in mm – median (IQR) 5 (5–15) 25 (15–35) 5 (5–6) 15 (10–15)
Duration in days – median (IQR) 2 (1–2) 3 (2–4) 1 (1–1.3) 4 (2.3–4)
Swelling – n (%) 0 12 (40)c 3 (10) 19 (59)c
Maximum size in mm – median (IQR) [range] 0 15 (11–33) 10 [5–65] 10 (10–15)
Duration in days – median (IQR) [range] 0 2.5 (2–3) 1 [1,2] 2 (2–4)
Induration – n (%) 3 (9) 11 (37)d 3 (10) 11 (34)d
Maximum size in mm – median (IQR) [range] 10 [5–25] 20 (10–20) 5 [5–65] 15 (10–20)
Duration in days – median (IQR) [range] 2 [2,3] 2 (2–3) 1 [1,2] 2 (1–3)
Soreness vaccination site – n (%) 16 (50) 17 (57) 15 (48) 5 (16)c
Arm stiffness – n (%) 13 (41) 9 (30) 11 (35) 5 (16)d
NA: not applicable. Medians, interquartile ranges (IQR) and ranges pertain to proportions that had the adverse event. p-Values for the comparison with the reference group:
0.09a, 0.002b, <0.005c, 0.02d (2 tests).
3.1. Vaccine delivery and adverse events
Intradermal delivery with the jet injector consistently produced
blebs of 8 mm, which correspond to the diameter of the skin con-
tact ring on the face of the needle-free syringe (Table 2). Vaccine
residual moisture was minimal and more moisture was not associ-
ated with reduced immunogenicity. Of note, the measured residual
moisture after vaccination with the jet injector was sometimes
overestimated, as it also measured liquid adherent to the syringe
face during filling, then transferred to the skin at the time of vac-
cine administration. Vaccination with a jet injector was less painful
than vaccination with a needle (Table 2). Erythema, swelling and
induration were more frequent after use of the jet injector. Soreness
and arms stiffness were considerably less frequent after intrader-
mal delivery with the jet injector than after intramuscular delivery
with either a needle or jet injector (Table 2).
Table 3
Log2 geometric mean antibody concentrations (GMC in IU/mL) at baseline and 7, 28 and 365 days after full- (0.5 mL) or fractional-dose (0.1 mL) intramuscular (IM) or
intradermal (ID) inactivated poliovirus booster vaccination, administered with a needle and syringe (NS) or a jet injector (JI).
IM-NS-0.5 IM-JI-0.5 IM-NS-0.1 ID-JI-0.1
At day 0 (baseline) n = 30 n = 30 n = 30 n = 30
Poliovirus type 1 2.57 (2.04–3.11) 2.72 (2.12–3.31) 3.42 (2.74–4.11)b 2.98 (2.15–3.81)
Poliovirus type 2 3.12 (2.41–3.82) 3.28 (2.61–3.95) 3.30 (2.61–3.98) 3.58 (2.80–4.36)
Poliovirus type 3 0.87 (0.13–1.61) 0.59 (−0.29–1.47) 1.13 (0.35–1.91) 1.53 (0.63–2.42)
At day 7 n = 30 n = 30 n = 30 n = 30
Poliovirus type 1 5.74 (5.11–6.37) 5.13 (4.55–5.72) 5.25 (4.60–5.89) 5.29 (4.54–6.04)
Poliovirus type 2 6.82 (6.06–7.58) 5.93 (5.31–6.56)b 5.27 (4.47–6.08)a 6.08 (5.46–6.70)
Poliovirus type 3 5.88 (4.60–7.16) 4.62 (3.58–5.67) 3.86 (2.81–4.91)a 4.38 (3.74–5.02)a
At day 28 n = 30 n = 30 n = 30 n = 30
Poliovirus type 1 7.14 (6.45–7.83) 6.35 (5.83–6.86)b 6.06 (5.39–6.74)a 6.94 (6.02–7.87)
Poliovirus type 2 8.13 (7.27–9.00) 7.55 (6.89–8.21) 6.54 (5.70–7.38)a 7.71 (6.88–8.55)
Poliovirus type 3 7.26 (6.32–8.21) 6.44 (5.60–7.28) 5.61 (4.52–6.71)a 6.19 (5.43–6.95)b
At day 365 n = 22 n = 21 n = 17 n = 19
Poliovirus type 1 6.70 (5.87–7.62) 6.52 (5.70–7.34) 5.31 (4.48–6.14)a 6.71 (5.85–7.57)
Poliovirus type 2 5.87 (5.17–6.57) 5.57 (4.78–6.36) 4.44 (3.46–5.41)a 5.95 (5.14–6.76)
Poliovirus type 3 6.53 (5.66–7.40) 6.21 (5.26–7.15) 5.04 (4.10–5.98) a 5.92 (5.21–6.63)
p-Value for the difference in GMC in comparison with reference group (IM-NS-0.5): [0.01–0.05]a, [0.06–0.09]b.
Mean log2 GMC with 95% confidence interval.
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3.2. Immunogenicity
At baseline, all subjects had seroprotective antibody concentra-
tions (Table 3). Baseline concentrations did not differ significantly
between the groups. Seven days after vaccination, GMC increased
for all poliovirus serotypes with a further increase at day 28
(Table 3). Reverse cumulative distribution curves of antibody titers,
before and 28 days after vaccination are depicted in Fig. 2.
The primary immunogenicity endpoint was the between-group
difference in the post-vaccination log2 GMC for each of the three
poliovirus strains. At day 28, log2 GMC did not differ significantly
between group ID-JI-0.1 and the reference group. The difference
between ID-JI-0.1 (minuend) and IM-NS-0.5 (subtrahend) was
−0.20 (95% CI −1.38 to 0.98) for PV1, −0.42 (95% CI −1.64 to 0.82)
for PV2, and −1.07 (95% CI −2.31 to 0.17) for PV3 (Fig. 3). The lower
limit of the 95% confidence intervals crossed −1, meaning that the
pre-defined criterion for non-inferiority was not met. Formally the
result can be classified as inconclusive regarding the question of
non-inferiority [19]. Skin fold measurement, body mass index and
spillage were not associated with the magnitude of the immune
response (data not shown).
At day 28, log2 GMC were significantly lower in group IM-NS-
0.1 (minuend) than in group IM-NS-0.5 (subtrahend): −1.08 (95%
CI −2.07 to −0.09) for PV1, −1.59 (95% CI −2.82 to −0.37) for PV2,
−1.65 (95% CI −3.13 to −0.17) for PV3 (Fig. 3). At day 28, log2 GMC
did not differ significantly between group IM-JI-0.5 (minuend) and
group IM-NS-0.5 (subtrahend): −0.79 (95% CI −1.67 to 0.08) for
PV1, −0.58 (95% CI −1.69 to 0.53) for PV2 and −0.82 (95% CI −2.11
to 0.47) for PV3 (Fig. 3).
After one year, GMC remained high in all groups (Table 3). Anti-
body concentrations declined by less than one serum dilution for
PV1 and PV3 and by approximately two serum dilutions for PV2.
The rate at which antibody concentrations declined was similar in
all four groups.
4. Discussion
Intradermal vaccination with a jet injector was less painful
and caused less vaccination site soreness than vaccination with
a needle. The jet injector caused more transient vaccination site
erythema and swelling. This is in line with previous reports
[20]. Fractional-dose intradermal vaccination was immunogenic,
but titers were somewhat lower than after standard full-dose
intramuscular vaccination. The differences were not statistically
significant. After one year, the differences were no longer apparent.
In contrast, intramuscular injection of fractional-dose IPV induced
significantly lower titers than full-dose IPV.
The immunogenicity results are in line with previous stud-
ies in Oman and Cuba [5,13]. They are also in line with another
recent trial in Cuba, in which infants who had not been vacci-
nated before received two ID fractional doses of IPV, delivered with
a jet injector [21]. A single fractional dose produced seroconver-
sion in almost half the infants and a priming response in almost all
of those who did not undergo seroconversion. The authors argue,
that for the post-eradication era, two doses of IPV given at the
ages of 4 and 8 months could suffice. However, in another recent
trial among Indian infants, supplemental fractional-dose ID IPV,
delivered with an investigational PharmaJet injector was signifi-
cantly less effective than full-dose IM vaccination [22]. Excessive
undelivered vaccine as a result of marginal investigational device
performance likely contributed to the low seroconversion and anti-
body titers in the ID group.
Our study shows that fractional-dose intramuscular IPV was sig-
nificantly less immunogenic than full-dose IPV, even when used
as a booster vaccination. Based on this result and the results of
Fig. 2. Reverse cumulative distribution curves of antibody titers at baseline and at
day 28. Dashed lines: baseline titers. Smooth lines: titers at day 28.
other studies, we conclude that dose reduction lowers immuno-
genicity but that fractional-dose intradermal vaccination is more
immunogenic than fractional-dose intramuscular vaccination. The
D-antigen content in IPV is not as superfluous for poliovirus type
3 as it is for type 1 and 2 [23,24]. This may be the reason why the
response to type 3 poliovirus seemed weaker than to type 1 and 2
after intradermal vaccination.
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Fig. 3. Differences in the post-vaccination log2 geometric mean antibody concentration at day 28 in the study groups (minuend) in comparison with the reference group
(IM-NS-0.5) (subtrahend). Mean differences with 95% confidence intervals. Zero indicates no difference. The non-inferiority margin was set at −1 (i.e. one titration step in
the neutralization assay). Only if the margin was not crossed for any of the three poliovirus strains (PV1, PV2, PV3) the overall verdict was non-inferior.
The sample-size in preliminary studies is commonly based on
a rule-of-thumb rather than a formal calculation. By using a non-
inferiority design, we forced ourselves to pre-define the criterion
by which fractional-dose IPV was to be judged vis-à-vis full-dose
IPV. The pre-defined criterion for non-inferiority was not met.
Ideally, one would want to base the primary outcome and non-
inferiority margin on a clinically relevant endpoint such as the
seroprotection rate. As expected, most participants in this study
had baseline titers well above the level that corresponds to sero-
protection. That is why the primary outcome and non-inferiority
margin was based on the log2 GMC. We found that baseline anti-
body concentrations were higher and that the variance in antibody
concentrations was larger than expected at the design stage of the
study. This is exemplified by the fact that, even at baseline the
confidence intervals for the between-group differences in antibody
concentrations exceeded the pre-defined non-inferiority margin of
one log2 GMC difference, i.e. one dilution step in the neutralization
assay.
This study has a number of strengths. Firstly, the study popula-
tion was homogenous and all participants had completed the same
childhood vaccination schedule without any additional booster
vaccinations. This increased the validity of the comparisons. Sec-
ondly, the study design made it possible to distinguish to what
extent the route of administration and to what extent the dose was
responsible for lower immunogenicity of fractional-doses. Further-
more, vaccination technique, residual moisture, bleb size and local
vaccination site reactions were well documented. Lastly, results
were reported in IU/mL, which facilitates comparison with other
studies.
This study also has limitations. First, it was not blinded, which
may have influenced results. Although Simon et al. describe a
method with which blinding of such a trial is possible, this could
not be done in our study, in which we used a different site
for intradermal vaccination than for intramuscular vaccination
[20]. Second, baseline antibody concentrations were higher than
we had expected which influenced the statistical evaluation for
86 | ii. novel vaccines
3694 D. Soonawala et al. / Vaccine 31 (2013) 3688–3694
non-inferiority. Third, the mean baseline antibody concentration
for PV1 was somewhat higher in the group that received fractional-
dose intramuscular IPV. It seems unlikely that this influenced
results in a significant manner, as the immune response to all three
poliovirus strains was weaker in this group. Finally, all vaccines
were delivered by a single user. Although this increases the valid-
ity of the comparisons by minimizing between-user differences in
vaccine delivery, it limits the generalizability to real life practice.
5. Conclusion
Fractional-dose intradermal IPV booster vaccination using a
PharmaJet injection system was well tolerated and immunogenic.
Antibody titers in the fractional-dose intradermal group were
slightly lower than after standard full-dose intramuscular vaccina-
tion. After one year, differences in antibody titers were no longer
apparent. In contrast, one-fifth of a standard dose administered
intramuscularly with a needle was statistically inferior to full-dose
intramuscular vaccination.
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a b s t r a c t
New TB vaccines are urgently needed because of the apparent lack of effect of the BCG vaccine on rates
of adult contagious pulmonary tuberculosis and the risk of disseminated BCG disease in immunocom-
promised individuals. Since BCG appears to protect children, the primary target for vaccine development
is a booster vaccine for adults but such vaccines ideally need to be able to efficiently prime mycobacte-
rially naïve individuals as well as boost individuals previously vaccinated with BCG and those latently
infected with TB. Protective immunity against Mycobacterium tuberculosis depends mainly on the gen-
eration of a Th1-type cellular immune response characterized by interferon-gamma (IFN-) production.
In the present study, we monitored safety and IFN- responses in healthy BCG-vaccinated and prior or
latently TB-infected individuals receiving a novel vaccine composed of the fusion protein Ag85B–ESAT-6
combined with the adjuvant IC31®, administered at 0 and 2 months. Vaccination caused few local or
systemic adverse effects besides transient soreness at the injection site, but it elicited strong antigen-
specific T cell responses against Ag85B–ESAT-6 and both the Ag85B and ESAT-6 components, that could
be augmented by second vaccination. The strong responses persisted through 32 weeks of follow-up,
indicating the induction of a persistent memory response in the vaccine recipients.
© 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Tuberculosis (TB) is caused by Mycobacterium tuberculosis, an
intracellular microorganism that is still considered to be among
the world’s most devastating pathogens. An estimated one third
of the world’s population is infected with TB, and 8–10 million
cases of disease and 2–3 million deaths annually are caused by this
pathogen [1]. Currently, the only widely available vaccine against
TB is BCG, the live attenuated vaccine derived from Mycobacterium
bovis by Calmette and Guérin early last century. BCG has shown to
protect against some childhood forms of TB but the protective effi-
cacy with regard to adult contagious pulmonary tuberculosis varies
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considerably, from 0 to 85% [2]. Adult pulmonary TB is the most
infectious form of the disease and as a consequence, BCG has had lit-
tle impact on the global TB epidemic. Improved second generation
TB vaccines are therefore urgently needed [3].
Multiple new TB vaccines are being developed – which include
recombinant BCG, attenuated M. tuberculosis, and DNA-based vac-
cines as well as recombinant proteins [4,5] and many of these have
reached clinical trials. We recently published the first human phase
I clinical trial data using a molecularly well-defined TB subunit
vaccine, consisting of a hybrid protein of Early Secretory Anti-
genic Target (ESAT-6) and Antigen 85 (Ag85B) [6]. These antigens
are strongly recognized by T cells from TB patients, are strongly
conserved in clinical strains [7] and they have demonstrated pro-
tective efficacy in animal models [8–10]. However, because the
protein component of the subunit vaccine is poorly immuno-
genic, the hybrid protein vaccine was adjuvanted with IC31®, a
novel, two-component adjuvant system composed of the cationic
polyaminoacid KLK and the oligodeoxynucleotide ODN1a [11–13].
This adjuvant was chosen on the basis of its ability to induce strong
0264-410X/$ – see front matter © 2011 Elsevier Ltd. All rights reserved.
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protective immunity in animal models of M. tuberculosis infection
[11], by delivering a TLR9 ligand into the endosomal pathway [14]
after comparison to the results of a substantial earlier adjuvant
screening program [15]. The immunogenicity findings of the first
trial showed that the adjuvanted Ag85B–ESAT-6 vaccine succeeded
in inducing strong and long lasting Th1 cellular immune responses
(>2 years after vaccination in a low endemic region) in volunteers
without detectable prior recall responses to mycobacterial anti-
gens [6]. This is encouraging, given earlier findings that protective
immunity against mycobacteria depends on the generation of a Th1
cellular immune response characterized by the secretion of IFN-,
and that the levels of IFN- appear to correlate with disease and
recovery in TB patients [16,17]. Thus, even though IFN- by itself is
clearly not the only factor required for immunity to M. tuberculosis,
it is universally used as a marker of “vaccine take” [18].
For a TB vaccine that is to be employed in developing countries,
showing safety and efficacy in mycobacterially naïve individuals is
not enough, as globally most individuals have been sensitized by
either prior BCG, by exposure to environmental mycobacteria or by
latent or manifest TB infection. However, as the IC31®/H1 vaccine,
containing both a new synthetic adjuvant and a novel recombinant
protein had no prior data on safety of either component in humans,
we adopted a cautious approach to testing. Therefore, only after the
first clinical trial with the TB subunit vaccine in mycobacterially
naïve individuals was shown to be safe and immunogenic, the vac-
cine was subsequently given to two groups of PPD (purified protein
derivative) positive subjects. The first group included PPD positive
BCG-vaccinated individuals with no known risk of M. tuberculosis
infection and the second group consisted of PPD positive subjects
with prior documented manifest or presumed latent TB infection.
The primary objective of the present phase I trial was to evaluate the
safety of the vaccine and the secondary objective was to evaluate
the immunogenicity in PPD positive individuals.
2. Materials and methods
2.1. Ethics statement
All subjects gave informed consent for blood sampling, X-rays
and tuberculin skin testing after verbal and written information
was provided. The study protocol (EUDRACT No.: 2006-006366-
42, ClinicalTrials.gov Identifier: NCT00929396, LUMC protocol
no.: P07.132), the Investigator’s Brochure and the Investigational
Medicinal Product Dossier were approved by the accredited Ethical
Review Board of LUMC and the relevant national authorities.
2.2. The investigational products
Ag85B–ESAT-6 is the recombinant fusion protein of Ag85B and
ESAT-6, developed and manufactured by Statens Serum Institute
(Copenhagen, Denmark). IC31® is a two-component adjuvant sys-
tem developed by Intercell AG (Vienna, Austria), composed of the
cationic polyaminoacid KLK and the oligodeoxynucleotide ODN1a
in specific molar ratio of 25:1 KLK to ODN1a. KLK is composed of the
amino acids lysine (K) and leucine (L). ODN1a is a single-stranded
oligodeoxynucleotide based on alternating sequences of the nucleic
acids inosine and cytidine. The final products were manufactured
by Statens Serum Institute, in an accredited GMP facility and sup-
plied to the study site as a sterile suspension for injection with a
pH of 7.4. The injected volume was 0.5 ml. The vaccine was ana-
lyzed and released according to documented specifications before
shipment to the clinical site. A GLP compliant repeated dose toxic-
ity study in rabbits was conducted on Ag85B–ESAT-6 + IC31® (LAB
Scantox, study no. 55926) in accordance with the CPMP Note for
Guidance on preclinical pharmacological and toxicological testing
of vaccines for human use (CPMP/SWP/465/95) providing guidance
in the EU as of June 1998.
2.3. Study design and objectives
The study was an open label, single-centre, non-randomized
phase I exploratory trial in PPD positive subjects. Two vaccinations
of 50 g Ag85B–ESAT-6 + IC31® (500 nmol KLK + 20 nmol ODN1a)
were administered intramuscularly in the deltoid muscle, the first
at time 0 of the study and the second at 2 months. The primary
objective was to evaluate safety. The primary endpoints com-
prised sequential monitoring of a standard set of laboratory safety
parameters (such as differential white blood cells, platelets, alanine
aminotransferase, and creatinine), active solicitation for local and
systemic adverse events following vaccine injections, and passive
surveillance for solicited and unsolicited local and systemic adverse
events by scheduled telephone interviews and self-reporting in a
diary for up to 8 months after the first vaccination.
The secondary objective was to evaluate the immunogenicity
of the vaccine. Cell-mediated responses were measured through
detection of IFN- spot-forming cells by ELISPOT and of IFN-
production in supernatants of peripheral blood mononuclear cells
(PBMC) by ELISA, after stimulation with Ag85B–ESAT-6 protein,
or with overlapping peptides of Ag85B and ESAT-6 (representing
the individual components of Ag85B–ESAT-6). Reactivity was also
monitored through detection of IFN- and TNF- levels in plasma
before and 7 days after the first and second vaccination. Finally,
humoral responses were measured by ELISA for total IgG to the
vaccine (Ag85B–ESAT-6).
2.4. Study subjects
The trial population consisted of 20 PPD positive volunteers
divided into two groups: the ‘BCG group’ (BCG) and the ‘TB infec-
tion group’ (TBI). The BCG group consisted of 10 subjects (3 female,
7 male) who had been vaccinated with BCG >2 years before, whose
tuberculin-skin-test (TST) was positive (range 6–15 mm or any doc-
umented value between 6 and 15 mm on medical file in the past),
who did not have active, chronic or past TB disease as confirmed
by chest X-ray at screening, a negative QuantiFERON®-TB Gold In
Tube test and a negative 6-day lymphocyte stimulation test (LST:
as described in [6]). The TB infection group consisted of 10 sub-
jects (4 female, 6 male) who were either known to have been
previously diagnosed with latent TB and whose TST was positive
(≥10 mm, or documented ≥10 mm positive on medical file in the
past), or of subjects with past documented (i.e., clinically mani-
fest) TB infection but with no currently (>2 years) active disease as
confirmed by chest X-ray at screening. According to the inclusion
criteria, subjects with a past or latent TB infection should not have
received treatment/chemoprophylaxis for TB within the preced-
ing 2 years. They should also have evidence of prior M. tuberculosis
infection as assessed by specific antigen recall responses. In the
screening, many persons with documented past or latent TB infec-
tion tested QuantiFERON®-TB Gold negative. Therefore, besides 6
subjects with positive QuantiFERON®-TB Gold test, we selected 4
subjects with documented previous TB infection who did not have
a positive QuantiFERON®-TB Gold test at screening, but who had
positive antigen-specific responses to ESAT-6 or CFP10 as evidences
by a response in the 6-day LST [6].
The general health of all participants was assessed by reviewing
their recorded medical history, and performing a physical examina-
tion, chest radiography, and standard blood (including hepatitis B,
hepatitis C and HIV testing) and urine tests. Exclusion criteria were
having clinically relevant laboratory parameters outside of normal
range, presence of a granulomatous disease (as evidenced by lab-
oratory screening and chest radiography), being vaccinated with a
chapter 8 | 91
2102 J.T. van Dissel et al. / Vaccine 29 (2011) 2100–2109
live vaccine within three months before the first vaccination, use
of immune modulating drugs (e.g., glucocorticosteroids, immuno-
suppressive drugs or immunoglobulins) within the three months
before the first vaccination, hypersensitivity to vaccine compo-
nents, HBV, HCV or HIV sero-positive, pregnant women/planned
pregnancy and/or breastfeeding within the trial period, or partic-
ipation in another clinical trial. For the BCG group, 13 volunteers
were screened and 3 were excluded: one because of an intention
to become pregnant, one withdrew consent and one because of
a positive TST > 15 mm. For the TB infected group, 16 volunteers
were screened and 6 were excluded: one because of an intention
to become pregnant, and 5 because of a negative QuantiFERON®-
TB Gold in association with a negative LST. The median age was
49 (IQR: 24–54) years in the BCG group and 26 (IQR: 21–34) years,
in the TB infected group, respectively. Volunteers were financially
compensated as approved by the Institutional Review Board for the
number and amount of blood and urine samples, inconvenience
with respect to the intramuscular administration and for the time
spent on trial visits and transportation to the study site.
The expected trial duration for each subject was 224 days
(32 weeks or 8 months) following the first vaccination (day 0),
which was preceded by a pre-vaccination screening period of
approximately 10–14 days. The second vaccine dose was admin-
istered 2 months after the first. Each subject was expected to
attend a total of 11 visits during the trial, two of which pre-
ceded the first vaccination. The final visit was planned eight
months after the first and 6 months after the second (and final)
vaccination.
2.5. Safety parameters
Volunteers remained under medical observation for 3 h after
each intramuscular vaccination, to monitor possible immediate
reactions. The volunteers were asked to record any symptoms and
their body temperature in a diary. During the first week after each
vaccination, symptoms and temperature (armpit) were recorded on
a daily basis, thereafter on a weekly basis (the temperature being
recorded in the evening). A medical examination of local reactions
and temperature was performed on days 0, 1 and 7 and 42 after
each vaccination. Extended physical examinations comprising ear,
nose and throat, cardiovascular, pulmonary, neurological, gastroin-
testinal, urogenital and dermatological systems were performed
at screening, just before the second vaccination and 98 and 224
days after the first vaccination. Adverse event recording took place
from day 0 to day 224. On days 14 and 70 a standardized telephone
interview was carried out.
Urine samples and blood sampling for hematologic and bio-
chemistry clinical safety tests were taken before the vaccinations,
1, 7 and 42 days after the first and second vaccination, and 24 weeks
after the last vaccination. All routine laboratory assays were per-
formed by the certified central laboratories at LUMC according to
standard procedures.
Adverse events were described in the Case Record Forms with
onset date, duration, intensity of symptoms (grade I, II or III; i.e.,
mild, moderate, severe), outcome of the event and relationship
(not related, possible, probable or certain related) of the event to
the vaccine. Abnormal laboratory findings were scored for sever-
ity into severity grades 1–4 (based on “Toxicity grading scale for
healthy adults and adolescent volunteers enrolled in preventive
vaccine clinical trials” – FDA 2007 guidelines).
2.6. Quantiferon-TB Gold assay
Blood samples for testing with the QuantiFERON®-TB Gold in-
tube assay were drawn before the first vaccination and at the
last visit and performed according to the manufacturer’s instruc-
tions with the result categorized as positive when the result was
≥0.35 IU/mL.
2.7. PBMC isolation and immunogenicity parameters
Baseline blood samples were collected two weeks before and
on the same day as (i.e., immediately prior to) the first vaccina-
tion, and at 6 weeks of follow-up (i.e., 2 weeks before the second
vaccination), and at weeks 14 and 32. Briefly, 40 ml of heparinized
blood was centrifuged (5 min/322 g), the plasma removed for stor-
age at −70 ◦C and cells resuspended and transferred to Leucosep
filter tubes (Greiner-bio-one) containing 15 ml Ficoll (LUMC phar-
macy #902861). After centrifugation, the fluid phase containing the
PBMCs was removed and washed three times with 45 ml of sterile
PBS (LUMC pharmacy). The PBMCs were aliquoted and stored in
liquid nitrogen in medium (IMDM, Cambrax #BE112-722F) con-
taining 20% fetal calf serum (FCS, PAA Laboratories #A15-043)/
10% DMSO (Sigma #41650) until assaying. Assays were batch-
processed with frozen cells to reduce variation. One ml aliquots
of PBMC were thawed in a water bath at 37 ◦C, supplemented
with 2 ml of 50% FCS/IMDM and centrifuged. PBMCs were pel-
leted, washed with 10 ml of serum-free culture medium (AIMV,
Invitrogen #12055-91), resuspended in 1 ml medium, and counted.
A minimum viability of 80% was considered acceptable for assay
purposes. Assays using PBMC samples from each individual were
performed in a single experiment or on the same day in case of
different assays, to minimize temporal and inter-assay variation.
2.8. Quantifying IFN- spot forming units (SFU) after PBMC
stimulation
To enable the determination of all longitudinal samples of single
volunteers on a single day, limiting as far as possible inter-assay
variability within subjects, it was necessary to start with frozen
samples. In this protocol, cells were thawed and pre-stimulated
for 16–18 h, followed by 24 h in the ELISpot plate. Of note, the
pre-incubation step is done in a different plate, and samples are
transferred to the ELISpot plate to reduce the background in the
ELISpot and enhance the sensitivity of the assay when proteins
or large peptides are used [19]. Briefly, 1 × 106 thawed cells/well
were stimulated in 24 well plates with the same antigens and
concentrations as described below for ELISA. All samples were
assayed in triplicate. Incubation was done overnight in a fully
humidified incubator at 37 ◦C, 5% CO2. Subsequently, cells were
resuspended and divided over 3 wells (250,000 cells/well, for
antigen-stimulated cells, 100,000/well for PHA-stimulated cells)
of a mixed cellulose ester-backed 96 well plate (MAHAS45, Mil-
lipore) which had been pre-coated with anti-IFN--antibody (mAb
1-D1K, Mabtech, Sweden) and blocked with AIMV medium. Plates
were incubated overnight in a fully humidified incubator at 37 ◦C,
5% CO2. The next day biotinylated detector antibody (mAb 7-B6-1,
Mabtech) was added and spots colored with alkaline phosphatase-
conjugated streptavidin (Mabtech, Sweden) and FastTMNBT/BCIP
(Sigma–Aldrich, The Netherlands), all according to the manu-
facturer’s instructions. Substrate incubation was done at room
temperature for 10 min and stopped by rinsing the plates with tap
water. Plates were dried and spots were counted in the Bioreader
3000 pro (BioSys, Germany) using calibrated parameters.
2.9. Quantifying IFN- production (ELISA) after PBMC stimulation
After thawing, 150,000 cells/well were stimulated in triplicate
in 96 well flat bottom plates (Greiner) with medium (AIMV, Invit-
rogen), 4 g/ml PHA (Remel Europe), 5 g/ml PPD (SSI, RT48 for
in vitro use), 10 g/ml Ag85B-ESAT-6 (SSI, GMP grade), an ESAT-6
peptide pool (9 peptides; 5 g/ml of each), or an Ag85B peptide pool
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(28 peptides; 5 g/ml of each). The peptide pools consisted of 20-
mer peptides, with an overlap of 10 amino acids. Every peptide was
elongated at the N terminus with two lysine residues (K) to improve
solubility. Cells were cultured for 6 days in a fully humidified incu-
bator at 37 ◦C, 5% CO2. Supernatants were harvested and stored
at −20 ◦C until performing the IFN- ELISA. For the IFN- ELISA,
MaxisorpTM plates (Nunc) were coated with mAb MD-2 (U-CyTech,
The Netherlands) followed by blocking with 0.2% (w/v) milk pow-
der (Fluka) in PBS (LUMC pharmacy). An IFN- standard (U-CyTech,
The Netherlands) ranging from 5 to 5000 pg/ml was used, and
to control for data consistency an external IFN- reference stan-
dard was included in all assays and demonstrated consistency over
the assays (NIBSC, UK). Supernatants were diluted two-fold in 1%
bovine serum albumin (BSA) in PBS. Following standard and sam-
ple incubation, biotinylated detector pAb (U-CyTech) was added.
The ELISA was developed with streptavidin–horseradish peroxi-
dase conjugate (CLB, The Netherlands) and tetramethylbenzidine
substrate (BioSource, The Netherlands). Substrate incubation was
done for 20 min at 37 ◦C. The reaction was stopped with H2SO4 and
the OD was read at 450 nm.
2.10. Quantifying anti-Ag85B–ESAT-6 specific IgG antibodies in
plasma by ELISA
PolysorbTM plates were coated with 4 g/ml H1 or human serum
albumin (Octalbine, Octapharma) as control for aspecific binding,
followed by blocking with 1% (w/v) BSA (Sigma–Aldrich, UK)/1%
(v/v) tween-20 (Sigma–Aldrich, UK) in PBS. A plasma dilution range
was added to the wells, starting with a 1:12 dilution, followed
by 2-fold dilution steps to 1:24,576 (12 dilutions in total). As a
positive control, plasma from a treated TB patient was used; as
negative control plasma from a healthy individual was used. After
overnight incubation at 4 ◦C, HRP conjugated detector pAb (Dako,
Denmark) was added. Development was done with TMB substrate
(BioSource, Denmark) for 15 min at room temperature. The reaction
was stopped with H2SO4, and the OD was read at 450 nm. Graphs
with dilution factor versus OD450 yielded an S-curve. The anti-
body titre was defined as the dilution factor corresponding with
the midpoint of the linear portion of this curve.
2.11. Quantifying IFN-� and TNF-˛ levels in plasma by ELISA
Plasma was harvested after centrifugation of blood, and stored
at −70 ◦C until performing the IFN- and TNF- ELISA (Sanquin,
Amsterdam). ELISAs were performed according to the instructions
of the manufacturer.
2.12. Statistical analysis
The statistical analysis of the THYB-02 data was performed
by JGConsult, an independent Contract Research Organisation in
accordance with GCP and ICH-Guidelines.
Primary and secondary laboratory endpoints were evaluated
within vaccination groups with respect to change from baseline to
last visit using Wilcoxon signed rank test and between vaccination
groups with respect to differences in change from baseline to end
of trial using Wilcoxon rank sum test. Pairwise comparisons were
conducted using Mann–Whitney. Adverse events were evaluated
descriptively.
No formal sample size calculation was performed in this trial.
A test significance level of 5% was used throughout the study. The
statistical analysis was performed using SAS software (SAS®, Cary,
NC 27513, USA, version 9.2 TS Level 1M0) on Platform Windows
XP PRO Version 5.1.2600. Further subanalyses at SSI to produce the
figures were conducted using Prism 4.0b MacOSX 10.5.8.
Table 1
Adverse events (AE), possibly vaccination-related, all classified as grade I, in BCG
vaccinated and previously or latently TB infected subjects given two intramuscular
injections with the Ag85B–ESAT-6 hybrid protein with IC31® adjuvant, relative to
group size (n/N) or episode relative to persons affected.
Vaccination Subjects
BCG vaccinated TB infected
I II I II
Any local adverse event (n/N) 5/10a 6/10 7/10 6/10
Stiffness 2 3 4 1
Soreness and/or pain at injection site 4 4 5 3
Erythema and/or swelling 1 1 1 5
Nodule at injection site – 2 – 3
Any systemic adverse event (n/N) 2/10 1/10 0/10 0/10
Fever 1 1b – –
Tired and/or malaise 2 1b – –
a Number of subjects affected in each group/number of subjects in group.
b Reactions in same individual, temperature once elevated.
3. Results
3.1. Safety
All 20 subjects completed both vaccinations and the follow-up
period. All subjects with at least one vaccination were included
with all data in the safety analysis. No serious adverse events
occurred in either of the two vaccination groups. In all, 52
local, potentially vaccine-related adverse events and 9 systemic,
potentially vaccine-related adverse events were reported. Local
vaccine-related adverse reactions included stiffness (defined as
injection site movement impairment, n = 6 at first vaccination) and
soreness and/or pain at injection site one day after vaccination
(n = 9 at first vaccination). After the first vaccination such reactions
were noted in about half of individuals in the BCG group and in
the TB infection group (Table 1). After the second vaccination these
reactions were more frequent. Most local adverse reactions were
classified as mild (grades I–II) which means the event did not inter-
fere with daily activities. In the BCG group however, one “injection
site pain” reaction and one “injection site movement impairment”
was classified as grade II, i.e., moderate, and one “injection site
pain” reaction as severe (grade III) i.e., temporarily interfering with
activities. All subjects with local reactions experienced full recov-
ery within a maximum of 4 days. None of the subjects required
analgesics. A small, cold nodule at the injection site was noted in
2 subjects in the BCG group and 3 in the TB infection group. This
was without signs of attendant inflammation: local vesiculation,
axillary lymphadenitis or fistula did not occur, and in all cases, the
nodule had disappeared within one week. The systemic, potentially
vaccine-related adverse events included fatigue (n = 1), malaise and
feeling cold (n = 2) and were mild except for one individual where
fatigue and malaise was classified as moderate.
Extensive follow-up of blood and urine parameters did not
reveal any obvious trends within or differences between the two
vaccination groups, or laboratory abnormalities with respect to
change from baseline that could be related to the vaccinations.
3.2. Immunogenicity: IFN-� ELISPOT and ELISA
Immune responses were evaluated by ELISA and ELISPOT.
Responses were monitored to the Ag85B–ESAT-6 fusion protein,
and also to the two individual components (ESAT-6 and Ag85B).
The data in all cases are shown and analyzed without background
subtraction.
For ELISA, there were no significant differences between any
of the groups with regard to the negative (culture medium only:
median value 8 pg/ml, Interquartile range 1 pg/ml) control or the
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Fig. 1. IFN- production by PBMC as assayed by ELISA (expressed as pg/ml) after stimulation with Ag85B–ESAT-6 hybrid protein or peptide mixes of Ag85B or ESAT-6, in
individuals given an intramuscular injection with the Ag85B–ESAT-6 hybrid protein antigen with IC31® adjuvant, at 0 and 2 months, with a subsequent 32 weeks follow-up.
Subjects had either received a BCG vaccination in the past, or had previously been diagnosed with an M. tuberculosis infection (either latent of manifest) >2 years prior to the
vaccinations (TBI). Vaccination time points are marked by dotted vertical lines. Samples for immune monitoring were taken just prior to (0) the first vaccination, six weeks
after the first vaccination (6), and 1, 6, and 24 weeks after the booster vaccination. Results shown are medians and quartiles of assays performed in duplicate, with medians
significantly different from those of the pre-vaccination bleeds marked (*p < 0.05, **p < 0.01, ***p < 0.0001).
positive control (PHA: median value 15,000 pg/ml, interquartile
range 226 pg/ml) (data not shown). Unlike in the previous study
[6] – but as expected – these mycobacterially exposed individu-
als had detectable immune responses prior to vaccination (Fig. 1,
time point 0). The magnitude of these responses were not sig-
nificantly different between the groups for Ag85B, or the fusion
molecule Ag85B–ESAT-6 (both had p > 0.1), but BCG vaccinees had
a significantly lower response to ESAT-6 pre-vaccination than the
TB infection group (Mann–Whitney, p = 0.002). By 6 weeks post-
vaccination, however, there was no difference between the groups
with regard to their ESAT-6 response (p = 0.7) and in both groups, it
was higher after the booster vaccination than at baseline (p = 0.05).
Although baseline immune responses were higher as compared
to the previous study in mycobacterially naïve individuals, for both
Ag85B and Ag85B–ESAT-6 prior to vaccination, both groups showed
significant increases in IFN- production to these antigens from 6
weeks post-vaccination (p < 0.001 for Ag85B–ESAT-6, p = 0.007 for
Ag85B), and this elevated response was maintained without any
apparent diminution up to 32 weeks after vaccination (Fig. 1).
The same overall pattern was observed when the response
was assessed by ELISpot (Fig. 2): a detectable immune response
to Ag85B and Ag85B–ESAT-6 was found prior to vaccination in
both BCG-vaccinated and TB infected groups, which was efficiently
boosted by the vaccination (p < 0.0001 for Ag85B–ESAT-6, p < 0.001
for Ag85B) in both groups. These p values were calculated using
the 32-week endpoint, but significant increases were also seen at
much earlier time points. As would be expected, the BCG vacci-
nees did not have a significant positive response to ESAT-6 prior
to vaccination (Median response 0 SFU/million, interquartile range
22 SFU) while the TB infected individuals had a substantial response
(median response 198 SFU/million, interquartile range 427 SFU,
p < 0.0001 compared to BCG group). At 32 weeks, post vaccination,
the response to ESAT-6 was significantly (p < 0.0001) higher than
at baseline in the BCG group. The same is true in the TB group,
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Fig. 2. IFN- production by PBMC as assayed by ELISPOT (expressed as spot-forming units per million peripheral blood mononuclear cells) after stimulation with Ag85B–ESAT-
6 hybrid protein or peptide mixes of Ag85B or ESAT-6, in individuals given an intramuscular injection with the Ag85B–ESAT-6 hybrid protein antigen with IC31® adjuvant, at
0 and 2 months, with a subsequent 32 weeks follow-up. Subjects had either received a BCG vaccination in the past, or had previously been diagnosed with an M. tuberculosis
infection (either latent of manifest) >2 years prior to the vaccinations (TBI). Vaccination time points are marked by dotted vertical lines. Samples for immune monitoring
were taken and just prior to (0) the first vaccination, six weeks after the first vaccination (6), and 1, 6, and 24 weeks after the booster vaccination. Results shown are medians
and quartiles of assays performed in triplicate, with medians significantly different from those of the pre-vaccination bleeds marked (*p < 0.05, **p < 0.01, ***p < 0.0001).
though the difference was less pronounced due to higher baseline
responses (p < 0.03).
We also tested the linker region between Ag85B and ESAT-6
to assess if any neo-epitopes were generated and were unable to
detect any responses above background, whether humoral or cell
mediated (data not shown). Thus, for both groups, in both assays,
vaccination with Ag85B–ESAT in IC31® drove either the emergence
of, or – in case of a preexisting response, an increase in – antigen-
specific T cell responses that persisted up to the end of 32 weeks
follow-up.
3.3. Kinetics of the response
While both groups increased their antigen-specific responses
significantly after vaccination (Figs. 1 and 2), it also appeared that
the kinetics of the response were somewhat different. This was
particularly noticeable in the magnitude of the T cell responses
against the hybrid protein at different times between the BCG-
vaccinated (but TB naïve) group and the TB infection group (i.e.,
subjects either with past manifest TB or a clinical history indica-
tive of latent TB infection). Prior to vaccination, the groups did
not respond differently to the Ag85B–ESAT-6 fusion protein or
to Ag85B. However, after vaccination, a relatively stronger T cell
response to Ag85B–ESAT and Ag85B emerged in the TB infection
group, compared to the BCG group, at the earliest time points, as
assessed by ELISPOT (p < 0.001) (Fig. 3). This difference in antigen-
specific ELISpot reactivity between BCG-vaccinated and the TB
infection group remained significant following the second vacci-
nation, until the numbers of IFN- positive cells in the ELISPOT
converged by week 32. If the results from the previous clinical
trial, THYB-01, where the same vaccine was given to individuals
with no prior mycobacterial sensitization (n = 11) [6] are com-
pared with the results from this study, it appears that the ELISpot
response to Ag85B–ESAT and Ag85B in mycobacterially naïve indi-
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Fig. 3. Comparison of median IFN- responses over time in mycobacterially naïve (dotted line: data drawn from [6]) previously BCG-vaccinated individuals (dashed line)
or in individuals previously been diagnosed with an M. tuberculosis infection >2 years prior to the vaccinations (solid line). IFN- production by PBMC was assayed after
stimulation with Ag85B–ESAT-6 hybrid protein or peptide mixes of Ag85B or ESAT-6, in individuals given an intramuscular injection with the Ag85B–ESAT-6 hybrid protein
antigen with IC31® adjuvant, at 0 and 2 months, with a subsequent 32 weeks follow-up. Subjects had either received a BCG vaccination in the past, or had previously been
diagnosed with an M. tuberculosis infection (either latent of manifest) >2 years prior to the vaccinations. Vaccination time points are marked by dotted vertical lines. Samples
for immune monitoring were taken just prior to (0) the first vaccination, six weeks after the first vaccination (6), and 1, 6, and 24 weeks after the booster vaccination. Results
shown are medians of the assays performed in duplicate (ELISA: expressed as pg/ml) or triplicate (ELISpot, expressed as SFU per 106 PBMC), with medians significantly
different between groups at the same time point marked (*p < 0.05, **p < 0.01, ***p < 0.0001).
viduals most resembled that of the BCG group in the present
study.
IFN- responses as assessed by ELISA, however, show a differ-
ent trend, though the differences were not significant through the
course of the study. The TB infection group responded more rapidly
to Ag85B–ESAT and Ag85B in terms of the numbers of cells pro-
ducing IFN- (Fig. 3), but not necessarily in the amount of IFN-
produced. This difference was even more marked for the mycobac-
terially naïve recipients (Fig. 3 and [6]).
For ESAT-6, the pattern was slightly different, with the TBI
group having a significantly higher baseline response (p < 0.001)
prior to vaccination than the two groups with M. tuberculosis
infection as assessed by ELISpot, but this difference diminished
post-vaccination and was not significantly different thereafter.
Again, despite higher levels of ESAT-6-induced IFN- in the ELISA, in
the TBI group, the results were not significantly different between
the three groups (Fig. 3).
These results indicate that after vaccination, all of the groups
respond to vaccination by significantly increasing both the num-
bers of cells producing IFN- and the overall amount of IFN-
produced, but that the kinetics of the response are different – not
only between the groups but also between the different assays.
This is interesting, given the trend (also seen in the prior study
in mycobacterially naïve vaccinees [6]) for the magnitude of the
ELISpot response to decline, even as the magnitude of the ELISA
response increased, suggesting that the nature of the responding
cells may be changing after vaccination, perhaps as a consequence
of the development of long-term immune memory.
3.4. Humoral response to vaccination
With respect to a humoral response to the vaccinations no
increase in anti-Ag85B–ESAT-6 IgG levels was observed after the
first vaccination (p > 0.15) in the BCG group, but a small increase was
seen in the TB group. However, after the booster vaccination, IgG
antibodies reactive against Ag85B–ESAT-6 hybrid protein were sig-
nificantly elevated above base-line by sampling at 14 weeks, in both
groups. Thereafter, antibody levels decreased significantly again
(p < 0.05) both in the BCG-vaccinated and TBI individuals (Fig. 4)
and although in the TBI group, the over all response was greater
and IgG levels remained above baseline at the final visit (32 weeks),
the trend was clearly identical for both groups. There was no clear
correlation at the individual level between the magnitude of IFN-
and IgG responses.
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Fig. 4. IgG antibody production against the Ag85B–ESAT-6 hybrid protein in individ-
uals given an intramuscular injection with the Ag85B–ESAT-6 hybrid protein antigen
with IC31® adjuvant, at 0 and 2 months, with a subsequent 32 weeks follow-up. Sam-
ples for antibody measurement were taken just prior to (0) the first vaccination, six
weeks after the first vaccination (6), and 1, 6, and 24 weeks after the booster vacci-
nation. Vaccination time points are marked by dotted vertical lines. Results shown
are geometric means and SD of the titre, from assays performed in triplicate, with
medians significantly different from those of the pre-vaccination bleeds marked
(*p < 0.05).
3.5. Plasma levels of IFN-� and TNF-˛
Before the first vaccination and the week after each of the
two vaccinations, blood was sampled for measurement of cytokine
levels. In neither of the two groups was TNF- above the limit
of detection (i.e., <5 pg/mL). The same was largely true of IFN-,
although in one instance in one individual in the BCG group, the
level of IFN- detected was just above the limit of detection one
week after first vaccination (data not shown). It can be concluded
therefore, that plasma levels of TNF- and IFN- are weakly – if at
all – increased by vaccination. Consistent with this, plasma cytokine
concentrations were not associated with occurrence or intensity of
adverse effects.
3.6. Infrequent QuantiFERON conversion after vaccination with
H1/IC31®
In the developed world, the QuantiFERON TB Gold test is now
broadly used as a diagnostic assay for detection of TB infection.
To assess the risk of conversion to a positive QuantiFERON TB Gold
after intramuscular administration of the adjuvanted Ag85B–ESAT-
6 vaccine to BCG-vaccinated individuals, the QuantiFERON TB Gold
assay was done before vaccination and 24 weeks after the last vacci-
nation. Test results of all subjects were negative before vaccination
(as per the inclusion criterion in this group); one of the 10 had
a positive response at the end of follow-up indicating that two
injections of the adjuvanted Ag85B–ESAT-6 vaccine can induce a
positive in vitro T cell response to ESAT-6 in a small percentage of
BCG-vaccinated subjects. This is consistent with earlier results in
mycobacterially naïve individuals [6]. In the TB-infected subjects, 6
out of 10 cases were QuantiFERON TB Gold positive before vaccina-
tion; of these, one subject tested negative after the last vaccination,
whereas of 4 with a negative QuantiFERON TB Gold one subject
reacted positively at the end of follow-up, indicative of boosting
of the response by the vaccination. There was no obvious differ-
ence in the magnitude or kinetics of the immune response to any
of the antigens between the QuantiFERON TB Gold converters and
the rest of the group, though the numbers were too small to draw
a definitive conclusion.
4. Discussion
This is the first study of a molecularly well-defined TB sub-
unit vaccine adjuvanted with IC31®, a new adjuvant aimed at
boosting the Th1-type immune reactivity, in BCG-vaccinated indi-
viduals and individuals with prior M. tuberculosis infection. The
findings indicate that intramuscular injection of the SSI-produced
Ag85B–ESAT-6 hybrid protein with adjuvant was safe and well tol-
erated. In TB-infected individuals, a single vaccine dose induced a
strong cellular immune response to the hybrid protein; the strong
reaction to the first vaccination is suggestive of a booster effect from
prior M. tuberculosis exposure. In individuals who had received
prior BCG vaccination, the ELISpot responses after the first vaccina-
tion lagged significantly behind those observed in the TB infected
group, though they did eventually converge. In both groups, T cell
responses were strongest against the Ag85B–ESAT-6 hybrid protein
and Ag85B component, and following a second administration were
sustained or even increased during the 32-week follow-up. The
adjuvanted vaccine thus induced a strong and lasting Th1-type cel-
lular immune response with a significant but perhaps less durable
antibody response against the hybrid protein or its components.
The present study extends previous findings in mycobacterially
naïve individuals that intramuscular injection of Ag85B–ESAT-6
hybrid protein with adjuvant IC31® is safe and well tolerated. In
this study, as in the prior one, no serious adverse events occurred
and systemic adverse events reported were all considered to be
unrelated to the administration of the vaccine. In the two cases in
which such a relation could not be excluded totally, the adverse
events were mild or moderate and disappeared within one day.
The only significant trial-related response that was observed in
about half of the subjects consisted of a feeling of soreness and
pain at the site of the injection, the day after administration of the
vaccine. In most of those affected, the pain at injection site was
generally mild, i.e., grade I, and disappeared within one to two
days, did not hinder function of the extremity nor require anal-
gesics, and was not accompanied by local lymphadenitis, febrile
responses or systemic symptoms. To further evaluate the safety of
vaccination, extensive hematological and biochemical assessments
were conducted before starting, at the time of each of the two
vaccinations, and after completing the long-term follow-up. The
vaccine did not noticeably affect any hematological or biochemical
measurement. Thus, the results of this clinical study demonstrate
that there are no safety concerns associated with the administra-
tion of the subunit vaccine to PPD positive individuals – obviously
within the limitations of any exploratory phase I study, which can
exclude with certainty only very frequent adverse reactions. On
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the other hand, the lack of any significant reactogenicity despite
impressive immunogenicity of the adjuvanted vaccine can only
be considered a breakthrough, given the current paucity of effec-
tive human adjuvants for the induction of cell-mediated immune
responses [20]. Based on these results, a phase I trial to evaluate
safety and immunogenicity in PPD negative volunteers, BCG vacci-
nees and volunteers with previous disease or latent TB infection is
currently ongoing in Ethiopia: the first-ever vaccine phase I trial in
Ethiopia.
The vaccination induced specific and strong Th1-type immune
reactivity to the vaccine antigen that persisted and in many
instances even increased up to 32 weeks following first vaccination.
In M. tuberculosis infected individuals, assessment by ELISpot indi-
cated that a single dose of antigen adjuvanted with IC31® induced
a significant cellular immune response – in general, stronger than
that observed previously in mycobacterially naïve subjects [6] or
in BCG vaccinated subjects, and the response to H1 was further
amplified by booster vaccination. In general, T cell responses were
strongest against the Ag85B–ESAT-6 hybrid protein and secondar-
ily against the Ag85B component and were sustained during a
follow-up, suggesting induction of potent immunological memory.
However, the differences in the kinetics of the response as assessed
by ELISpot and ELISA observed here suggest that the nature of the
immune response is slightly – but perhaps importantly – differ-
ent between the groups, with those assumed to have a high level of
prior exposure to mycobacterial antigens – the TBI group – respond-
ing to vaccination with a rapid increase in the number of cells
making IFN-, but a much smaller increase in the amount of IFN-
 produced. In our previous study we found that individuals with
no prior markers of mycobacterial sensitization responded by more
slowly inducing antigen-specific cells (as assessed by numbers) but
reaching a peak – in terms of IFN- concentration – higher than
that seen in the TBI group [6]. The BCG group, who presumably
fall in between the other two groups in terms of mycobacterial
exposure also fell between them in terms of the difference in the
number of IFN- producing cells compared to total amount of IFN-
produced.
There are no defined surrogate biomarkers of protective immu-
nity in TB. It appears clear that host defense against TB involves
a number of factors, but that it crucially depends on establish-
ment of a Th1-type immune response [21,22]. IFN- in particular
appears to be essential, and the IFN- response is rapid and robust.
Therefore, the number of IFN--releasing M. tuberculosis antigen-
specific T-cells and the amount of IFN- released – even though
imperfect markers – remains widely used as a surrogate marker of
potential vaccine efficacy in TB vaccines [18]. Although the mech-
anism controlling the composition of immune responses to M.
tuberculosis-derived antigens is unclear, it is not unexpected that
individuals with different immunological histories will respond dif-
ferently to re-exposure to antigen. The data presented in Fig. 3
thus underline the importance of looking at vaccine induced immu-
nity using different approaches and using well defined cohorts that
can be differentiated with regard to their history of mycobacterial
exposure.
Consistent with earlier findings in mycobacterially naïve indi-
viduals, the adjuvanted vaccine induced a strong and persistent Th1
cell immune response, with a relatively modest antibody response
against the Ag85B–ESAT-6 protein, increasing after the second
dose. The IgG response, though significant, showed a tendency to
wane that was not observed for IFN- production. This suggests
an initial response heavily biased towards the cell-mediated arm
of the immune response. While this is unusual, it matches results
obtained with this vaccine in mice, where relatively weak humoral
responses were generated alongside high levels of antigen specific
IFN- production [11], across a range of dosing regimens, pos-
sibly due to the apparent targeting of dendritic cells [12]. It is
not clear if this response is specific for the M. tuberculosis anti-
gens used, but if these characteristics of IC31® are confirmed for
other types of vaccines, it may establish this adjuvant as one of
the first adjuvants that may specifically induce a cellular immune
response in humans. This is different from currently approved
adjuvants like aluminum salts and MF59, both of which primar-
ily promote a Th2 or humoral immune response [20,23–25], and
also from the report from von Eschen and colleagues who recently
reported that the mtb72F/AS02A adjuvanted protein vaccine gave
a mixture of both Th1 T cell activity and a humoral response
[26].
ESAT-6 is included in several widely used commercial diagnostic
tests (the QuantiFERON and T.Spot.TB tests) and a positive response
to ESAT-6 due to vaccination may interfere with follow up of poten-
tially M. tuberculosis sensitized/infected patients. In the present
study, vaccination was associated with conversion of the QuantiF-
ERON assay in only one out of ten BCG-vaccinated volunteers. Even
if subsequent trials gave higher levels of ESAT-6 responses, this is
not anticipated to be a major problem: it should be realized that the
employment of in vitro diagnostics for tuberculosis and vaccination
against M. tuberculosis are quite distinct: the former is mostly used
in western, low TB-incidence countries whereas the latter is aimed
primarily towards TB endemic regions. Nonetheless, the interac-
tion between diagnostic tests based on in vitro IFN--production
and the possible impact of the vaccine on the usefulness of the
QuantiFERON assay is being studied in ongoing trials in Ethiopia.
Sustained responses seen here compare well with that induced
by BCG vaccination in adolescents, where waning of the overall
response is already be observed after 12 months [27]. Given the
previous report of long lasting and persistent T cell responses in
mycobacterially naïve individuals, and the present sustained T cell
responses in PPD positive subjects, the Ag85B–ESAT-6 subunit vac-
cine may well be able to overcome what has previously been a
stumbling block in vaccination against TB – the requirement for a
long-lasting memory response [28,29]. Prolonged maintenance of
immune memory elicited by an adjuvanted subunit vaccine is in
good agreement with recent observations from a mouse study of
Ag85B–ESAT-6 in an adjuvant consisting of cationic liposomes, and
suggest that the adjuvants, perhaps through establishment of an
antigen depot and subsequent slow release, or targeting of dendritic
cells [12], may have unique abilities to maintain strong immune
memory [30].
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a b s t r a c t
Here, we report on a first-in-man trial where the tuberculosis (TB) vaccine Ag85B-ESAT-6 (H1) was adju-
vanted with escalating doses of a novel liposome adjuvant CAF01. On their own, protein antigens cannot
sufficiently induce immune responses in humans, and require the addition of an adjuvant system to
ensure appropriate delivery and concomitant immune activation. To date no approved adjuvants are
available for induction of cellular immunity, which seems essential for a number of vaccines, includ-
ing vaccines against TB. We vaccinated four groups of human volunteers: a non-adjuvanted H1 group,
followed by three groups with escalating doses of CAF01-adjuvanted H1 vaccine. All subjects were vacci-
nated at 0 and 8 weeks and followed up for 150 weeks. Vaccination did not cause local or systemic adverse
effects besides transient soreness at the injection site. Two vaccinations elicited strong antigen-specific
T-cell responses which persisted after 150 weeks follow-up, indicating the induction of a long-lasting
memory response in the vaccine recipients. These results show that CAF01 is a safe and tolerable, Th1-
inducing adjuvant for human TB vaccination trials and for vaccination studies in general where cellular
immunity is required.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Tuberculosis (TB) is caused by Mycobacterium tuberculosis
(MTB). A third of the world’s population is infected with MTB, in
2013 there was a global estimated 8.6 million cases of TB and 1.3
million deaths caused by this pathogen [1]. Currently, the only
available vaccine against TB is bacillus Calmette-Guérin (BCG), a
live attenuated vaccine derived from Mycobacterium bovis. BCG pro-
tects against severe forms of childhood TB but its efficacy against
pulmonary TB in adults is highly variable. Therefore, there is an
urgent need for second generation TB vaccines [2,3].
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Several novel vaccines are being explored, among which a
prime-boost strategy using new TB vaccine candidates to boost
BCG is considered a promising strategy [4]. In a recent phase IIb
trial, an experimental vaccine MVA85A (modified vaccinia virus
Ankara expressing antigen 85A) was given to infants who had pre-
viously been BCG-vaccinated, however the MVA85A vaccine failed
to demonstrate efficacy against TB infection as well as TB disease
emphasizing that there is a continued need for developing and test-
ing novel vaccination strategies against TB [5]. We have published
two human clinical trials investigating the Hybrid 1(H1) subunit
vaccine; based on the hybrid protein of Early Secretory Antigenic
Target (ESAT-6) and Antigen 85B (Ag85B) adjuvanted with IC31®
(H1:IC31) [6,7]. These reports demonstrated that the H1:IC31 vac-
cine was safe and generated long-lasting antigen-specific Th1 T-cell
responses against the hybrid protein [6,7].
Here we report on an independent H1 TB vaccine trial in which
the adjuvant IC31® is replaced by the CAF01 adjuvant. CAF01
is a novel two-component liposomal adjuvant system composed
of a cationic liposome vehicle (dimethyldioctadecyl-ammonium
http://dx.doi.org/10.1016/j.vaccine.2014.10.036
0264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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(DDA)) stabilized with a glycolipid immunomodulator (trehalose
6,6-dibehenate (TDB)) which is a synthetic variant of cord fac-
tor located in the mycobacterial cell wall. In addition to acting as
an immunomodulator, TDB also ensures long-term stability of the
DDA liposomes. Based on immunological data as well as physico-
chemical stability data the optimal weight ratio of DDA to TDB was
found to be 5:1 [8]. In animal models, CAF01 promotes a broad
and complex immune response characterized by multifunctional
T-cells with a Th1 profile and possesses the same ability to induce
long-lived immune responses as IC31® presumably through the
establishment of a vaccine depot [8–13]. In preclinical studies,
CAF01 also induced a Th17 response due to TDB signaling through
the C-type lectin receptor Mincle [14]. CAF01 adjuvanted H1 vac-
cine was protective in animal models of TB [11–13,15], but safety
and immunogenicity of a CAF01-adjuvanted vaccine has not yet
been assessed in humans.
We report herein the first phase I clinical trial in human
volunteers employing a CAF01-adjuvanted subunit TB vaccine
(H1:CAF01), with safety as primary endpoint. The secondary objec-
tive of the trial was to evaluate the immunogenicity of H1:CAF01
in humans.
2. Materials and methods
An elaborated description of materials and methods can be
found in the online supplement.
2.1. Ethics statement
All subjects volunteered to participate in the clinical trial and
gave informed consent after verbal and written information was
provided. The trial protocol (EUDRACT No.: 2008-006003-23, Clin-
icalTrials.gov Identifier: NCT00922363, LUMC protocol: P09.111),
the Investigator’s Brochure and the Investigational Medicinal Prod-
uct Dossier were following good clinical practice (GCP) and the
declaration of Helsinki and were approved by the accredited Ethical
Review Board of LUMC and the relevant national authorities.
2.2. The investigational vaccine
CAF01 is a two-component liposomal adjuvant system devel-
oped by SSI [16,8,9,10]. One component, DDA, is a cationic
quaternary ammonium salt and the other component, TDB, is a gly-
colipid. Both components are synthetically manufactured. When
these two components are mixed and rehydrated in the specific
weight ratio 5:1, DDA to TDB, the liposomal adjuvant is named
CAF01. The H1 recombinant fusion protein of Ag85B and ESAT-6, is
developed and manufactured by Statens Serum Institut (SSI, Copen-
hagen, Denmark). H1 sterile solution and CAF01 sterile suspension
were manufactured by SSI, in an accredited GMP facility and sup-
plied to the LUMC pharmacy in separate vials of relevant strengths.
The vaccine was reconstituted by addition of the specified volume
of adjuvant to the antigen concentrate, and injected into the deltoid
muscle with a 25 mm 22–25 Gauge needle in a volume of 0.5 ml.
2.3. Trial design
The trial was an open label, single-center, non-randomized
phase I exploratory trial in mycobacteria-naïve individuals defined
by a negative TST (<10 mm, 2 units RT-23 PPD (SSI, Denmark))
and a negative Quantiferon®-TB Gold In-Tube test (QFT; Qia-
gen, Venlo, The Netherlands). All individuals were HIV negative.
The trial comprised four vaccination groups. Subjects in group
1 received 50 g H1 with no adjuvant, whereas groups 2–4
received the same amount of antigen with 125/25 g, 313/63 g
and 625/125 g CAF01, respectively. In all vaccination groups, the
subjects were vaccinated on trial days 0 and 56. After the orig-
inal trial was completed, a protocol amendment was approved
(CCMO 12.1306/MA/26270, NL26270.000.09) and all trial partic-
ipants were invited to attend a long-term visit 150 weeks after
initial enrolment. Long-term visits were successfully conducted for
31 out of the original 34 volunteers that received 2 vaccinations
within the appropriate time window. Timing of the long-term visit
was on average 150.7 weeks (median 152.1 weeks; range 123–167
weeks) post primary vaccination and is referred to as ‘150 weeks’
throughout the manuscript.
2.4. Trial subjects
The trial population consisted of 38 volunteers, healthy adult
females or males between 18 and 55 years of age who had not been
BCG vaccinated and who did not have active, chronic or past TB
disease, and who had no MTB infection as confirmed by a nega-
tive QFT and a negative TST at screening. The general health of all
participants was assessed by reviewing their recorded medical his-
tory, and performing a physical examination, and standard blood
(including hepatitis B, hepatitis C and HIV testing) and urine tests.
The volunteers were financially compensated as approved by
the Institutional Review Board for the number and amount of blood
and urine samples, inconvenience with respect to the intramus-
cular administration and for the time spent on trial visits and
transportation to the trial site.
2.5. Safety parameters
The subjects remained under medical observation for 3 h after
each intramuscular vaccination, for possible immediate adverse
reactions. During the first week after each vaccination, symptoms
and evening armpit temperature were recorded on a daily basis,
thereafter on a weekly basis. A medical examination of local adverse
reactions and temperature was performed on days 0, 1, 7 and 42
after both vaccinations.
Adverse events were coded into system organ class (SOC) and
preferred terms (PT) according to MedDRA version 10.0 and were
classified into local (loco-regional) and systemic adverse events.
The intensity of adverse events was graded as mild (grade 1/eas-
ily tolerated), moderate (grade 2/sufficient to interfere with daily
activities) or severe (grade 3/preventing normal activity).
The relatedness of adverse events to the vaccination was graded
as not related, possibly related, probably related or certainly
related. Abnormal laboratory findings were scored for severity into
severity grades 1–4 (based on “Toxicity grading scale for healthy
adults and adolescent volunteers enrolled in preventive vaccine
clinical trials” – FDA 2007 guidelines).
2.6. Quantiferon®-TB Gold In-Tube test
QFT testing was done according to the manufacturer’s instruc-
tions and categorized as positive when the result was ≥0.35 IU/ml
at baseline, and at 32 and 150 weeks after the primary vaccination.
2.7. PBMC isolation and immunogenicity parameters
Blood samples for cellular immunity and antibody determina-
tions were collected at baseline and at 1 and 6 weeks after both
vaccinations, and at weeks 32, 52 and 150 post the primary vaccina-
tion. Briefly, 40 ml heparinized blood was centrifuged on Leucosep
tubes (Greiner-bio-one, Austria) containing 15 ml Ficoll (LUMC
pharmacy #902861) (20 min/800 g), after centrifugation plasma
was removed for storage at −70 ◦C and PBMCs were removed and
washed three times with sterile PBS (LUMC pharmacy). PBMCs
were aliquoted and stored in liquid nitrogen in RPMI (Invitrogen
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#22409-015) containing 20% fetal calf serum (PAA Laboratories
#A15-043, Netherlands)/10% DMSO (Sigma #41650). After defrost-
ing a minimum PBMC viability of 80% was considered acceptable
for assay purposes.
2.8. Flow cytometry
PBMCs were stimulated with pools from Ag85B or ESAT-6 pep-
tides for 6 h or left unstimulated before staining for CD3, CD4, CD14,
CD19, CD45RO, IFN-, IL-2, TNF-, IL-22, IL-17A and CD154 (see
online supplement) [18].
2.9. Quantifying IFN- producing cells
IFN- was determined using ELISpot from frozen samples to
enable batch processing of longitudinally collected samples [19,20].
In this protocol, cells were thawed and pre-stimulated for 16–18 h,
followed by 24 h incubation in the ELISpot plate [10] (see online
supplement).
2.10. Multiplex analysis of cytokine release
PBMCs were stimulated 6 days with H1 fusion protein and a
panel comprising cytokines (IFN-, IL-2, IL-4, IL-10, IL-13, IL-17A,
IL-22, TNF-), chemokines (IP-10, MIG, MCP-1, MIP-1b) and growth
factors (VEGF and GM-CSF) were measured in undiluted cell culture
supernatant samples using a Milliplex multiplex bead assay (see
online supplement).
2.11. Statistical analysis
Clinical data were collected in CRFs, subject diaries and labora-
tory records. The statistical analysis of the data was performed by JG
Consult, an independent Contract Research Organization in accor-
dance with a statistical analysis plan and GCP and ICH-guidelines
and documented in the clinical trial report. Here we report safety
results and safety analysis based on the statistical trial report which
was performed using SAS software (SAS®, Cary, NC 27513, USA,
version 9.2 TS Level 1M0) on Platform Windows XP PRO Version
5.1.2600. Adverse events were evaluated descriptively.
Immunogenicity results shown here were analyzed at SSI and
LUMC using Prism 6.04 for Windows (GraphPad Software, Inc., La
Jolla, CA 92037, USA). Change from baseline to each observed visit
within groups and comparisons between groups were compared
using Kruskal–Wallis test with Dunn’s correction. No formal sample
size calculation was performed in this trial. An alpha <0.05 was
considered significant throughout the trial.
3. Results
3.1. Trial subjects
Of 49 screened subjects 38 were included in the clinical trial.
The safety population consisted of all included subjects. Mean
ages were 20.7, 22.2, 30.5, and 24.6 years in vaccination groups
1, 2, 3 and 4, respectively, overall mean age of 24.9 years, ran-
ging from 18–51 years. Seven subjects (7 females) were vaccinated
with 50 g H1 (no adjuvant), 10 subjects (2 male, 8 female) with
50 g H1 + 125/25 g CAF01 (low adjuvant group), 11 subjects (2
male, 9 female) with 50 g H1 + 313/63 g CAF01 (intermediate
adjuvant group) and finally, 10 subjects (1 male, 9 female) with
50 g H1 + 625/125 g CAF01 (high adjuvant group). A total of 34
subjects were included in the per-protocol population and 7, 9, 10
and 8 from groups 1, 2, 3 and 4, respectively, were included in the
immunogenicity analysis (Fig. 1). Long-term visits, 150 weeks after
initial enrolment, were successfully conducted for 31 out of the
original 34 per protocol trial subjects; 7, 9, 9 and 6 from groups
1–4, respectively.
3.2. Safety results
All 38 subjects with at least one vaccination were included in
the safety analysis. No vaccine related serious or severe adverse
reactions occurred during the trial. Loco-regional injection site
reactions occurred more frequently in those given the CAF01-
adjuvanted antigen, and mainly included stiffness (defined as
injection site movement impairment) and pain at the injection site
one day after the vaccinations (Table 1). Of note, these reactions
were not more frequent after the second vaccination and there
was no significant difference between the three adjuvant doses.
In total, any local adverse reactions were distributed with 6 events
in 2 (29%) subjects in the non-adjuvanted group 1, 26 events in 10
(100%) subjects in group 2, 24 events in 9 (82%) subjects in group 3
and 26 events in 9 (90%) subjects in group 4. None of the subjects
required analgesics and all experienced full recovery within a max-
imum of 4 days. A small, cold nodule at the injection site was noted
in 1 subject in the intermediate CAF01 dose group 3. No signs of
attendant inflammation or local vesiculation, axillary lymphadeni-
tis or fistula did occur, and the nodule had disappeared within one
week. One subject in group 4 (in concomitant treatment with tra-
madol) did not receive the second vaccination due to rash and itch
on knees, hips and elbows, as a relation to the trial vaccine could
not be ruled out. Three individuals observed reactivity at the TST
injection site after vaccination, two were in the mid- and high-dose
adjuvant groups (reporting erythema and induration) and one was
in the group receiving H1 without adjuvant (reporting erythema
and swelling). A fourth individual observed erythema and indura-
tion at the site of the first vaccination after the 2nd vaccination
(Table 1).
Systemic adverse reactions included headache, fatigue, malaise
and fever in one subject given antigen only. Extensive follow-
up of blood and urine parameters did not reveal any obvious
trends within or differences between the three vaccination groups,
or laboratory abnormalities with respect to change from base-
line that could be related to the vaccinations. In the two subjects
who developed a transient fever the day after vaccination, a small




Stimulation with H1, Ag85B and ESAT-6 gave rise to an increased
number of spot forming units (SFU) in all adjuvant groups (Fig. 2A
and B). The highest proportion of responders to vaccination was
seen in the low CAF01 group at week 32 and in the intermedi-
ate CAF01 group at week 32 and 52 (Fig. 2C). At this time point
median responses were 301 SFU/per million PBMC (inter quartile
range (IQR) 111–668 SFU) for H1; 308 SFU (IQR 108–558 SFU) for
Ag85B and 39 SFU (IQR 9.5–136 SFU) for ESAT-6, p < 0.05 (Fig. 2B).
No changes from baseline were seen in the non-adjuvant group at
any time points. Overall, there was a clear trend in the adjuvant
groups that responses increased after the first vaccination and that
a second vaccination further increased the magnitude of responses
(Fig. 2A).
3.3.2. Multiplex analysis of secreted biomarkers
To assess the breadth of the vaccine-induced immune memory,
we performed an exploratory multiplex analysis of 14 cytokines
and chemokines in supernatants of 24 h H1 stimulated PBMCs. We
observed a broad induction of multiple cytokines and chemokines
at both weeks 14 and 32 for the three groups vaccinated with
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Fig. 1. Study overview and flow chart. Overview of volunteers screened and included into the clinical trial. All volunteers vaccinated were included in the safety population,
whereas only those that received both vaccinations were included in the per-protocol population used for immunological analyses.
adjuvanted H1, responses in the intermediate CAF01 group are
presented in Fig. 3 (all groups in supplementary Figure 1). The dom-
inating markers were Th1 associated (IFN-, TNF-, IP-10, MIG,
MIP-1b and GM-CSF), but we also observed a substantial release of
IL-13, but not IL-4. IL-2, IL-10 and IL-17 followed the same kinetic
pattern, but levels were very low (<20 pg/ml) and failed to reach
significance (Fig. 3 and data not shown). No clear pattern emerged
for VEGF, IL-22 and MCP-1 (supplementary Figure 1).
Table 1
Group 1 Group 2 Group 3 Group 4
H1 only H1 + 125/25 g CAF01 H1 + 313/63 g CAF01 H1 + 625/125 ug CAF01
Safety analysis set, n 7 10 11 10
Local adverse reactions; number of subjects (%), total number of reactions
Reactions at site of injection
Injection site stiffness 1 (14) 1 3 (30) 3 9 (82) 13 7 (70) 8
Injection site pain 0 (0) 0 10 (100) 15 2 (18) 2 5 (50) 6
Injection site swelling 0 (0) 0 2 (20) 2 2 (18) 2 4 (40) 5
Injection site erythema 0 (0) 0 2 (20) 2 1 (9) 1 3 (30) 3
Injection site induration 0 (0) 0 1 (10) 1 1 (9) 1 0 (0) 0
Injection site pruritus 0 (0) 0 1 (10) 1 0 (0) 0 1 (10) 2
Injection site bruising 0 (0) 0 1 (10) 1 0 (0) 0 0 (0) 0
Other local reactions
Lymphadenopathy 0 (0) 0 1 (10) 1 1 (9) 1 0 (0) 0
Reactions at site of tuberculin skin testing
Erythema 1 (14) 1b 0 (0) 0 1 (9) 2b,a 1 (10) 1b
Induration 0 (0) 0 0 (0) 0 1 (9) 2b,a 1 (10) 1b
Swelling 1 (14) 2b 0 (0) 0 0 (0) 0 0 (0) 0
Reactions at site of first vaccination
Erythema 1 (14) 1 0 (0) 0 0 (0) 0 0 (0) 0
Induration 1 (14) 1 0 (0) 0 0 (0) 0 0 (0) 0
Any local adverse reaction 2 (29) 6 10 (100) 26 9 (82) 24 9 (90) 26
Systemic adverse reactions; n (%), total number of reactions
Fatigue 2 (29) 3 1 (10) 1 0 (0) 0 3 (30) 3
Malaise 0 (0) 0 0 (0) 0 0 (0) 0 2 (20) 3
Pyrexia 1 (14) 1 0 (0) 0 0 (0) 0 0 (0) 0
Rhinitis 1 (14) 1 0 (0) 0 0 (0) 0 0 (0) 0
Musculoskeletal stiffness 0 (0) 0 0 (0) 0 1 (9) 1 0 (0) 0
Myalgia 1 (14) 1 0 (0) 0 0 (0) 0 0 (0) 0
Headache 1 (14) 1 1 (10) 1 1 (9) 1 2 (20) 3
Pruritus 0 (0) 0 0 (0) 0 1 (9) 1 1 (10) 1
Rash pruritic 0 (0) 0 0 (0) 0 0 (0) 0 1 (10) 1
Any systemic adverse reaction 3 (43) 7 2 (20) 2 3 (27) 4 4 (40) 11
Injection site stiffness reactions (MedDRA PT term Injection site movement impairment) were of mild intensity (easily tolerated) except for one of moderate intensity.
a One subject had erythema and induration at the 1st injection site after the 2nd vaccination.
b Three subjects had erythema, induration and or swelling at the Tuberculin injection site (of original PPD skin testing) after the 1st and/or 2nd vaccination.
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Fig. 2. IFN- spot forming units (SFUs) per 1 million PBMCs measured by ELISpot. (A) Healthy volunteers were given two doses of intramuscular injection of 50 g of
H1 antigen without CAF01 adjuvant (n = 7), low dose CAF01 adjuvant (n = 9), intermediate dose CAF01 adjuvant (n = 10) or high dose CAF01 adjuvant (n = 8). Vaccinations
were done at week 0 and week 8 and PBMC samples were collected at weeks 0, 1, 6, 9, 14, 32, 52 and 150 and stimulated with H1 protein. Interconnected dots represent
median, error bars interquartile range.  indicates vaccination, * indicates p < 0.05 compared to week 0 (Kruskal–Wallis, with Dunn’s multiple comparisons test). (B) Healthy
volunteers were given two doses of intramuscular injection of 50 g of H1 antigen in intermediate dose CAF01 adjuvant (n = 10). Vaccinations were done at week 0 and
week 8 and PBMC samples were collected at week 32. PBMCs were stimulated with H1 protein or Ag85B or ESAT-6 peptide pools and IFN- producing spots quantified
using ELISpot. Responses are presented as median error bars interquartile range. * indicates p < 0.05, **p < 0.005 compared to week 0 (Kruskal–Wallis, with Dunn’s multiple
comparisons test). (C) The proportion of responders to H1 stimulation was defined as the number of H1 induced IFN--producing spots greater than the mean + 2.5 SD of
unstimulated cells and was expressed as percentage of the group size.
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Fig. 3. Cytokine secretion in supernatants of 6 day H1 stimulated PBMCs. PBMCs were collected at baseline and at weeks 14 and 32 after two doses of intramuscular injection
of 50 g of H1 antigen. PBMCs were stimulated with H1 antigen for 6 days, supernatants were collected and cytokines and chemokines were measured using multiplex bead
arrays. Only individuals from the intermediate dose CAF01 adjuvant are shown (n = 10). Responses are presented as individual measurements, * indicates p < 0.05 compared
to week 0 (Kruskal–Wallis, with Dunn’s multiple comparisons test).
3.3.3. Flow cytometry
To further assess the long-term immunogenicity of H1:CAF01,
PBMC samples at week 150 were analyzed by Intracellular flow
cytometry. Compared to the non-adjuvant group, intermediate
and high dose CAF01 groups had increased frequencies of Ag85B-
specific CD4 T-cells producing IFN- and/or IL-2 and/or TNF-
(Fig. 4A). Moreover, intermediate and high dose CAF01 groups
induced significant TNF- production, but only the intermediate
CAF01 group reached significant levels of IL-2 (Fig. 4B) ESAT-6 spe-
cific CD4 T-cells were seen in the adjuvant groups, but responses
were not significantly different from those in the non-adjuvant
group. The most prevalent subset was IL-2/TNF- double producing
CD4 T-cells, and significantly increased frequencies of these cells
were seen in the intermediate and high adjuvant groups compared
to the non-adjuvant group (Fig. 4C). Responses were also detected
in the triple positive subset and TNF- single positive subset, but
neither reached significance. No significant IL-17 responses to anti-
genic stimulation were detected (data not shown). No CD8 T-cell
responses were observed following Ag85B or ESAT-6 stimulation
(data not shown).
3.3.4. Antibody responses
No statistically significant changes from baseline were seen in
any of the vaccination groups in IgG anti-Ag85B-ESAT-6 specific
antibody titer (data not shown, methods in online supplement).
3.3.5. Quantiferon®-TB Gold conversion
QFT was performed at baseline at week 32, and 150 weeks after
the last vaccination. All subjects were negative before vaccination
(as per the inclusion criteria) and none in the non-adjuvanted group
became QFT positive. However introducing CAF01 adjuvant in the
vaccine caused 3 out of 8 (38%) individuals in the low CAF01 group
to convert to a positive test, 6 out of 10 (60%) in the intermediate
CAF01 group and 3 out of 8 (38%) in the high adjuvant group (Fig. 5).
All but two of the QFT converters had reverted to negative at week
150. One QFT converter was lost to the extended follow up.
4. Discussion
This report describes the first clinical trial in humans investigat-
ing the TB vaccine H1:CAF01, combining a new liposomal adjuvant
CAF01 with a well-defined TB subunit vaccine antigen H1. In this
study, the vaccine was safe, well tolerated and generated long-
lasting (3 years) T-cell responses, as monitored by IFN- ELISpot,
intracellular cytokine staining and multiplex analysis of 14 secreted
cytokines and chemokines.
Two vaccinations with H1:CAF01 did not lead to any serious
adverse reactions. All adverse events that were assessed as related
to the vaccination were mild or moderate and disappeared within
days. The main H1:CAF01-related adverse event was stiffness and
pain at the injection site, of mild to moderate severity, mostly
the day after administration of the vaccine. A mild to moderate
transient local reactogenicity of H1:CAF01 was anticipated based
on the findings in nonclinical GLP toxicity studies and was also
observed in previous vaccination studies in humans with the H1
antigen [6,7,21]. The vaccine did not consistently affect hematolog-
ical or biochemical measurements. In conclusion, this clinical trial
found no safety concerns associated with the administration of the
CAF01-adjuvanted vaccine to healthy adults. As this was a phase
I trial, the limitation to this conclusion is the limited number of
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Fig. 4. Ag85B- and ESAT-6-specific CD4 responses in PBMCs collected at week 150 measured by flow cytometry. (A) Long-term visits at week 150 after vaccinations were
successfully conducted for 31 out of the original 34 per protocol trial subjects; 7, 9, 9 and 6 from groups 1–4, respectively. PBMCs were isolated and frequencies of IFN-,
IL-2 or TNF- producing CD4+CD154+T-cells were measured after stimulation with Ag85B or ESAT-6 peptide pools. Responses are presented as box and whiskers, wherein
the box represents median and interquartile range, whiskers range. For each individual, background values (DMSO) were subtracted. Kruskal–Wallis, with Dunn’s multiple
comparisons test, * indicates p < 0.05 compared to the no adjuvant group. (B) Frequency of IFN- (left), IL-2 (middle) or TNF- (right) producing CD4+CD154+T-cells were
measured after stimulation of week 150 PBMCs with Ag85B or ESAT-6 peptide pools. Responses are presented as box and whiskers, wherein the box represents median and
interquartile range, whiskers range. For each individual, background values (DMSO) were subtracted. Kruskal–Wallis, with Dunn’s multiple comparisons test, * indicates
p < 0.05 compared to the no adjuvant group. (C) Patterns of single or combined production of IFN-, IL-2 or TNF- by CD154+CD4+T-cells after stimulation of with Ag85B
peptide pool are shown. The median frequency for each cytokine-producing cell subset is represented by the horizontal line, the interquartile range by the box, and the range
by the whiskers. For each individual, background values (DMSO) were subtracted. Kruskal–Wallis, with Dunn’s multiple comparisons test, * indicates p < 0.05 compared to
the no adjuvant group.
subjects, and we can exclude with certainty only frequently occur-
ring adverse reactions. On the other hand, the lack of any significant
reactogenicity despite the immunogenicity of the CAF01-
adjuvanted vaccine is important, given the paucity of effective
human adjuvants for the induction of cell-mediated immune
responses [22].
Successful vaccination against TB disease would be a major step
to diminish TB disease burden and spread, however an important
challenge remains to determine vaccine efficacy. Despite signifi-
cant investments in the search for an accurate surrogate endpoint
for protection against TB disease, no such biomarker has been
identified. However, there is general consensus that an effective
TB vaccine needs to be able to elicit at least a Th1 cell response
which is essential for bacterial containment [23]. Importantly,
due to the nature of the pathogen, a novel vaccine will need to
induce long-lived protection, most likely through the induction of
central memory T (TCM) cells. Whereas IFN- production is the
classical hallmark of Th1 cell responses and for many years has
been used as the primary measurement in TB vaccine clinical test-
ing, CD4 T-cells with a regenerative potential are typically IL-2
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Fig. 5. Quantiferon TB Gold in tube (QFT) IFN- responses after vaccination with H1 alone and adjuvanted with low, intermediate and high CAF01 dose. Whole blood was
collected in QFT blood collection tubes at baseline, week 52 and week 150 and incubated 16–24 h. Plasma was isolated by centrifugation and IFN- was determined using
ELISA. Responses were classified as positive if the antigen-specific level (Ag-Nil) was ≥0.35 IU/ml.
positive and TCM are usually functionally defined by the expression
of IL-2 and CCR7/CD62L. Two vaccinations of H1:CAF01 induced
a strong long-lasting cellular immune response to H1 and its two
antigen components ESAT-6 and Ag85B. Responses were strongest
to the Ag85B antigen, as observed previously also for H1:IC31
[6,7]. Measured by IFN- ELISpot, the vaccine led to increased
responses at subsequent visits which were sustained also after 150
weeks, demonstrating a clear and long-term vaccine take in all
three adjuvanted vaccine groups, but not in the non-adjuvanted
group, as observed previously also for H1:IC31 [6,7]. This pattern
was confirmed by the broad induction of mainly Th1 associated
cytokines (IFN-, IL-2, TNF-, GM-CSF) and chemokines (MIG, IP-
10 and MIP-1). Three years after vaccination, the intermediate
and high H1:CAF01 dose groups showed significant numbers of
antigen-specific CD4 T-cells secreting IL-2 and TNF-, consistent
with a central memory differentiation state, ready to become effec-
tor T-cells if required [24]. These results are in line with two
recent and closely related TB vaccine trials investigating H1:IC31
in HIV-infected individuals, and H56:IC31 in healthy individuals
with or without latent TB (Klaus Reiter, Gavin Churchyard, Thomas
Scriba, personal communication), and recent results from a phase
I/II trial of the subunit vaccine M72 adjuvanted in the liposome
based AS01E [25]. These results underpin that estimates of vaccine
immunogenicity based on IFN- detection alone will miss other
relevant vaccine-induced immune responses. The prolonged main-
tenance of immune competence elicited by the CAF01-adjuvanted
subunit vaccine is in good agreement with observations from
mouse studies [11,12], and suggests that the adjuvant, likely
through establishment of an antigen depot and subsequent slow
release and targeting of dendritic cells [16], may have particu-
lar abilities to maintain immune memory [26]. In this regard, it
is interesting to note that the development of immune profiles
differ markedly between viral vectored vaccines and adjuvanted
subunit vaccines with the latter having a slowly developing
response dominated by IL-2/TNF- double positive T-cells and with
no tendency of a waned response over the three years observa-
tion time. Although MVA85A induces highly durable Th1 responses,
peak responses were observed already 7 days post-vaccination [27]
and with triple and double positive TNF-/IFN- T-cells resembling
a more effector-memory profile [28]. Whether this difference has
any influence on the overall protective capability remains to be
seen.
Significant amounts of IL-13 were also found in the intermedi-
ate and high dose CAF01 groups. IL-13 is traditionally associated
with Th2-type immune responses and together with IL-4 involved
in inflammatory disorders, however, a number of recent findings
suggest a more complex lineation. Gallo and Katzman identified
IL-13 producing CD4 T-cells in mice co-expressing IFN- and IL-
17 generated both during autoimmune diseases but also upon
immunization [29]. Although the induction of IL-13 in human vac-
cine trials is a relatively unexplored field, IL-13 responses has also
been observed in volunteers receiving the Th1-promoting adjuvant
MPL® [30] and synthetic HIV-1 peptides coupled to a palmytoil tail
was found to induce both IFN- and IL-13 in a phase II trial [31].
These novel data show that IL-13 is an integrated component of a
vaccine-induced Th1/Th17 response and an important role of IL-
13 could be to down-regulate the vigorous inflammatory response
induced by these novel generation adjuvants. We recently iden-
tified IL-13 secretion after vaccination with CAF01-based subunit
vaccines in mice and the cellular origin and the regulatory role in
balancing Th1/Th17 responses is currently under exploration (Diet-
rich, unpublished).
This trial demonstrated promising immunogenicity results,
a good safety profile and no dose dependent adverse events.
Immunogenicity data suggests that the intermediate and high dose
of adjuvant induced superior TCM profile, however this phase 1
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safety trial was not designed for firm conclusion on dose selection.
If these characteristics of CAF01 are confirmed for other disease
targets, this adjuvant would be among the first candidates capa-
ble of inducing long-term memory cellular immune response in
humans. This property is unique and not shared with currently
approved adjuvants like aluminum salts and MF59, both of which
primarily promote a Th2 or humoral immune response [22,32–34].
Based on results from animal models we expected CAF01 adju-
vanted vaccines to also induce antibody responses to the vaccine
antigen, however herein two vaccinations with H1:CAF01 did not
induce significant IgG responses. Similarly, H1 in IC31® also failed
to induce significant H1-specific IgG levels after two injections. We
recently found specific IgG after a third administration of H56:IC31
(Hoff, Andersen, unpublished observation), suggesting that a third
dose is required to induce IgG responses to this particular vaccine
antigen in humans.
ESAT-6 is included in Interferon gamma release assay (IGRA)
diagnostic test kits. In the present trial, similar to previous
H1:IC31® trials, vaccination was associated with a transient con-
version of the QFT in about half of the vaccinated subjects. Induction
of ESAT-6 specific immune responses by vaccination with an ESAT-
6-containing vaccine may very well interfere with current ESAT-6
based diagnostics. However, this may not pose a major diagnostic
problem, as IGRAs are indicated in low endemic settings and TB
vaccines will mainly be used in high endemic settings [35].
In conclusion, we report the first in man studies of the CAF01
adjuvant and demonstrate its safety in a phase I trial. Vaccination
with CAF01 together with the H1 fusion protein resulted in long
lasting T-cell immunity characterized by mainly IL-2 and TNF-
producing T-cells indicating that CAF01 is of relevance for future
human vaccination studies.
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Abstract
Background: Yellow fever vaccination (YF-17D) can cause serious adverse events (SAEs). The mechanism of these SAEs is
poorly understood. Older age has been identified as a risk factor. We tested the hypothesis that the humoral immune
response to yellow fever vaccine develops more slowly in elderly than in younger subjects.
Method: We vaccinated young volunteers (18–28 yrs, N = 30) and elderly travelers (60–81 yrs, N = 28) with YF-17D and
measured their neutralizing antibody titers and plasma YF-17D RNA copy numbers before vaccination and 3, 5, 10, 14 and
28 days after vaccination.
Results: Ten days after vaccination seroprotection was attained by 77% (23/30) of the young participants and by 50% (14/
28) of the elderly participants (p = 0.03). Accordingly, the Geometric Mean Titer of younger participants was higher than the
GMT of the elderly participants. At day 10 the difference was +2.9 IU/ml (95% CI 1.8–4.7, p= 0.00004) and at day 14 +1.8 IU/
ml (95% CI 1.1–2.9, p= 0.02, using a mixed linear model. Viraemia was more common in the elderly (86%, 24/28) than in the
younger participants (60%, 14/30) (p = 0.03) with higher YF-17D RNA copy numbers in the elderly participants.
Conclusions: We found that elderly subjects had a delayed antibody response and higher viraemia levels after yellow fever
primovaccination. We postulate that with older age, a weaker immune response to yellow fever vaccine allows the
attenuated virus to cause higher viraemia levels which may increase the risk of developing SAEs. This may be one piece in
the puzzle of the pathophysiology of YEL-AVD.
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Introduction
The live attenuated 17D yellow fever vaccine is regarded as one
of the safest and most effective vaccines [1]. However, in
immunocompromized individuals yellow fever vaccination can
cause fatal adverse events [2,3]. A hampered immune response
could allow the vaccine virus to replicate unrestrictedly, leading to
vaccine-associated disease that resembles wild type yellow fever
(yellow fever vaccine associated viscerotropic disease, YEL-AVD).
YEL-AVD is fatal in 50% of cases [4]. In the last decade, a series
of these serious and sometimes fatal adverse events following
yellow fever vaccination has been reported [5–11]. The risk of
YEL-AVD is increased for those with a history of thymectomy
[12], male gender [13] and with increasing age. For vaccinees of
60–69 years this risk is estimated to be 1:100.000 doses and for
vaccinees of $70 years it is 2.3–3.2:100.000, which is approx-
imately a 4 and 11 fold higher risk than the risk for young adults
[13,14]. The higher risk of YEL-AVD in elderly travelers has
resulted in a more restrictive policy towards vaccinating travelers
of 60 years and older, also advised by the World Health
Organisation and Centers for Disease Control en Prevention
[15–18]. In this group the risk of serious adverse events following
vaccination is weighed against the risk of infection, using disease
surveillance data of the WHO and reports of yellow fever
outbreaks.
The biological mechanism for the association between adverse
events and older age has not yet been elucidated [4]. Both innate
and adaptive immune responses wane with increasing age [19].
This may allow the attenuated vaccine virus more time to replicate
and cause adverse events in elderly subjects. In this study we
focused on humoral immunity, as this is considered to confer
protective immunity against yellow fever. We tested the hypothesis
that the adaptive immune response to yellow fever vaccine
develops more slowly in elderly than in young subjects.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e27753
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Methods
The protocol for this trial and supporting checklist are available
as supporting information; see Checklist S1 and Protocol S1.
Ethics statement
The protocol and consent forms were approved by the Dutch
Central Committee of Human Research (CCMO) and by the
Medical Ethical Committee of the Leiden University Medical
Center (LUMC) in the Netherlands. The trial was registered under
NTR1040 and ISRCTN42180653, (http://irsctn.org). Written
informed consent was obtained from each participant prior to
inclusion.
Objectives
This study was conducted to determine whether the adaptive
immune response to yellow fever vaccine is slower to develop in
persons of 60 years or older compared with persons aged 18 to 40
years. Primary outcomes were the humoral response to yellow
fever vaccination, measured by Plaque Reduction Neutralization
Test (PRNT), and Yellow Fever 17D (YF-17D) viraemia after
vaccination, which was quantified by real time PCR (qRT-PCR).
Secondary outcomes were adverse events.
Study design and Participants
In this prospective controlled cohort study, participants were
recruited at the Travel Clinic of the Leiden University Medical
Center (LUMC), and Municipal Health Centers of Leiden and
The Hague, the Netherlands. Healthy volunteers aged between
18 and 40 years and eligible for inclusion into the control group
were invited to participate. Participants in the control group were
not necessarily planning to travel to a yellow fever endemic area.
The study group consisted of healthy travelers aged 60 years or
above, who had an indication for yellow fever vaccination based
on their travel destination (National Coordination Center for
Travelers’ Health, LCR) [20]. Individuals who had previously
received yellow fever vaccine or who had a compromised
immunity due to underlying illness or immunosuppressive
medication and those who were pregnant were excluded. The
study was carried out between April 2008 and April 2009.
Vaccinations were administered at the Travel Clinic of the
LUMC by AR. The trial ended because the number of inclusions
was met.
Yellow fever vaccine
The live, attenuated, 17D vaccine used in this study was
manufactured on embryonated chicken eggs according to WHO
regulations and stored according to manufacturer’s guidelines. All
administered vaccines originated from the same vaccine lot
(Stamaril, Lot no B5355, Sanofi Pasteur, France). The vaccine
was administered subcutaneously in the deltoid region of the right
arm.
Data collection
At the time of inclusion, data on demographic characteristics of
the participants were obtained. Blood samples for the determina-
tion of neutralizing antibodies (NA) and YF-17D viraemia were
collected before (day 0), and 3, 5, 10, 14 and 28 days after
vaccination. Participants were asked to document any injection
site and systemic adverse events after vaccination in a three-week
diary. Solicited symptoms were: erythema, pain and swelling at the
site of injection, fever and myalgia. Non-solicited symptoms could
also be reported.
Constant virus – varying serum dilution Plaque Reduction
Neutralization Test (PRNT)
The tests were carried out in 6-well plates (Corning Inc., USA)
using a slightly modified technique described originally by De
Madrid and Porterfield [21]. Briefly, approximately 66105 Vero
cells/mL were seeded per well in 6-well plates and cultured to
obtain a confluent monolayer. Coded sera were complement
inactivated at 56uC for 1 hour. Pre-vaccination sera were tested in
1:16 dilution, to which 100 plaque forming units (PFU) of 17D-YF
were added. Post vaccination sera were tested in two-fold dilutions
starting from 1:4 to 1:1024. One hundred PFU of YF-17D virus
were added to each serum dilution. All test sera were assayed in
duplicate. After 1 hour incubation on ice, the mixtures of virus
and serum were added to the Vero cell monolayers and incubated
for 1 hour at 37uC. An overlay of 26DMEM and 2% agarose was
added. After 5 days of incubation at 37uC, the overlay was
discarded and cell monolayers were stained with crystal violet.
Plaques were counted by eye by a person who had no access to the
sample code. Virus neutralization (VN) was calculated for each
serum dilution (i) with the following formula: VN(i) = 100612(-
number of PFU in diluted post vaccination serum/number of PFU
in pre-vaccination serum (in a 1:16 dilution)). The serum dilution
at which log10 neutralization index 0?7 (80% VN) occurred was
taken as endpoint, as this corresponds to the World Health
Organization (WHO) definition of protection [22]. A reference
serum, obtained from the National Institute for Biological
Standards and Control (http://www.nibsc.ac.uk/) was used for
quantification of International Units per milliliter (IU/ml). In our
hands a 0.7 log10 plaque reduction in 1:10 diluted serum
corresponds to a titer of 0.5 IU/ml [95%CI 0.3–0.8 IU/ml]
[23]. Similar values have been found by others [24]. Geometrical
mean titers (GMT) were compared between the two groups.
Reverse Transcriptase-Polymerase Chain Reaction (RT-
PCR)
Viral RNA was isolated from 200 ml plasma using a MagNa
Pure LC Total Nucleic Acid Isolation Kit (Roche Molecular
Diagnostics, Penzberg, Germany). cDNA was synthesized with
10 ml elute (200 ml total) in a professional ThermoCycler
(Biometra, Germany), and quantitative reverse transcription-
PCR (qRT-PCR) of YFV RNA was performed in a BioRad i-
cycler IQTM real-time PCR detection system (BioRad, Veenen-
daal, The Netherlands). The following YFV specific primers and




FAM (6-carboxyfluorescein) was used as 59-reporter dye and
BHQ (Black Hole Quencher) as 39-quencher dye. In order to
quantify YFV RNA, log10 dilutions of in vitro transcribed RNA
standards were included as standard curves. RNA virus levels were
calculated with standard curves from Cycle threshold (Ct) values to
compare viraemia in both groups quantitatively, and were
expressed as IU/ml.
Statistical methods
Power calculations were based on an expected 80% virus
neutralization of 95% in the control group and 66% in the elderly
group at day 14, based on previous observations at the Travel
Clinic (unpublished data). With an a of 0?05 and b of 0?2, 26
participants per group were needed to confirm a significant
difference under these assumed conditions. To take into account a
possible attrition rate of 15%, 30 participants were included per
Yellow Fever Vaccination of Elderly
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group. We analyzed the between group difference in GMT over
the four time points (day 5, 10, 14, 28) using a mixed linear model.
This model takes into account that each subject had repeated
measurements of the antibody titer over time. More specifically, a
unique identification number for each subject was entered as a
random effect in the model and separate variables for all time
points and for the groups (elderly versus young) were entered as
fixed effects. Antibody titers below the detection threshold were
assigned an arbitrary value of 0.05 IU/ml, which is twofold lower
than the lowest detectable titer (i.e. 0.2 IU/ml). Where appropri-
ate, Chi-square tests were used, and Wilcoxon’s test for non-
parametrical distributed numerical data. Statistical analysis was
performed using a computer-assisted software package (SPSS
version 16.0, SPSS Inc., Chicago, IL).
Results
Population
We enrolled 60 participants, none of whom withdrew
prematurely. In 2 elderly participants, 17D-YF neutralizing
antibodies were already present at day 0. In retrospect, these
participants remembered that they were vaccinated against yellow
fever many years ago. These two individuals were excluded from
further analysis. In both groups 70% were female and 30% had
visited flavivirus endemic countries in the past. The median age of
the younger participants was 21 years (interquartile range 20–22.5)
and of the elderly was 66 years (interquartile range 65–69).
Although we invited persons of 18 to 40 years of age for the
control group, the oldest participant in this group was 28 years old.
Therefore the control group is defined as age 18–30 years. We
recorded the incidence of previous travel to countries that are
endemic for flaviviruses because past infections with other
flaviviruses can cause cross-neutralization in the YF PRNT.
Neutralizing antibody response
At day 3 and 5 after vaccination, no neutralizing antibodies
were found in any of the participants. Ten days after vaccination
seroprotection was attained by 77% (23/30) of the young
participants and by 50% (14/28) of the elderly participants
(p = 0.03, Chi-square test) (figure 1). The average GMT taken over
the four time points after vaccination was higher in the group of
young participants compared with the group of elderly partici-
pants. The average difference in GMT was +1.7 IU/ml (95% CI
1.2–2.4, p=0.007). At day 10 the difference was +2.9 IU/ml (95%
CI 1.8–4.7, p=0.00004) and at day 14 +1.8 IU/ml (95% CI 1.1–
2.9, p=0.02). At day 28 the difference was no longer statistically
significant (+1.5 IU/ml, 95%CI 0.9–2.4, p=0.12). Female
participants in the elderly group had a higher antibody response
10 days after vaccination (female vs. male 0.04 IU/ml (95% CI
0.01–0.15) vs. 0.002 IU/ml (95%CI 0.0005–0.01), p=0.03). Such
a difference between men and women was not seen in the group of
young participants.
Yellow fever vaccine virus RNA
YF-17D viraemia was measured by qRT-PCR at day 0, 3, 5, 10
and 14 (table 1). Viraemia was detected more often in elderly (24/
28, 86%) than in young participants (18/30, 60%) (p = 0.04, Chi-
square test). In addition, the elderly had higher viraemia levels
detectable for longer periods and two had detectable viraemia at
day 10, compared with none of the younger participants (table 1).
Adverse events
Participants reported the occurrence and duration of adverse
events after yellow fever vaccination in a 3-week diary (table 2). In
younger participants vaccination evoked erythema at the site of
inoculation more frequently and for a longer period than in the
elderly participants. In both groups, viraemia peaked at day 5. In
the group of elderly participants the mean viraemia level at day 5
was higher in those who experienced a systemic adverse event
(fever and/or myalgia) than in those who did not (viraemia level
31.3 versus 11.5 IU/ml, 95% CI for the difference 0.4–40.0 IU/
ml), p = 0.05). In the group of young participants mean viraemia
levels did not differ significantly between those who did experience
Figure 1. Neutralizing antibody response against YF-17D in young and elderly participants. Reverse cumulative distribution curves of
yellow fever neutralizing antibody titers at 5, 10, 14 and 28 days after vaccination in 30 young and 28 elderly participants. Antibody titers were
determined with Plaque Reduction Neutralization Tests and reflect the serum dilution at which 80% of virus was neutralized.
doi:10.1371/journal.pone.0027753.g001
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a systemic adverse event and those who did not (viraemia level 6.1
versus 3.9 IU/ml respectively).
Discussion
The main finding of this study was that after primary
vaccination with 17D YF vaccine, elderly persons ($60 years)
were slower to develop an antibody response and had higher
viraemia levels than younger persons. Only half of the elderly
vaccinees had protective antibody levels 10 days after vaccination
compared with over three quarters of younger vaccinees. In
addition, GMT of neutralizing antibodies were significantly lower
at 10 and 14 days after vaccination. The difference was less
pronounced and no longer statistically significant 28 days after
vaccination. Besides showing higher levels of viraemia in elderly
subjects, our data also suggest that the duration of viraemia is
prolonged in these subjects as two elderly participants and none of
the younger participants had detectable viraemia at day 10.
These results provide insight into the etiology of the increased
susceptibility to YEL-AVD after yellow fever vaccination in old
age. Immunosenescence leading to an impaired ability to clear the
vaccine virus has been put forth as a possible explanation for the
increased risk of YEL-AVD in elderly people [26]. However, in a
retrospective study of two large 17D vaccine trials involving 4,532
subjects, neutralizing antibody responses at 30 days after
vaccination were equivalent in younger and elderly subjects.
Due to the retrospective nature of that study, early responses (i.e.
,30 days after vaccination) could not be compared and were
assumed to be equal in both groups. Our results show that this
assumption needs to be modified, as we show that elderly
vaccinees are slower to develop an antibody response than
younger vaccinees. This cannot entirely explain higher age as a
risk factor for YEL-AVD, as viraemia levels peak at day 5, before
the development of neutralizing antibodies. The innate immune
response is probably also an important factor influencing viral
replication after vaccination, as suggested by Silva and colleagues
[27]. We think that the higher viraemia levels in elderly subjects
may be due to a weaker innate immune response. Such a
hampered innate immune response together with a slower
humoral response could allow the YF-17D virus to replicate more
efficiently and for a longer period of time increasing the chance of
YEL-AVD. In this respect it is interesting to note that the
incidence of adverse events at the injection site was lower in elderly
than in younger subjects. If reactions at the injection site are the
result of immune activation, observing less injection site adverse
events in elderly subjects could reflect a weaker or slower innate
immune response in elderly persons. Similar observations were
Table 1. YF-17D viraemia measured by qRT-PCR in the elderly
group compared to young participants.
YF-17D viraemia Young N=30 Elderly N=28 p-value
Day 0 Number
positive (%)
0 (0) 0 (0) -
Day 3 Number
positive (%)
6 (20) 11 (39) 0.1
IU/ml (95% CI) 1.4 (0.9–1.9) 2.9 (2.1–4.4) 0.04
Day 5 Number
positive (%)
16 (53) 23 (82) 0.02
IU/ml (95% CI) 4.8 (0–10.7) 20.8 (10.2–31.5) 0.07
Day 10 Number
positive (%)
0 (0) 2 (7) 0.2
IU/ml (95% CI) - 1.00 (0.8–1.2) -
Day 14 Number
positive
0 (0) 0 (0) -
1 time point positive (%) 14 (78) 12 (50) 0.02
2 sequential time points
positive (%)
4 (22) 12 (50)
YF-17D RNA virus levels were calculated with standard curves from Cycle
threshold (Ct) values and were expressed as IU/ml. Comparison of number of
participants positive for viraemia was calculated by Fisher’s Exact test.
Comparison of quantitative viraemia (only of participants who had measurable
viraemia) was calculated with Student’s t-test. IU = International Units, 95%
CI = 95% Confidence Interval.
doi:10.1371/journal.pone.0027753.t001
Table 2. Solicited adverse events after primary and booster YF-17D vaccination.
Adverse event (AE) Young N=30 Elderly N=28 p-value
Injection site AE Any Yes (%) 9 (30) 4 (14) 0.15
Days to onset (range) 0 (0-2) 0.5 (0-6) 0.6
Erythema Yes (%) 8 (27) 2 (7) 0.05
Days duration (range) 2.5 (1-8) 2 (1-3) 0.4
Swelling Yes (%) 3 (10) 1 (4) 0.3
Days duration (range) 2 (1-5) 2 (-) 1.0
Pain Yes (%) 3 (10) 2 (7) 0.7
Days duration (range) 1 (1-3) 2 (2-2) 0.5
Systemic AE Any Yes (%) 12 (40) 8 (29) 0.4
Days to onset (range) 0.5 (0-4) 5 (1-6) 0.002
Myalgia Yes (%) 12 (40) 6 (21) 0.4
Days to onset (range) 1 (0-6) 5 (1-6) 0.12
Fever Yes (%) 3 (10) 4 (14) 0.6
Days to onset (range) 0 (0-4) 5 (5-6) 0.03
Safety of vaccination expressed in various parameters. Numbers of days are medians. Fever was defined as self-measured temperature above 38 degrees Celsius. P-
values based on Chi-square test and Wilcoxon’s test. AE = Adverse event.
doi:10.1371/journal.pone.0027753.t002
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made in an earlier study of yellow fever vaccination in elderly
subjects [26].
Beside immunosenescence in elderly subjects, other factors
contributing to YEL-AVD have been postulated. For example, it
has previously been suggested that the vaccine virus reverts or
mutates to a more virulent form during replication in a vaccinated
individual, but extensive genetic analyses of the viral strains
extracted from patients with YEL-AVD do not provide evidence
to support this hypothesis [4]. The possibility of host genetic
susceptibility for developing YEL-AVD seems more plausible.
Pulendran and colleagues found a heterozygous CCR5D32
mutation in a patient who suffered from YEL-AVD [28]. Since
the prevalence of heterozygosity of the CCR5D32 mutation in the
general population is 15% [29] and the occurrence of YEL-AVD
among yellow fever vaccinees is significantly less [13,14],
additional host factors (e.g. immunosenescence) must also play a
role in the development of YEL-AVD [30]. On the other hand,
milder forms of YEL-AVD might occur more frequently, but
might not be severe enough to be published, thus introducing
publication bias. Supportive of the hypothesis of genetic
susceptibility, other recently discovered genetic host factors,
including complement protein C1qB and eukaryotic translation
initiation factor 2 alpha kinase 4- (an orchestrator of the integrated
stress response) predicted YF-17D CD8+ T cell responses with up
to 90% accuracy and a B-cell growth factor, TNFRS17, predicted
the neutralizing antibody response with up to 100% accuracy [31].
Although occurrence of YEL-AVD is very rare, fear of this
adverse event could reduce utilization of yellow fever vaccine. An
‘‘International Laboratory Network for Yellow Fever Vaccine-
Associated Adverse Events’’ has been established in 2008, to
complement the USA and the European Yellow Fever Vaccine
Safety Working Groups [32]. Its goal is to determine the
pathogenesis of severe adverse events following yellow fever
vaccination through systematic and coordinated laboratory
evaluation of reported cases. A greater understanding of the
pathogenesis of YEL-AVD may lead to new approaches to prevent
this serious complication. One strategy may be to inject less
vaccine virus in a more immunostimulant manner (e.g. intrader-
mally) [33]. Alternatively, inactivated YF-17D vaccine could be
used to prime the immune response which can be boosted later
with live attenuated YF-17D. This strategy has been successfully
used in mice, hamsters and cynomolgous monkeys [34], and more
recently Monath en co-workers have demonstrated an adequate
antibody response against yellow fever following inactivated yellow
fever vaccine [35].
The findings of our study can have the following practical
implication: in travelers of 60 years and older, it would be prudent
to vaccinate against yellow fever at least 14 days instead of 10 days
before departure to guarantee that all vaccinees have obtained
protective antibody levels.
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Response to 2009 Pandemic Influenza A (H1N1) Vaccine
in HIV-Infected Patients and the Influence of Prior
Seasonal Influenza Vaccination
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Abstract
Background: The immunogenicity of 2009 pandemic influenza A(H1N1) (pH1N1) vaccines and the effect of previous
influenza vaccination is a matter of current interest and debate. We measured the immune response to pH1N1 vaccine in
HIV-infected patients and in healthy controls. In addition we tested whether recent vaccination with seasonal trivalent
inactivated vaccine (TIV) induced cross-reactive antibodies to pH1N1. (clinicaltrials.gov Identifier:NCT01066169)
Methods and Findings: In this single-center prospective cohort study MF59-adjuvanted pH1N1 vaccine (FocetriaH, Novartis)
was administered twice to 58 adult HIV-infected patients and 44 healthy controls in November 2009 (day 0 and day 21).
Antibody responses were measured at baseline, day 21 and day 56 with hemagglutination-inhibition (HI) assay. The
seroprotection rate (defined as HI titers $1:40) for HIV-infected patients was 88% after the first and 91% after the second
vaccination. These rates were comparable to those in healthy controls. Post-vaccination GMT, a sensitive marker of the
immune competence of a group, was lower in HIV-infected patients. We found a high seroprotection rate at baseline (31%).
Seroprotective titers at baseline were much more common in those who had received 2009–2010 seasonal TIV three weeks
prior to the first dose of pH1N1 vaccine. Using stored serum samples of 51 HIV-infected participants we measured the
pH1N1 specific response to 2009–2010 seasonal TIV. The seroprotection rate to pH1N1 increased from 22% to 49% after
vaccination with 2009–2010 seasonal TIV. Seasonal TIV induced higher levels of antibodies to pH1N1 in older than in
younger subjects.
Conclusion: In HIV-infected patients on combination antiretroviral therapy, with a median CD4+ T-lymphocyte count above
500 cells/mm3, one dose of MF59-adjuvanted pH1N1 vaccine induced a high seroprotection rate comparable to that in
healthy controls. A second dose had a modest additional effect. Furthermore, seasonal TIV induced cross-reactive antibodies
to pH1N1 and this effect was more pronounced in older subjects.
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Most guidelines recommend annual influenza vaccination of all
HIV-infected patients [1]. The rationale for this recommendation is
that in the era of widespread use of combination antiretroviral therapy
(cART) influenza is still associated with increased rates of morbidity in
HIV-infected patients [2,3] and that vaccination prevents disease [4,5].
The immunogenicity of adjuvanted 2009 pandemic influenza
A(H1N1) (pH1N1) vaccines in HIV-infected patients and the effect
of recent and past trivalent inactivated influenza vaccines (TIV) is a
matter of current interest. We measured the humoral immune
response to a monovalent MF59-adjuvanted surface-antigen vaccine
containing 7,5 mg hemagglutinin of strain A/California/7/2009
(H1N1) (X-181) (FocetriaH, Novartis) in HIV-infected patients and in
healthy controls. In addition we tested whether recent vaccination with
seasonal TIV induced cross-reactive antibodies to pH1N1.
Methods
Ethics statement
This study was approved by the ethics committee of Leiden
University Medical Center (protocol number 09.187). Subjects
provided written informed consent for participation in the study
and for the use of stored serum samples for the purpose of this
study.
Study design and source population
This was a single-center prospective cohort study at Leiden
University Medical Center in The Netherlands. The pH1N1
vaccine was administered twice to 58 adult HIV-infected patients
(patients) and 44 healthy hospital employees (controls) in
November and December 2009 (day 0 and day 21). Exclusion
criteria were: use of systemic immunosuppressive medication,
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ongoing febrile illness, pregnancy or laboratory confirmed pH1N1
influenza before the first vaccination. At inclusion, participants were
asked whether they had experienced symptoms of influenza in the
two preceding months. In addition, all participants filled out a
standardized diary on symptoms of influenza during the 56 day
follow-up period. Influenza-like illness was defined as sudden onset
of fever of .38uC and cough or sore throat in the absence of other
diagnoses [6]. Serum was collected at baseline, at day 21 (just before
the second dose) and at day 56 (35 days after the second dose). In a
subset of 51 participants (29 patients and 22 controls) serumwas also
collected at day 7. We retrieved stored serum samples of a subset of
51 HIV-infected patients who had been vaccinated with unadju-
vanted 2009–2010 seasonal trivalent inactivated influenza vaccine
(TIV) a month before receiving the first pH1N1 vaccination. In
addition, we retrieved stored samples of 14 of these 51 HIV-infected
patients who had also participated in an influenza vaccination trial
in 2005 [7]. There were no such samples available of the healthy
controls. The stored serum samples were used to measure whether
2009–2010 and 2005–2006 seasonal TIV induced cross-reactive
antibodies to pH1N1 influenza.
Laboratory analysis and main outcome measures
Antibodies to the vaccine strain A/California/7/2009 (H1N1)
and to the seasonal influenza vaccine strains A/NewCaledonia/
20/1999 and A/Brisbane/59/2007 were measured using the
hemagglutination-inhibition (HI) assay, according to standard
methods [8]. Titers below the detection limit (i.e. ,1:10) were
assigned a value of 1:5. Geometric mean titers (GMTs) and
seroprotection rates (defined as HI titers $1:40) were the main
outcome measures. Seroconversion was defined by a post-
vaccination HI titer of at least 1:40 combined with at least a
four-fold increase in titer in accordance to European and
international guidance [9,10].
Statistical methods
The between group difference in GMT taken over the three
time points (day 0, 21, 56) was analyzed using a mixed linear
model. This model takes into account that each subject had
repeated measurements of the HI titer over time. We analyzed
which variables predicted the level of post-vaccination GMT in
the group of HIV-infected patients using a linear regression model
with step-wise introduction of the continuous variables ‘log of the
HI titer at baseline’, ‘age in years’, ‘CD4+ T-lymphocyte count
(cells/mm3)’, ‘nadir CD4+ T-lymphocyte count (cells/mm3)’ and
the categorical variables ‘HIV-1 RNA’ (,20 copy/ml, 20–400
copy/ml, .400 copy/ml) and ‘gender’. Proportions were
compared with Pearson x2 or Fisher’s exact tests as appropriate.
We explored which variables were associated with a baseline HI
titer of $1:40 using a logistic regression model by step-wise
introduction of the continuous variable ‘age’ and the categorical
variables ‘HIV-status’ (i.e. infected or healthy control), ‘gender’,
‘an influenza-like illness prior to inclusion’, ‘vaccination with
2009–2010 seasonal influenza vaccine’, ‘vaccination with 2008–
2009 seasonal influenza vaccine’ and ‘vaccination with 2007–2008
seasonal influenza vaccine’.
In an exploratory analysis we looked at the effect of age on the
level of cross-reactive antibodies to pH1N1 following 2009–2010
seasonal TIV using a linear regression model with step-wise
introduction of the continuous variables ‘age in years’, ‘CD4+ T-
lymphocyte count (cells/mm3)’, ‘nadir CD4+ T-lymphocyte count
(cells/mm3)’ and the categorical variable ‘HIV-1 RNA’. This
analysis was restricted to HIV-infected patients who had received
seasonal TIV before pH1N1 vaccine and who had no measurable
HI titer to pH1N1 prior to receiving 2009–2010 seasonal TIV.
Results
Follow-up was complete for 98% (57/58) of HIV-infected
patients and all healthy controls. The mean age of the patients was
52 (SD 11) years and of the controls 49 (SD 10) years. Of the
patients, 91% (52/57) was on cART of whom 87% (45/52) had
undetectable plasma HIV-1 RNA (,20 copies/mL) at baseline.
The median CD4+ T-lymphocyte count was 507 (IQR 349-697)
cells/mm3 and only three patients had a count below 200 cells/
mm3. In the month preceding inclusion, 89% (51/57) of HIV-
infected patients and 64% (28/44) of controls had been vaccinated
with non-adjuvanted 2009-2010 seasonal TIV (Table 1).
Three patients (5%) and 3 controls (7%) reported an influenza-
like illness in the two months preceding inclusion, of whom 2
patients and 1 control had a baseline HI titer $1:40. The baseline
GMT was higher in patients (23, 95% CI 15–35) than in controls
(12, 95% CI 8–16) (Figure 1a). At baseline, 44% (25/57) of
patients and 23% (10/44) of controls had a HI titer $1:40. Titers
above 80 were uncommon at baseline (Figure 1b).
Immunogenicity results are summarized in Figure 1 and
Table 2. In a mixed linear model, the age-adjusted average
GMT taken over the three time points after vaccination was a
factor 1.6 higher in controls than in HIV-infected patients (95%
CI 1.0-2.5, p=0.06) (Figure 1a). In a linear regression model
restricted to the HIV-infected patients, only higher baseline titers
(p=0.02) were associated with higher HI titers at day 21. This
association was not seen at day 56.
The seroprotection rate, defined as a titer $1:40, was 88% (50/
57) for HIV-infected patients three weeks after the first pH1N1
vaccination and 91% (52/57) after the second vaccination. For
controls this was 93% (41/44) and 89% (39/44) respectively
(Figure 1b). In a separate analysis, restricted to participants with a
baseline titer below the detection limit, the seroprotection rate was
72% (18/25) for HIV-infected patients after the first and 88% (22/
25) after the second vaccination. For the controls this was 89%
(24/27) and 85% (23/27).
After the first vaccination only 53% (30/57) of HIV-infected
patients achieved seroconversion compared with 73% (32/44) of
controls. After the second vaccination this was 63% (36/57) and
70% (31/44) (Table 2). The GMT was lower in those who did not
seroconvert than in those who did. The GMT in HIV-infected
patients who did not seroconvert was 72 (95% CI 42–124) and was
161 (95% CI 122–212) in those who did seroconvert. For controls
this was 61 (95% CI 25–147) and 347 (95% CI 233–516). As is to
be expected, seroconversion rates were lower in those with high HI
titers at baseline. In a separate analysis of 25 HIV-infected patients
who had HI titers below the detection limit at baseline, 72% (18/
25) achieved seroconversion after the first pH1N1 vaccination and
88% (22/25) after the second vaccination. For the 27 controls this
was 89% (24/27) and 85% (23/27).
After the first vaccination, between day 0 and day 21, an
influenza-like illness was reported by 5 HIV-infected patients (9%)
and 6 controls (14%). Of these participants, 4/5 patients (80%)
and 6/6 controls (100%) had a HI titer $1:40 at day 21. In
addition, one patient and 1 control reported an influenza-like
illness between day 21 and day 56 of follow-up. Both had HI titer
$1:40 at day 56.
There were no serious adverse events following vaccination and
HIV-1 RNA remained below the detection threshold in a random
selection of 20 patients with undetectable viral loads at baseline.
All except 1 of the 35 subjects with a baseline pH1N1 titer
$1:40 had received 2009–2010 seasonal TIV. Prior vaccination
with 2009–2010 seasonal TIV (OR 14, 95% CI 2–113, p= 0.01)
and higher age (OR 1.04, 95% CI 1.0–1.1 for an increase in age
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by 1 year, p = 0.05) were associated with a baseline pH1N1 HI
titer $1:40.
Using stored serum samples of 51 of the HIV-infected patients
we measured the pH1N1 specific response to 2009–2010 seasonal
TIV administered a median of 17 days (IQR 14–23 days) before
the first pH1N1 vaccination. We found that the seroprotection
rate to pH1N1 increased from 22% to 49% following vaccination
with 2009–2010 seasonal TIV and that 31% seroconverted
(Table 2). This effect was age dependent. In a regression analysis
restricted to 40 HIV-infected patients who all had undetectable HI
titers to pH1N1 prior to vaccination with 2009–2010 seasonal
TIV, we found that 2009–2010 seasonal TIV induced higher HI
titers in older than in younger subjects (HI titer increased by a
factor 1.05 95% CI 1.01–1.08 for an increase in age by 1 year,
p = 0.01). This effect was independent of the CD4+ T-lymphocyte
count, nadir CD4+ T-lymphocyte count and HIV-1 RNA. Of
note, we found no evidence indicating that the immune response
to pH1N1 vaccine was augmented by prior vaccination with
seasonal TIV.
In a subset of 14 HIV-infected patients we measured (cross-
reactive) pH1N1 HI titers following three different influenza
vaccinations (i.e. 2005–2006 seasonal TIV, 2009–2010 seasonal
TIV and pH1N1 vaccine). In 2005 the seroprotection rate to
pH1N1 for this cohort of 14 HIV-infected patients increased from
14% to 43% after vaccination with 2005–2006 seasonal TIV
(Table 3). In 2009 the seroprotection rate to pH1N1 had dropped
back to 7% but increased to 50% after vaccination with 2009–
2010 seasonal TIV. The subjects who developed cross-reactive
antibodies to pH1N1 after 2005–2006 seasonal TIV were not
necessarily the same subjects who did so after 2009–2010 seasonal
TIV (p = 0.5, Fisher’s exact test for the association between
seroconversion to pH1N1 following 2005–2006 seasonal TIV and
2009–2010 seasonal TIV).
Discussion
In HIV-infected patients on cART, with a median CD4+ T-
lymphocyte count above 500 cells/mm3, one dose of MF59-
adjuvanted 2009 pandemic influenza A(H1N1) vaccine induced a






Male - n (%) 48 (84) 27 (61)
Age, years - mean (SD) 52 (11) 49 (10)
Age categories - n (%)
18–44 years 14 (25) 12 (27)
45–59 years 26 (46) 28 (64)
.60 years 17 (30) 4 (9)
combination antiretroviral
therapy (cART) - n (%)
52 (91) -
baseline value CD4+ T-lymphocytes,
cells/mm3 - median (IQR)
507 (349–697) -
CD4 category, at the time
of vaccination n (%)
-
,350 cells/mm3 14 (25) -
.350 cells/mm3 43 (75) -
nadir CD4+ T-lymphocytes,
cells/mm3 - median (IQR)
143 (32–281) -
baseline HIV-1 RNA - n (%) -
,20 copy/ml 45 (79) -
20-400 copy/ml 7 (12) -
.400 copy/ml 5 (9) -
past seasonal trivalent inactivated
influenza vaccination - n (%)
2009–2010 51 (89) 28 (64)
2008–2009 50 (88) 27 (61)
2007–2008 45 (79) 29 (66)
doi:10.1371/journal.pone.0016496.t001
Figure 1. Immunogenicity of two doses of pH1N1 vaccine. Monovalent MF59-adjuvanted pandemic influenza vaccine (A/California/7/2009)
administered to a group of 57 HIV-infected patients (HIV) and 44 healthy controls (HC). The vaccine was administered at day 0 (baseline) and at day
21. Age adjusted geometric mean titers with 95% confidence intervals at baseline, day 7, day 21 and day 56 (Panel A). Reverse cumulative distribution
curves on hemagglutination inhibition assay at baseline and at day 21 (Panel B).
doi:10.1371/journal.pone.0016496.g001
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high rate of seroprotection comparable to that in healthy controls.
The second dose showed no effect on GMT 5 weeks after it had
been administered, but it did have a modest additional effect on
the seroprotection rate in HIV-infected patients. Post-vaccination
GMT was lower in HIV-infected patients than in healthy controls.
Furthermore we found that seasonal TIV induced seroprotection
to pH1N1 in just under half of the participants and that this effect
was more pronounced in older subjects.
There are three published studies and there is one set of
preliminary data on the humoral response to a single dose of 2009
pandemic influenza A(H1N1) vaccine in comparable groups of
HIV-infected patients (Table 4) [11–14]. This study is the first to
report the effect of this particular vaccine in HIV-infected patients
and the first to report the effect of a second dose in HIV-infected
patients. It is also the only study on pH1N1 vaccine in HIV-
infected patients that included a comparator control group. In two
of the other studies with ASO3-adjuvanted vaccine, the seropro-
tection rate exceeds 90%. A third study reports a lower
seroprotection rate. In a head to head comparison, squalene
based adjuvanted influenza vaccine clearly outperforms unadju-
vanted influenza vaccine in HIV-infected patients [11], as has also
been found for healthy adults [15]. Due to relatively high baseline
HI titers, the seroconversion rate in our study was lower than in
other studies. A fourfold increase in titer is more difficult to
achieve if the baseline titer is already high. This reasoning is in line
with the fact that we found higher seroconversion rates for the
participants who had undetectable pH1N1 HI titers at baseline.
Our interpretation of the data is that most participants in our
study were clinically protected following vaccination with MF59-
adjuvanted pH1N1 vaccine.
In this study just under half of the participants had a HI titer
$1:40 at baseline, i.e. at or above the threshold that defines
seroprotection. Although the peak incidence of the influenza
pandemic in the Netherlands coincided with the start of the
vaccination campaign [16], less than 10% had a recent influenza-
like illness before receiving the first pH1N1 vaccine. Therefore, it
seems unlikely that infection with influenza accounted for the high
seroprotection rate at baseline. There was a strong association
between recent vaccination with 2009–2010 seasonal TIV and
seroprotection at baseline. This association was confirmed by
analyses of stored serum samples, which showed that 2009–2010
seasonal TIV induced cross-reactive antibodies to pH1N1 and that
2005–2006 seasonal TIV had a comparable effect. In other studies
baseline seroprotection rates vary from 0 to approximately 30%
[15,17–27]. Some studies do [17,20,26] and others do not [23,24]
report an association between baseline HI titers to pH1N1 and
prior vaccination with seasonal TIV. The fact that we found a
stronger association between vaccination with seasonal TIV and
induction of cross-reactive antibodies to pH1N1 than most other
studies can be due to a number of reasons. Firstly, as opposed to
most other studies, the majority of subjects in our study had
received 2009–2010 seasonal TIV before inclusion. Secondly, the
time between having received seasonal influenza vaccine and
pH1N1 vaccine was much shorter in our study than in other
studies. Lastly, we studied HIV-infected patients and it could be
that this group produces larger quantities of cross-reactive
Table 2. Humoral immune response to two doses of pH1N1 vaccine.
HIV-infected n=57 Healthy Control n=44













pre-baseline, before 2009-2010 seasonal TIV (day –95)*
HI titer $1:40 - n (%) 11 (22) - - - - -
GMT – value (95% CI) 9
(7–12)
- - - - -
baseline, after 2009–2010 seasonal TIV but before 1st pH1N1 vaccine (day 0)
HI titer $1:40 - n (%) 25 (49) 0 25 (44) 9 (32) 1 (6) 10 (23)










after 1st pH1N1 vaccine (day 21)
HI titer $1:40 - n (%) 47 (92) 3 (50) 50 (88) 25 (89) 16 (100) 41 (93)
seroconversion – n (%)# 27 (53) 3 (50) 30 (53) 16 (57) 16 (100) 32 (73)












after 2nd pH1N1 vaccine (day 56)
HI titer $1:40 - n (%) 47 (92) 5 (83) 52 (91) 23 (82) 16 (100) 39 (89)
seroconversion – n (%)# 31 (61) 5 (83) 36 (63) 15 (54) 16 (100) 31 (70)












Seroprotection- and seroconversion rates and geometric mean titers (GMT) to 2009 pandemic influenza A(H1N1) (pH1N1) virus for 57 HIV infected individuals and 44
healthy controls following vaccination with two doses of monovalent MF59-adjuvanted pandemic influenza vaccine (A/California/7/2009). Results are stratified by
whether or not participants had been vaccinated with 2009–2010 seasonal trivalent inactivated influenza vaccine (TIV) before receiving the first pH1N1 vaccine.
*For 51 HIV-infected participants who had already been vaccinated with 2009–2010 seasonal TIV at baseline (day 0), we also determined HI titers to 2009 pandemic
influenza A(H1N1) virus in stored serum samples that had been collected before they received 2009–2010 seasonal TIV.
#Baseline titers (day 0) were used as denominaters to determine seroconversion rates.
doi:10.1371/journal.pone.0016496.t002
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antibodies upon vaccination because of a less well regulated B-cell
immune response [28,29].
Using virus neutralization assays, others have shown that cross-
reactive antibodies that are induced by seasonal TIV are functional
against pH1N1 [30]. This entails that these antibodies do confer
protection against pH1N1. There is epidemiological evidence that
supports this claim although there is also evidence to the contrary
[31–34]. The surface hemagglutinin and neuraminidase proteins in
recent seasonal trivalent inactivated influenza vaccines are antigen-
ically very distant from those of pH1N1. Therefore seasonal TIV is
generally not expected to confer a significant degree of cross-
protection to pH1N1 [35]. Only older age by way of exposure to
pre-1957 influenza strains has consistently been found to confer a
relevant degree of cross-reactive antibodies to pH1N1 [17,36–39].
In this respect it is interesting that we found that seasonal TIV was
more likely to induce cross-reactive antibodies to pH1N1 in older
than in younger subjects, which contradicts the conclusion of
Hancock et al. who found that seasonal TIV induces little to no
cross-reactive antibody response to pH1N1 in any age group. We
think that our findings show that seasonal influenza vaccines do not
induce a relevant degree of cross protection to pH1N1 in (younger)
immunologically naı̈ve subjects but that seasonal influenza vaccines
can boost relatively unrelated influenza specific memory B-cells. In
older individuals who have been exposed to influenza strains or
vaccines that are antigenically more related to pH1N1, such
boosting induces measurable levels of antibodies to pH1N1, which
may augment clinical protection against pH1N1.
This study has strengths and limitations. It was a prospective
well controlled cohort study in a fairly homogenous group in
which follow-up was complete for 99% of participants. This study
is unique in that it shows the immune response to vaccination with
pH1N1 and the effect of seasonal influenza vaccines in the same
HIV-infected patients. Although symptoms of an influenza-like
illness were systematically assessed, respiratory samples were not
collected to confirm pH1N1 infection and therefore intercurrent
infections can not be excluded. However, only 11 participants had
an influenza-like illness between day 0 and day 21. Regarding the
generalizability of our results: 91% of our HIV-infected patients
were successfully being treated with combination antiretroviral
therapy (cART) and very few HIV-infected participants had a
CD4+ T-lymphocyte count below 200 cells/mm3.
In conclusion, a single dose of MF59-adjuvanted 2009
pandemic influenza A(H1N1) vaccine in HIV-infected patients
on cART with a median CD4+ T-lymphocyte count above 500
cells/mm3 induced a high rate of seroprotection comparable to
that in healthy controls. A second dose had a modest additional
effect in HIV-infected patients but not in healthy controls. Post-
vaccination GMT, a sensitive marker of the immune competence
of a group, was lower in HIV-infected patients than in healthy
controls, reflecting the underlying immunodeficiency. Further-
more we found that recent seasonal TIV induced a high rate of
age-dependent cross-reactive seroprotection to pH1N1. We think
that in general, seasonal TIV boosts pre-existent influenza specific
memory B-cells. In older people who in the past have been
Table 3. (Cross-reactive) antibody titers following two different seasonal influenza vaccines in a cohort of 14 HIV-infected patients.
HIV-infected (n=14)*
influenza strain used in HI assay A/NewCaledonia/20/1999 (seasonal strain) A/California/7/2009 (pandemic strain)
Before 2005–2006 seasonal TIV
HI titer $1:40 - n (%) 7 (50) 2 (14)
GMT – value (95% CI) 39 (16–92) 10 (5–17)
after 2005–2006 seasonal TIV
HI titer $1:40 - n (%) 11 (79) 6 (43)
seroconversion - n (%) 4 (29) 3 (21)
GMT – value (95% CI) 118 (52–272) 21 (10–45)
influenza strain used in HI assay A/Brisbane/59/2007 (seasonal strain) A/California/7/2009 (pandemic strain)
Before 2009–2010 seasonal TIV
HI titer $1:40 - n (%) 12 (86) 1 (7)
GMT – value (95% CI) 55 (34–90) 6 (4–9)
after 2009–2010 seasonal TIV but before 1st pH1N1 vaccine
HI titer $1:40 - n (%) 14 (100) 7 (50)
seroconversion - n (%) 2 (14) 6 (43)
GMT – value (95% CI) 103 (57–187) 23 (12–43)
after 1st pH1N1 vaccine
HI titer $1:40 - n (%) - 13 (93)
seroconversion - n (%) - 8 (57)
GMT – value (95% CI) - 114 (62–209)
Seroprotection- and seroconversion rates and geometric mean titers (GMT) to 2005–2006 seasonal influenza A(H1N1) virus, to 2009–2010 seasonal influenza A(H1N1)
virus and to 2009 pandemic influenza A(H1N1) (pH1N1) virus for 14 HIV infected individuals following vaccination with seasonal trivalent inactivated influenza vaccine
(TIV) in 2005 (A/New Caledonia/20/1999 (H1N1) like strain), with seasonal TIV in October 2009 (A/Brisbane/59/2007 (H1N1) like strain) and with a first dose of
monovalent MF59-adjuvanted pH1N1 vaccine (A/California/7/2009) in November 2009.
*Population characteristics in 2009: 86% male, median age 48 years (IQR 47–66), 86% on cART, median CD4+ T-lymphocytes 532 cells/mm3 (IQR 349–725), baseline HIV-1
RNA 71% ,20 copy/ml, 14% 20–400 copy/ml, 14% .400 copy/ml. Population characteristics in 2005: 64% on cART, median CD4+ T-lymphocytes 473 cells/mm3 (IQR
285–752), baseline HIV-1 RNA 57% ,50 copy/ml, 14% 50–400 copy/ml, 29% .400 copy/ml.
doi:10.1371/journal.pone.0016496.t003
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exposed to influenza strains that are antigenically more alike to
pH1N1, this effect induces measurable levels of cross-reactive
antibodies to pH1N1. If such an effect is true and if it adds to
clinical protection against pH1N1, it is an additional benefit of
annual influenza vaccination.
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BACKGROUND
The surface hemagglutinin (HA) and neuraminidase 
proteins in recent seasonal trivalent inactivated influenza 
vaccines (TIV) are antigenically very distant from 
those of 2009 pandemic influenza A(H1N1) (pH1N1). 
Therefore seasonal TIV is generally not expected to 
confer a significant degree of cross-protection to pH1N1.1 
Only older age by way of exposure to pre-1957 influenza 
strains has consistently been found to confer a relevant 
degree of cross-reactive antibodies to pH1N1.2-6 We were 
surprised to find that in our study, 2009–2010 seasonal 
TIV induced cross-reactive antibodies to pH1N1 in a 
sizeable proportion of subjects.7 In the hemagglutination-
inhibition (HI) assay,  the seroprotection rate to pH1N1 
increased from 22% to 49% following vaccination with 
TIV with 31% showing seroconversion. This effect 
was age dependent. Using virus neutralization assays, 
others have shown that cross-reactive antibodies that are 
induced by seasonal TIV are functional against pH1N1.8 
This suggests that these antibodies confer protection 
against pH1N1. There is epidemiological evidence that 
supports this claim, although there is also evidence to the 
contrary.9-12 We determined whether the cross-reactive 
antibodies to pH1N1 that were detected in the HI assay, 
were also present in the virus neutralization (VN) assay.
METHODS
Study design and source population
From the original cohort, we selected 14 HIV-
infected individuals who had been vaccinated with 
2009–2010 seasonal TIV, a median of 19 days before 
being vaccinated with pH1N1 vaccine (interquartile 
range, IQR 15–24 days). Their pH1N1 antibody titer 
was below the detection limit before vaccination with 
seasonal TIV. Of these subjects 8 of 14 developed cross-
reactive antibodies to pH1N1 after vaccination with 
TIV, according to the HI assay. Antibody responses 
before seasonal TIV (day -140), after seasonal TIV (day 
0), after the first dose of pH1N1 vaccine (day 21) and 
after the second dose of pH1N1 vaccine (day 56) were 
measured with HI assays and VN assays.
Virus neutralization (VN) assay
50 μl volumes of heat-inactivated serum samples 
were diluted 1:10 and serially diluted two-fold and 
incubated with an equal volume of virus suspension 
containing 100 TCID50 for two hours at 37 ◦C. The virus 
A/California/4/2009 (H1N1) was used. Subsequently 
the mixture was transferred to confluent MDCK cells 
grown in 96-well plates, incubated for two hours at 
37 ◦C and then aspirated. The cells were washed once 
with infection medium and then cultured for 3–7 days 
at 37 ◦C. Then the culture supernatants were tested for 
HA activity as a measure for residual virus replication. 
The serum titers were expressed as the reciprocal of the 
dilution that still prevented virus replication. If there was 
no inhibition of virus replication, the titer was assigned 
a value of 1:5.
Hemagglutination-inhibition (HI) assay 
Antibodies to the vaccine strain A/California/7/2009 
(H1N1) were measured using the hemagglutination-
inhibition (HI) assay, according to standard methods.13 
Titers below the detection limit (i.e., 1:10) were assigned 
a value of 1:5. Seroconversion was defined by a post- 
vaccination HI titer of at least 1:40 combined with 
at least a four-fold increase in titer in accordance to 
European and international guidance.
RESULTS
The median age of this group of 14 HIV-infected 
subjects was 57 (IQR 48–67) years. The median CD4+ 
T-lymphocyte count was 529 (IQR 324-706) cells/mm3. 
The titers obtained in the VN assay correlated reasonably 
well with those obtained in the HI assay for most 
serum samples tested (Figure 1). Pearson’s correlation 
coefficient was 0.64 (95% Confidence Interval, CI 
0.46–0.77, p-value <0.0001). There were a number of 
samples with discrepant values. These were mainly seen 
if titers were at the lower end of the spectrum. Some 
of the samples with discrepant values had a negative HI 
titer and a weak VN titer. Others had a negative VN titer 
and a moderate HI titer. Most of the discrepant titers 
were seen in the pre-vaccination samples that had been 
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obtained during routine outpatient visits a median of 140 
(IQR 65-205) days before vaccination with TIV and in 
the samples obtained after vaccination with TIV (day 0). 
In the HI assay, none of the 14 subjects had antibodies 
to pH1N1 before vaccination with seasonal TIV. Eight 
subjects (57%) developed a  cross-reactive anti-pH1N1 
titer ≥1:40 after vaccination with TIV. No such response 
was seen in any of these subjects when measured with 
the VN assay. This was reflected in the geometric mean 
titers (GMT), as is depicted in Figure 2. In the HI assay, 
GMT for cross-reactive antibodies to pH1N1 increased 
from 5 (95% CI 5–5) to 30 (95% CI 15-61) after 
vaccination with seasonal TIV.  In the VN assay there 
was no increase in cross-reactive antibody titers: pre-
vaccination GMT 13 (95% CI 8-22), post-vaccination 
GMT 11 (95% CI 7-19).
Figure 1. Comparison of serum antibody titers against 
influenza virus A/California/7/2009 (pH1N1) obtained 
in virus neutralization (VN) assay with those obtained in 
the hemagglutination-inhibition (HI) assay.
Figure 2. Comparison of geometric mean titers 
(GMT) for serum antibody titers against influenza 
virus A/California/7/2009 (pH1N1) obtained in virus 
neutralization (VN) assay with those obtained in the 
hemagglutination-inhibition (HI) assay, in response 
to seasonal TIV and to two doses of monovalent 
MF59-adjuvanted pandemic influenza vaccine (A/
California/7/2009) (pH1N1), in a group of 14 HIV-
infected patients.
DISCUSSION
Seasonal TIV did not induce cross-reactive antibodies 
to pH1N1 according to the VN assay. This was in 
contrast to the result obtained from the HI assay. The 
discrepancy between the results of the HI assay and VN 
assay, is unexpected, since HI titers for influenza virus 
antibody in human sera closely match VN titers.14,15 
However, VN and HI antibody repertoires do not fully 
overlap.16 In our study, discrepant values were mainly 
seen if titers were at the lower end of the spectrum. Most 
of these samples had a negative HI titer and a weak VN 
titer. One can speculate on the cause of the discrepancy. 
Antibody assays such as the HI assay and VN assay 
have limited sensitivity to distinguish small difference 
in antibody titers, such as a two-fold dilution step 
difference. Since ours was a fairly small study, the play 
of chance may have magnified the inherent limitations 
of the assay and introduced a bias that led us to believe 
that TIV induced a significant degree of cross-protection 
to pH1N1 based on the HI assay results. Alternatively, 
aspecific binding of nonimmune or immune factors may 
prevent hemagglutination.17 
The VN assay is a functional assay and is considered 
the gold standard. Therefore, we conclude that seasonal 
TIV did not confer a significant degree of cross-reactive 
protective antibodies to pH1N1. However, to complicate 
matters, there is compelling new evidence that supports 
our previous observation of a relevant increase in pH1N1 
titer after vaccination with seasonal TIV. Li et al. have 
recently shown that memory B cells, reactive to pH1N1 
are present in many people, before pH1N1 emerged.18 
They also show that pH1N1 influenza vaccination 
induces a recall response of certain memory B cells, 
that leads to broadly cross-reactive antibodies that bind 
to conserved regions of hemagglutinin.18-20 One can 
speculate that in our study, seasonal TIV activated cross-
reactive memory B cells in older individuals which led 
to the production of antibodies that cross-reacted with 
the HA protein of pH1N1. Maybe these antibodies were 
capable of inhibiting hemagglutination in the HI assay, 
but were not capable of neutralizing pH1N1 virus in the 
VN assay. 
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Summary and discussion 

SUMMARY AND DISCUSSION
The content of  this thesis is based on research that was conducted at the travel and 
vaccination clinic at Leiden University Medical Centre. It covers a variety of  topics 
relating to travel medicine and immunity. This final chapter starts by discussing 
methodological aspects of  the various studies. Next it discusses the results of  the studies 
on travel medicine and finally the chapters pertaining to immunity and vaccination. 
METHODOLOGICAL ISSUES
Based on the method that was used, the chapters in this thesis can be categorised as either 
experimental studies (i.e. trials) (chapters 6, 7, 8 and 9) or non-experimental studies (i.e. 
observational studies) (chapters 1, 2, 3, 4, 5, 10 and 11). Experimental studies are defined 
as prospective follow-up studies in which the exposure to a determinant is manipulated 
and assigned at random, thus creating an index- and a reference group.1 The purpose of  
random allocation is to create groups that differ only randomly at the time of  allocation 
with regard to subsequent occurrence of  the study outcome.2 The goals of  the study, 
rather than the subject’s needs, determine the exposure assignment, so as to prevent 
‘confounding by indication’.2 Furthermore, for ethical reasons, the treatment possibilities 
in an experimental study must be equally acceptable given current knowledge.2 This 
is called the principal of  equipoise.3-9 Therefore in many trials, the reference group is 
treated with an active comparator as opposed to a placebo. For ethical reasons and 
for methodological reasons, it is essential that people who are assigned to a reference 
group are exposed to the best available active comparator. When feasible, clinical trials 
should attempt to employ blinding with respect to treatment assignment. This prevents 
certain biases that could affect assignment, compliance, treatment or assessment.2 In an 
experimental study, the sample size depends on pre-defined assumptions and variables: 
(i) an assumption about the incidence of  the primary endpoint, (ii) an assumption about 
the difference in the effect of  treatment between the index- and the reference group., (iii) 
the magnitude of  the type I error that is deemed acceptable (α) (i.e. asserting something 
that is absent) and (iv), the magnitude of  the type II error that is deemed acceptable 
(β) (i.e. failing to assert what is present). Table 1 summarizes the methodology of  the 
experimental studies that are described in chapters 6 and 7 of  this thesis. Chapters 8 and 
9 were open label, non-randomized phase I exploratory trials. 
Non-experimental studies differ from experimental studies in that randomization is not 
used to assign treatments.10 The researcher is an observer rather than an agent who assigns 
interventions.2 There are four main types of  non-experimental studies: cohort studies, 
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table 1 
Summary of methodological 
aspects of the experimental 
studies that are described in 
chapters 6 and 7 of this thesis.
table 2 (page 140) 
Summary of methodological 
aspects of the non-
experimental studies that are 
described in chapters 1, 2, 3, 4, 


















































































































































































































































































































































































































































































































































































































































in which all subjects in a source population are classified according to their exposure 
status and followed over time to ascertain disease incidence; case control studies, in which 
investigators compare exposures between subjects with a particular disease outcome 
(cases) and people without that outcome (controls); cross-sectional studies, in which one 
ascertains exposure and disease status at a particular time; and ecological studies, in which 
the units of  observation are groups of  people.2,11 The objective of  an epidemiological 
study is to obtain a valid and precise estimate of  the frequency of  a disease or of  the 
effect of  an exposure on the occurrence of  a disease in the source population of  the 
study. Often, a further objective is to obtain an estimate that is generalizable to relevant 
target populations.2 Errors in estimation may occur due to random- or systematic errors 
and are of  influence on the internal validity of  a study. Violations of  internal validity 
can be classified into three categories: confounding, selection bias and information bias. 
Confounding produces relations that are factually right, but that cannot be interpreted 
causally because some underlying, unaccounted for factor is associated with both 
exposure and outcome.11 Bias is a systematic deviation of  a study’s result from a true 
value. Typically, it is introduced during the design or implementation of  a study and 
cannot be remedied later. Bias arises from flawed information or subject selection so that 
a wrong association is found.11 Table 2 summarizes some methodological aspects of  the 
non-experimental studies that are described in chapters 1, 2, 3, 4, 5, 10 and 11. 
TRAVEL AND INFECTION
The first chapter of  this thesis describes a study that was designed to improve the quality 
of  medical electives.12 It describes the health risks and the quality and comprehensiveness 
of  pre- and post-travel care fore a group of  Dutch medical students after an elective 
abroad. Most students engaged in procedures that constitute a risk of  blood-borne viral 
infection, often in countries with high HIV prevalence rates. None of  the participants 
took action following mucosal or percutaneous exposure to potentially infectious body 
fluids. This was also the case in a survey among British medical students.13 Furthermore, 
the allocation of  post exposure prophylaxis kits for HIV (PEP) was inadequate. Regarding 
other health risks: 20% stopped using mefloquine due to adverse effects, which left a 
sizeable proportion unprotected in countries that are hyperendemic for malaria. Post-
travel screening for schistosomiasis, tuberculosis and methicillin-resistant Staphylococcus 
aureus (MRSA) was conducted for approximately half  of  all students who should have 
been screened. Based on the results of  this study we adopted an integral set of  measures 
to reduce the health risks associated with an elective abroad. Pre- and post-travel 
consultations as also the distribution of  PEP has been centralized and standardized. 
Furthermore, student and supervisor in Leiden are required to fill out a checklist to assess 
whether the student is sufficiently experienced to participate in certain procedures, such as 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































suturing or assisting in the operating theatre or delivery room. If  new skills are to be 
acquired abroad, it should be specified beforehand whether the medical staff  abroad 
has the time and facilities to supervise and teach new skills. Students also receive a 
brochure that describes how to act in case of  exposure to potentially infectious body 
fluids. Upon return, all students fill out a standard short web-based checklist which 
assesses certain health risks, such as exposure to potentially infected body fluids and the 
risk of  schistosomiasis and  tuberculosis. The checklist results in a computer generated 
recommendation stating whether the student needs to contact the occupational health 
department or another care provider for a post-travel consult. Finally, the department of  
student affairs is creating a list of  so called preferred partners. These are long standing 
partnerships with hospitals abroad, where medical staff  are familiar with supervising 
foreign students and where student responsibilities and access to care are well-defined. A 
more comprehensive pre- and post travel survey will assess the effectiveness of  the new 
policy. In addition this study will address other aspects, such as the incidence of  culture 
shock, (traffic) accidents, violence and post-travel irritable bowel syndrome. 
For most travellers to the tropics, diarrhoea is the most common health hazard. It can be 
a major nuisance but it is very seldom fatal. In the second chapter we assess the burden 
of  illness due to travellers’ diarrhoea in adults who travelled to the (sub)tropics for a 
median of  23 days.14 We conclude that conventional definitions of  travellers’ diarrhoea 
encompass many mild cases (in our study at least a third of  all cases) for which treatment 
is unlikely to provide a significant health benefit. We recommend that the degree of  
inconvenience should be incorporated as an endpoint in clinical studies on travellers’ 
diarrhoea. This will enable scientists and policy makers to better distinguish ‘significant’ 
travellers’ diarrhoea from mild travellers’ diarrhoea, thus allowing for a more precise 
estimate of  the size of  the target population for vaccination or stand-by antibiotic 
prescription and of  the benefit of  such measures.
Chapter three describes a questionnaire study on travel experiences in which we 
investigated pre-travel preparation of  Dutch patients with inflammatory bowel disease 
(IBD).15 We also surveyed health problems encountered during travel and investigated 
whether travel increased the risk of  an exacerbation of  IBD. Faecal urgency and incontinence 
were the main IBD-related inconveniences. Onset of  a new episode of  diarrhoea was 
reported by 32%, which surprisingly is not higher than the incidence of  travellers’ 
diarrhoea in the general population.16 Probably, people with chronic bowel disease are 
less inclined to regard gastro-intestinal complaints as new episodes of  diarrhoea. We did 
not find that travel increased the risk of  an exacerbation of  IBD within a 2-month period 
after travel. However, the individual’s self-reported number of  exacerbations over the past 5 
years may not be a valid marker for the expected incidence of  an exacerbation after travel. 
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Lastly, pre-travel advice for IBD patients was often deficient. We recommend that 
physicians caring for patients with IBD raise awareness of  the benefit of  pre-travel 
counselling and that they refer patients to travel medicine clinics in a timely fashion. 
Sufficient time is required to check serology after hepatitis A vaccination in those who 
use systemic immunosuppressants. Even if  seroprotection is not attained after one dose, 
a second dose is often effective, as has been shown in organ transplant recipients.17,18
Chapter four describes a study in which we aimed to determine the utility of  routine 
post-travel screening of  asymptomatic long-term travellers to the (sub)tropics for 
intestinal parasites using molecular diagnostics and for schistosomiasis using serology.19 
Only one infection with Strongyloides stercoralis was found in over 400 travelers and no 
infection with Entamoeba histolytica in over 500 travelers. The incidence of  infection with 
Schistosoma spp. was higher. However, each case was associated with exposure to highly 
endemic lakes in Malawi and Tanzania. We conclude that routine screening of  stool 
samples for parasitic infection is not indicated for asymptomatic people, who travel to 
the (sub)tropics for up to 3 months. Screening for Schistosoma spp. should be offered to 
travellers with fresh-water contact in endemic regions. Post-travel screening of  specific 
groups of  asymptomatic travellers, such as migrants, expatriates, or aid workers may 
yield higher infection rates.
Chapter six describes a randomized trial on the efficacy of  a live attenuated oral cholera 
vaccine, CVD 103-HgR, to prevent all-cause travellers’ diarrhea.20 The vaccine failed to 
provide protection. The power of  the study was limited by the unexpected low incidence 
of  LT–ETEC-associated diarrhoea. Other studies that evaluated the protective efficacy of  
ETEC-specific vaccines also failed to demonstrate clinically important benefits.21,22 Future 
studies attempting to prevent travellers’ diarrhoea through vaccination should target a 
broader range of  enteropathogenic Escherichia coli and other enteropathogens.23-26 Newer 
vaccines have therefore included more colonization factor antigens that are expressed by 
Escherichia coli.27-31 Furthermore, future trials should include large numbers of  travellers, 
or limit the investigation to countries for which detailed data concerning aetiology of  
travellers’ diarrhoea is available. Lastly we recommend that trials should incorporate the 
degree of   inconvenience as a clinical endpoint.
IMMUNITY
Immunology from an evolutionary perspective
From the beginning of  their existence, metazoan recruited a basic diversity of  molecular 
categories able to interact with proteins, sugars or lipids, i.e. an innate immune system 
that was able to recognize pathogens. The interactions with pathogens were articulated to 
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signalling cascades that were sometimes shared with other functions, such as fertilization 
control, development, metamorphosis and regeneration pathways. These signals were 
coupled to a diversified set of  effector mechanisms.32-34 Later in evolution, jawed 
vertebrates developed a so-called adaptive immune system.35 This system consists of  
a set of  gene segments that are assembled during the ontogeny of  lymphocytes. After 
selection, it provides each individual with an unparalleled diversity of  recognition 
capacity.32 According to Du Pasquier, the reason why most life-forms did not develop 
an adaptive immune system, may be related to the relative value of  individuals for the 
survival of  a species. In species with large progenies and in which individuals reproduce 
only once and relatively early, and in which older individuals are less important for the 
survival of  the species, innate immunity may suffice. This avoids the complexity of  an 
adaptive immune system.32
Immunity and vaccines against tuberculosis
In the realm of  immunology, a leap of  faith may be required to imagine it possible 
to apply vaccines to prevent infectious diseases, such as malaria and tuberculosis, to 
which no sterile immunity occurs in people who are infected with the wild type micro-
organism. From an epidemiological viewpoint, it is not necessary to achieve complete or 
‘‘sterile’’ eradication of  bacteria to effectively reduce the incidence of  active tuberculosis. 
The natural state of  most humans is protective immunity, since only a minority (~5%) 
develop clinically active tuberculosis after infection.36 Various host-derived factors 
increase the risk: malnutrition, aging, stress, type-2 diabetes, vitamin D deficiency and 
genetic factors that affect innate and adaptive immunity.37-52 Furthermore, temporary 
or permanent skewing of  the immune system due to co-infections influences cellular 
immunity and may increase the risk of  developing active tuberculosis.53-58 On the other 
hand, infection with Mycobacterium bovis may mitigate the risk of  developing active 
tuberculosis. This has been demonstrated in the 1940s in Denmark, where the incidence 
of  tuberculosis was compared between the island Zealand and South Jutland.59,60 On 
Zealand, bovine tuberculosis had been eradicated by 1930, whereas in South Jutland it 
was still prevalent at the time. In Zealand the incidence of  morbidity due to MTb was 
higher than  in South Jutland.
Morbidity occurs after primary infection, or after reactivation of  latent tuberculosis. In 
areas with a high incidence of  MTb infection, re-infection is also an important cause of  
active tuberculosis. This has been shown by Dutch pathologists, who analyzed lungs of  
people who died of  causes, other than tuberculosis, in the ‘30s, ‘50s and ‘60s.61-63 Based 
on histology, they selected cases with a primary calcified complex in the apex of  the lung, 
indicating past or latent MTb infection. They then looked how many of  these cases also 
had morphologically different active complexes, which were categorized as reinfections 
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figure 1
Tuberculosis in The Netherlands: incidence, mortality, number of patients that have been treated, total 
number of patients and estimated chance of contracting tuberculosis.  
(Reproduced by permission of KNCV Tuberculosefonds. Source: CBS, CIb and NTR).
figure 2
Prevalence of tuberculosis infection 
(total bar charts) and reinfections (filled 
sections of barcharts) by age and by year 
in which the studies were conducted.63 
(Reproduced by permission from 
Nederlands Tijdschrift voor Geneeskunde 
1962. Copyright Bohn Stafleu Van 
Loghum).
with MTb. If  these more active lesions were caused by reinfection and not by reactivation 
of  latent MTb, such lesions should be less prevalent in the ‘60s than in the ‘30s and ‘50s, 
owing to the dramatic decrease in the incidence and prevalence of  infection with MTb 
though time (figure 1). This is exactly what they found (figure 2). This observation has been 
corroborated by DNA fingerprinting of  MTb isolates.64,65
Public health programs have had a large impact on the incidence of  infection with MTb. 
This has been achieved by adequate treatment of  people with active tuberculosis and 
by screening and treating the contacts that surrounds such a case. In a similar manner, 
preventing active tuberculosis with effective vaccines will impact the incidence of  MTb 
infection, by reducing the reservoir of  people who can transmit MTb. Vaccination 
strategies focus on preventing infection and/or active disease by inducing immunity 
to antigens that are expressed early in the course of  infection, such as Early Secretory 
Antigenic Target (ESAT-6) and Antigen 85 (Ag85B). The subunit vaccine H1 consists of  
the fusion protein Ag85B-ESAT6.66-68 To prevent active disease it also seems important to 
induce immunity to late stage antigens, that are expressed during bacterial dormancy.52 
The vaccine, H56 is based on this concept and combines Ag85B, ESAT-6 and Rv2660c. 
Rv2660 is expressed in late stage infection.69
Correlates of  protection against MTb, vaccines and adjuvants
Despite increasing knowledge on the crucial role of  individual cell types, genes and 
molecules in the protective host defence against MTb, we lack a true understanding of  
what exactly constitutes protection and protective immunity. This creates a roadblock 
for tuberculosis vaccine development and the identification of  surrogate endpoints of  
protection, that can be used in clinical research.70 Nevertheless, there is general consensus 
that a Th1 cell response is essential for bacterial containment during infection.71 Inducing 
such a response with subunit vaccines, requires new types of  adjuvants. Aluminum salts 
(i.e. alum), which were the only approved adjuvants until the end of  the 20th century, 
promote the ‘wrong’ type of  immune response, a Th2 antibody mediated response.72 
Initially, alum was added to vaccines, because it caused a precipitate (i.e. solid form), and 
because of  the observation that precipitates improved vaccines’ antigenic properties.73 The 
mechanism governing the enhanced immunogenicity was thought to be the formation of  
a depot at the injection site, and subsequent slow release of  antigen. This assumption has 
been disproven.74 It seems that alum induces cytotoxicity and the release of  host DNA, 
which acts as a damage associated molecular pattern (DAMP); an immunostimulatory 
signal.75 Furthermore, alum allows host DNA to access the cytoplasm of  dendritic cells 
(DCs), which activates pathways that promote MHC class II presentation and DC-T-cell 
interactions.76 Activation of  the inflammasome, directly by alum, or indirectly by local 
accumulation of  uric acid, may also contribute to the adjuvant effect.74 
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In chapter eight and nine of  this thesis, two clinical trials are described in which two 
new adjuvants were combined with a MTb subunit vaccine.77,78 The first adjuvant, 
IC31® was developed by Intercell AG (Vienna, Austria) and consist of  the artificial 
antimicrobial peptide KLK and the oligodeoxynucleotide ODN1a. KLK acts as a 
vehicle, enhancing uptake into antigen presenting cells (APC). ODN1a stimulates Toll-
like receptor 9 (TLR9) signalling and activates APC. This causes a mixed Th1 and 
Th2 type response.79-82 The second novel adjuvant, CAF01, was developed by Statens 
Serum Institute (Copenhagen, Denmark). It consists of  liposomes formed by N,N’-
dimethyl-N,N’-dioctadecylammonium (DDA) and of  the synthetic immunomodulator 
α,α’-trehalose 6,6’-dibeheneate (TDB), which is inserted into the lipid bilayers.83-85 DDA 
liposomes target cell membranes of  APC, which subsequently leads to enhanced uptake and 
presentation of  antigen and a weak Th1 cell response.86 TDB is a synthetic analogue of  the 
mycobacterial cell wall component trehalose 6,6’-dimycolate (TDM) often referred to as cord 
factor. TDB stabilizes DDA liposomes and enhances the Th1 and Th17 cell response.84,85,87-89 
This is mediated by recognition of  TDB by the C-type lectin Mincle, which induces IL-1 
production which in turn induces MyD88-dependent Th1/Th17 cell responses.90-92
H1-IC31® induced a long-lasting Th1 cell response in naïve subjects, characterized by 
IFN-γ producing lymphocytes.93 The immune response was faster and generally stronger 
in subjects who had been vaccinated with BCG in the past and in subjects with past 
or latent MTb infection.77 H1-CAF01 also induced a robust and long lasting Th1 cell 
response.78 Despite these encouraging results, these surrogate immunological endpoints 
are not true correlates of  protection. This is exemplified by a recent large phase 2b trial 
in which a vaccine consisting of  a recombinant strain of  modified Vaccinia Ankara virus 
that expresses Ag85A, induced excellent immune responses, but failed to protect South 
African infants against active tuberculosis.94 Commenting on this result, Dr. Dye and 
Dr. Fine write: “The stakes are high. The venture is costly and risky, but has a huge 
potential payoff. We need to go on playing the high-stakes game.”95 
Poliovirus eradication, fractional doses and adjuvants
The Global Polio Eradication Initiative is another high-stakes venture.96 Through thoughtful 
work, dedication and concerted effort, polio cases have decreased by over 99% since 1988, 
from an  estimated 350 000 cases then, to 416 reported cases in 2013.97 Furthermore, the 
last case of  infection with  poliovirus type 2 occurred in 1999 and of  poliovirus type 3 in 
2012.97 In 2015, only 3 countries (Afghanistan, Nigeria and Pakistan) remain polio-endemic, 
down from more than 125 in 1988. War and displacement of  people are currently the 
main obstacles to achieving complete interruption of  the transmission of  poliovirus. After 
eradication, cessation of  oral poliovirus vaccine (OPV) is needed to prevent outbreaks due 
to circulating vaccine derived poliovirus.98-100 IPV is a factor 20 more expensive than OPV. 
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Therefore, one of  the prerequisites for cessation of  the use of  OPV is to make IPV 
affordable and suitable for use in developing countries.101 Using fractional (reduced) 
doses may impact affordability and optimize the utilization of  the production capacity 
for IPV. Intradermal administration has the potential to lower the dose without reducing 
immunogenicity. A needle-free jet injector may be a reliable way to administer vaccines 
intradermally. In chapter seven of  this thesis, a study is described that found that 
fractional-dose intradermal IPV booster vaccination using a jet injection system was well 
tolerated and immunogenic.102 Antibody titres in the fractional-dose intradermal group 
were slightly lower than after standard full-dose intramuscular vaccination. A way to 
further increase immunogenicity of  fractional-dose IPV, may be to add an adjuvant. In 
mice, an IPV-CAF01 formulation has been tested.103 IPV-CAF01, containing 2 D-Units 
(DU) of  poliovirus type 1, 2 and 3 was compared to unadjuvanted IPV with either 
2 or 20 DU of  poliovirus type 1, 2 and 3. Intramuscular (IM) delivery of  fractional-
dose adjuvanted vaccine induced stronger antibody responses than IM fractional-dose 
unadjuvanted vaccine. The response to the fractional-dose adjuvanted vaccine was as 
strong as the response to the full-dose unadjuvanted vaccine. Furthermore, the adjuvant 
also induced an increased cellular response, as  measured by multiplex cytokine analysis. 
In another experiment, IPV-CAF01 was injected simultaneously at an intradermal and 
an intramuscular site. Interestingly, this elicited an intestinal immune responses against 
poliovirus, measured as faecal IgA. This is important, because intestinal immunity 
shortens the time during which an infected person sheds poliovirus.104-106 In the IPV 
vaccination trial described in this thesis, mucosal immunity was a secondary endpoint, 
which remains to be analyzed.
  
Digging up memory
In our study on IPV vaccination there was a fast and strong antibody response; i.e. a ≥ 40 
fold increase in antibody titre within 7 days after a booster vaccination. This is typical of  
a memory immune response, which is characterized by a logarithmic increase in antibody 
titre within days after re-exposure to an antigen, combined with avidity maturation. Such 
a memory response depends on long lived-memory B cells.107,108 
In a primary humoral immune response to a novel antigen, antigen-specific helper T cells 
that have been activated by antigen-bearing dendritic cells trigger some antigen-specific 
B cells to migrate towards follicular dendritic cells (FDCs), initiating the germinal centre 
reaction. In GCs, B cells receive additional signals from follicular T cells (Tfh) and undergo 
massive clonal proliferation, switch from IgM towards IgG, IgA or IgE, undergo affinity 
maturation and differentiate into plasma cells secreting large amounts of  antigen-specific 
antibodies.109 At the end of  the GC reaction, a few plasma cells exit nodes/spleen and migrate 
to survival niches, where they survive through signals provided by supporting stromal cells.110 
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The duration of  antibody responses is proportional to the number of  long-lived plasma 
cells generated by immunization. In absence of  subsequent antigen exposure, antibody 
persistence may be reliably predicted by the antibody titres that are reached 6–12 months 
after immunization, i.e. after the end of  the short-term plasma cell response. This is 
illustrated by the accuracy of  mathematical models predicting the kinetics of  anti-HBsAg 
and anti-hepatitis A antibodies.109,111,112 Long-lived plasma cells preferentially reside in 
niches in the bone marrow,113 in the spleen114 and in the tonsils.115-117
In parallel to plasma cells, memory B cells are generated in response to T-dependent 
antigens, during the GC reaction. When memory B cells exit the GC, they migrate to 
extrafollicular areas of  the spleen and lymph nodes.118 This migration occurs through the 
blood, in which post-immunization memory B cells are transiently present on their way 
towards lymphoid organs. The spleen harbours most memory B cells, followed by tonsils, 
bone marrow and peripheral blood.119 Their phenotype does not differ in the different 
compartments. Memory B cells do not produce antibodies and do not protect, unless re-
exposure to antigen or cross-reacting antigens drives their differentiation into antibody 
producing plasma cells. Since the affinity of  surface Ig from memory B cells is increased, 
their requirements for reactivation are lower than for naïve B cells. Memory B cells may 
thus be recalled by lower amounts of  antigen and without CD4+ T cell help. Therefore 
this reactivation is characterized by a rapid increase of  the antibody titer.109 
As we observed in a study on influenza vaccination in chapter eleven of  this thesis, 
rechallenge with influenza subunit vaccines often fails to induce a typical booster humoral 
response.120 This is peculiar, since influenza vaccines do induce a memory response with 
memory B cells and long-lived plasmablasts that can produce IgG antibodies with high 
levels of  somatic hypermutation.121,122 However, in individuals who have been primed by 
past vaccination or influenza infection, the recall response may be negatively influenced 
by residual cross-reactive anti-influenza antibodies. Upon vaccination, antigen-antibody 
complexes may reduce the load of  antigen available for B cell binding. Alternatively, 
antibodies may have a negative feedback on B cells. Consequently, individuals with residual 
antibodies to a given antigen may only show a limited increase of  their antibody response; 
such that vaccine responses are better described by the proportion of  individuals above 
a given threshold than by those showing a 2- or 4-fold increase of  antibody titers.109 In 
chapter eleven geometric mean titers and seroprotection rates (defined as HI titers ≥1:40) 
were the main outcome measures. 
 
Don’t just do something, stand there.
Much in medicine remains uncertain. When faced with an incomplete pathophysiological 
model of  a mechanism of  disease and with an incomplete understanding of  the effects 
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of  treatment modalities, clinicians must rely on controlled studies to determine what 
is best. When such studies are lacking or when the results cannot be generalized to 
an individual patient, individual and collective experience must be combined with an 
understanding of  pathophysiology to decide what is good. However, even impeccable 
logic doesn’t always suffice and may have grave consequences.123 To decide what is wisest, 
a doctor requires conscious knowledge of  his inclination for cognitive error and of  the 
fundament of  intuition and reason. “I call that man awake who, with conscious knowledge 
and understanding, can perceive the deep unreasoning powers in his soul, his whole innermost 
strength, desire and weakness, and knows how to reckon with himself.”124,1
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1 Wach nenne ich den, der mit dem Verstand und Bewusstsein sich selbst, seine innersten unvernünftigen Kräfte, Triebe 
 und Schwächen kennt und mit ihnen zu rechnen weiß.
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Het onderzoek dat in dit proefschrift wordt beschreven werd grotendeels verricht op de 
vaccinatiepolikliniek in het Leids Universitair Medisch Centrum (LUMC). In die kliniek 
verlenen gespecialiseerde verpleegkundigen advies aan mensen die van plan zijn op reis 
te gaan. Dankzij de nauwe samenwerking met de afdeling Infectieziekten, heeft men 
expertise over specifieke groepen reizigers, zoals mensen met een verminderde afweer 
en mensen met een chronische ziekte. De unieke locatie van een vaccinatiecentrum 
binnen een academisch ziekenhuis faciliteert het verrichten van onderzoek. Zo is er een 
ervaren groep artsen en verpleegkundigen, een constante stroom reizigers en de kennis 
en infrastructuur die nodig zijn voor microbiologisch, virologisch en parasitologisch 
onderzoek. Voorbeelden van onderzoek dat voortkomt uit de mogelijkheden die de 
vaccinatiepolikliniek biedt zijn: studies over vaccinatie tegen malaria,1,2 gelekoorts,3-6 
reizigers diarree,7,8 poliomyelitis9 en hepatitis B,10 vaccinatie van patiënten met een 
verminderde afweer,11-14 onderzoek naar de incidentie van dragerschap van multiresistente 
micro-organismen in de darm na een reis15 en onderzoek naar het nut van het routinematig 
screenen van mensen op darmparasieten na een reis naar de tropen.16
REIZEN EN INFECTIE
Volgens ‘the World Tourism Barometer’, reisden in 2014 meer dan een miljard mensen 
naar het buitenland.17 Meer dan 500 miljoen mensen reisden naar een opkomende 
economie.1 Naar verwachting zal dit aantal in 2015 stijgen met 3 tot 4%, waarbij de 
sterkste groei plaats zal vinden in Midden- en Zuid-Amerika, in Azië en in Oceanië. 
Jaarlijks reizen er naar schatting twee miljoen Nederlanders naar zogenaamde ‘low 
and middle income countries’, één miljoen naar Turkije (800.000) en Egypte (200.000), 
400.000 naar landen in Azië, 400.000 naar Zuid-Amerika en 90.000 naar ‘Sub-Saharan 
Afrika’.18,19 Deze aantallen zijn aan verandering onderhevig, onder andere door politieke 
instabiliteit in bepaalde regio’s. Reizen gaat gepaard met een aantal risico’s voor de 
gezondheid. Reisgerelateerde ziekten zijn die ziekten, waarvan de kans op het oplopen 
ervan toeneemt door een veranderde blootstelling aan risicofactoren als gevolg van een 
tijdelijke wijziging van de verblijfsplaats. Data over de incidentie van reisgerelateerde 
morbiditeit is samengevat door Steffen et al. en door Cobelens (figuur 1 en 2 u introductie, 
pagina 14 en 15)20,21,22 Het GeoSentinel Surveillance Network publiceert data over regionale 
verschillen in proportionele morbiditeit; het aantal reizigers met een bepaalde ziekte 
gedeeld door het totale aantal zieke reizigers.23,24,25 Diarree is de voornaamste oorzaak 
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van reisgerelateerde morbiditeit.21,26 Ongevallen zijn de voornaamste oorzaak van 
mortaliteit.26-28
Hoofdstuk één van dit proefschrift betreft een studie naar de gezondheidsrisico’s die 
studenten lopen tijdens een medische stage in het buitenland en naar de kwaliteit en 
volledigheid van het medische reisadvies en de medische zorg voor en na de reis.29 Zoals 
mag worden verwacht verrichtte het merendeel van de studenten procedures die gepaard 
gaan met een verhoogd risico op besmetting met, via het bloed overdraagbare virale 
ziekten. Vaak was dat in landen met een hoge prevalentie voor HIV infectie. Het is zorgelijk 
dat geen van de studenten de juiste stappen ondernam na een spat- of  prikaccident. Dit 
kwam overeen met de bevinding van een studie onder Britse medische studenten.30 Verder 
bleek de toewijzing van ‘post exposure prophylaxis’ kits voor HIV (PEP) inadequaat te 
zijn. Wat de overige gezondheidsrisico’s betreft: 20% stopte voortijdig met het gebruik 
van mefloquine vanwege bijwerkingen. Hierdoor waren zij niet beschermd tegen malaria, 
vaak in hoog-endemische landen. Na de reis werd, van de studenten die onderzocht 
hadden moeten worden, slechts de helft onderzocht op asymptomatische infectie met 
schistosomiasis, tuberculose en methicilline-resistente Staphylococcus aureus (MRSA). 
Op basis van de resultaten van dit onderzoek is een aantal maatregelen genomen om 
de gezondheidsrisico’s voor studenten, die op stage gaan, te verminderen. De medische 
advisering voor en na de reis is gecentraliseerd, evenals de uitgifte van PEP. Verder 
dienen de studenten en hun Leidse supervisoren vooraf  aan de stage een formulier in 
te vullen om te bepalen of  de student bekwaam wordt geacht om bepaalde procedures 
uit te voeren, zoals hechten en assisteren bij operaties en bevallingen. Indien een nieuwe 
procedure tijdens de stage aangeleerd wordt, dient duidelijk te zijn of  de begeleiders in 
het buitenland voldoende tijd en mogelijkheden hebben om de student te begeleiden. 
De studenten ontvangen ook een folder waarin staat hoe ze dienen te handelen in geval 
van een spat- of  prikaccident. Na terugkomst vullen de studenten op het internet een 
korte vragenlijst in, om te bepalen of  zij contact op moeten nemen voor een ‘post-travel’ 
consult. Tot slot maakt de dienst onderwijs- en studentenzaken een lijst van klinieken 
in het buitenland waar studenten bij voorkeur heen kunnen gaan voor een stage. Een 
vervolgonderzoek wordt uitgevoerd. Bij dit onderzoek wordt ook aandacht geschonken 
aan andere aspecten, zoals het psychosociale welbevinden, de incidentie van ongevallen 
en de incidentie van het  prikkelbare darm syndroom na een episode van reizigersdiarree.
Diarree is de voornaamste oorzaak van reisgerelateerde morbiditeit.21,26 Het kan erg 
vervelend zijn, maar is zelden dodelijk. In het tweede hoofdstuk wordt een studie 
beschreven, die tot doel had om te bepalen hoe groot het ongemak is dat reizigers 
ondervinden wanneer zij diarree oplopen tijdens een reis met een mediane duur van 23 
dagen.8 Onze conclusie is dat de gangbare definitie van reizigersdiarree ruim is. Ongeveer 
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een derde van de gevallen van reizigersdiarree was mild van aard en veroorzaakte weinig 
ongemak. Het is onwaarschijnlijk dat behandeling van dit soort gevallen zal resulteren in 
gezondheidswinst. Wij bevelen aan om de mate van ongemak als eindpunt te gebruiken 
in klinische studies naar behandeling van reizigersdiarree. Zodoende zullen onderzoekers 
de groep met ‘significante’ reizigersdiarree beter kunnen onderscheiden van de groep 
met ‘niet-significante’ reizigersdiarree. Dit zal beleidsmakers in staat stellen om met 
een grotere nauwkeurigheid de omvang van de groep reizigers te bepalen, die baat zou 
kunnen hebben bij maatregelen die tot doel hebben om diarree op reis te voorkomen 
of  te behandelen. Tevens zal het effect van deze maatregelen nauwkeuriger kunnen 
worden geschat, indien de maatregelen worden beperkt tot de groep met ‘significante’ 
reizigersdiarree. 
Hoofdstuk drie richt zich op mensen met de ziekte van Crohn of  colitis ulcerosa.31 In 
een retrospectieve studie werd met vragenlijsten onderzocht hoe deze groep reizigers 
zich voorbereidt op een reis en welke gezondheidsklachten zij ervaren tijdens een reis. 
Tevens werd onderzocht of  het reizen het risico doet verhogen op een opvlamming van 
de darmziekte. De beschikbaarheid van sanitaire voorzieningen was het voornaamste 
punt van zorg en ongemak, aangezien mensen met deze darmaandoeningen last kunnen 
hebben van frequente en sterke defaecatiedrang en van incontinentie. Een derde van de 
deelnemers rapporteerde dat zij tijdens de reis een episode met reizigersdiarree hadden 
doorgemaakt. Verrassend genoeg was dit qua incidentie niet groter dan de incidentie in 
de algemene bevolking.32 Het reizen leidde niet tot een hoger risico op een opvlamming 
van de darmziekte gedurende de eerste twee maanden na de reis. Echter, deze meting 
kent beperkingen, aangezien het aantal zelfgerapporteerde exacerbaties in een periode 
van 5 jaar vooraf  aan de reis misschien geen betrouwbare schatting oplevert van de 
te verwachten incidentie van een exacerbatie na een reis. Tot slot werd geconstateerd 
dat de voorbereiding op een reis en het medische advies vooraf  aan een reis gebreken 
vertoonden. Wij raden aan dat zorgverleners, mensen met een inflammatoire darmziekte 
bewust maken van het belang van een bezoek aan een reizigerspolikliniek voordat zij op 
reis gaan naar de (sub)tropen en dat zij hen op tijd verwijzen. Er is namelijk meer tijd 
nodig om, in geval van het gebruik van medicatie die de afweer onderdrukt, te controleren 
of  iemand na vaccinatie beschermd is en om zonodig een tweede dosis toe te dienen.33,34
Hoofdstuk vier betreft een studie naar het nut van het routinematig screenen van mensen 
op darmparasieten na een reis naar de tropen, met moleculaire technieken en serologie.16 
Slecht één van 400 reizigers raakte geïnfecteerd met Strongyloides stercoralis. Geen van 500 
reizigers had een infectie met Entamoeba histolytica opgelopen. De incidentie van infectie 
met Schistosoma spp. was hoger (6%), waarbij elk geval was geassocieerd met blootstelling 
aan hoog endemische meren in Malawi en Tanzania. Concluderend is het na een reis 
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van 3 maanden of  korter naar de (sub)tropen niet nodig om asymptomatische reizigers 
routinematig te onderzoeken op darmparasieten. Uitzondering hierbij is dat screening op 
schistosomiasis wel is gewenst bij reizigers die zoetwatercontact hebben gehad in hoog-
endemische gebieden. 
IMMUNITEIT 
In hoofdstuk vijf wordt de humane immuunrespons tegen Schistosoma spp. onderzocht.35 
Hierbij werd gebruik gemaakt van een uniek cohort van twintig Nederlandse reizigers, 
die in het verleden tijdens een groepsreis in Mali, schistosomiasis hadden opgelopen.36 
Sommige geïnfecteerde reizigers maakten destijds een acuut ziektebeeld door dat bekend 
staat als het Katayama syndroom en anderen niet. Acht jaar later werden bloedmonsters 
verzameld en werd in vitro de cellulaire en humorale immuunrespons tegen schistosoma 
worm- en ei-antigenen gemeten. De immuunrespons werd vergeleken tussen de groep die 
het Katayama syndroom had doorgemaakt en de groep die een asymptomatische infectie 
had doorgemaakt. Mensen die het Katayama syndroom hadden doorgemaakt bleken acht 
jaar later een sterkere immuunrespons te hebben tegen de schistosoma antigenen dan de 
mensen die een asymptomatische infectie hadden doorgemaakt. De verschillen waren 
echter niet significant volgens de gangbare statistische grenswaarde.
De meest gangbare oorzaak van diarree op reis is de enterotoxine producerende Escherichia 
coli (ETEC). Omdat het ziekmakende, hitte-labiele toxine dat door ETEC wordt gemaakt 
qua structuur lijkt op het choleratoxine, bieden choleravaccins een zekere mate van 
kruisbescherming tegen infecties met ETEC. Hoofdstuk zes betreft een onderzoek naar 
de werkzaamheid van een levend verzwakt oraal cholera vaccin, CVD 103-HgR, om 
diarree tijdens een reis te voorkomen.7 In deze studie hadden de 69 reizigers die het 
vaccin hadden gebruikt even vaak diarree als de 65 reizigers die placebo hadden gebruikt. 
De interpretatie van het resultaat werd beperkt door de onverwacht lage incidentie van 
LT–ETEC geassocieerde diarree in de groep die deelnam aan het onderzoek. Andere 
onderzoeken naar vaccins tegen ETEC zijn eveneens ineffectief  gebleken.37,38 Een 
effectief  vaccin tegen reizigersdiarree dient waarschijnlijk te beschermen tegen meerdere 
enteropathogene Escherichia coli en ook tegen andere enteropathogenen.39-42 In nieuwere 
vaccins, die worden ontwikkeld, worden derhalve ook antigenen van kolonisatiefactoren 
toegevoegd. Dit zijn antigenen die tot expressie worden gebracht door veel verschillende 
typen Escherichia coli.43-46
Onderdelen van het aangeboren en het verworven mucosale immuunsysteem beschermen 
het lichaam tegen pathogenen die via de mucosa proberen binnen te dringen. Sommige 
pathogenen, zoals enteropathogene Escherichia coli, veroorzaken ziekte door de mucosa 
binnen te dringen of  te beschadigen. Andere pathogenen, zoals poliovirus doorkruisen 
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de mucosa om uiteindelijk op een andere plek in het lichaam ziekte te veroorzaken. 
Overdracht van poliovirus vindt plaats via de faeco-orale route. Een infectie met het wild 
type poliovirus veroorzaakt mucosale en systemische immuniteit.47 Het levend verzwakte 
orale poliovirus vaccin (OPV) bootst een infectie met wild-type virus na en veroorzaakt 
ook een vergelijkbare immuunrespons.48 Daarentegen ontstaat er na intramusculaire 
vaccinatie met het geïnactiveerde poliovirus vaccin (IPV) uitsluitend een systemische 
immuunrespons, zonder mucosale respons.48,49 IPV is desalniettemin een zeer effectief  
vaccin, omdat het een betrouwbare en sterke systemische immuunrespons opwekt 
en zodoende voorkomt dat het poliovirus zijn weg weet te vinden naar het centrale 
zenuwstelsel. Dit verschil tussen OPV en IPV vertaalt zich in het feit dat mensen, die 
gevaccineerd zijn met OPV, minder makkelijk een herinfectie met wild-type poliovirus 
oplopen en in geval van infectie gedurende een kortere periode het virus uitscheiden, dan 
mensen die gevaccineerd zijn met IPV.50,51 Het gebruik van OPV kent echter ook nadelen. 
Zo treedt er bij vaccinatie met het trivalente vaccin interferentie op tussen de drie polio 
subtypen waardoor de respons tegen subtype 1 en 3 zwakker is dan tegen subtype 2.52 Een 
ander nadeel is dat het levende verzwakte virus dat in OPV zit, soms terug kan muteren 
naar het wild type virus.53-55 Daarom dient het gebruik van OPV uiteindelijk gestaakt 
te worden, om bestendige wereldwijde erradicatie van polio te bewerkstelligen. Het is 
aannemelijk dat deze transitie gepaard zal gaan met het vervangen van OPV door IPV. 
IPV is echter 20 keer zo duur als OPV en de productiecapaciteit is niet groot genoeg 
om de hele wereld van vaccin te voorzien. Daarom is het van belang om IPV goedkoper 
en geschikter te maken voor gebruik in ontwikkelingslanden.56 Dit kan wellicht worden 
gedaan door een fractie van de gebruikelijke dosis toe te dienen. Intradermale toediening 
kan in potentie het gebruik van een lagere dosis mogelijk maken, zonder dat dit ten koste 
gaat van de mate van bescherming. Het gebruik van een naald-vrije jet injector, die door 
gebruik van hoge druk een dunne straal vloeistof  in de huid of  spier kan toedienen, 
kan een betrouwbare methode zijn om op grotere schaal intradermaal te vaccineren. 
Hoofdstuk zeven betreft een studie waarin 125 proefpersonen een booster vaccinatie 
met IPV kregen toegediend. De proefpersonen werden gerandomiseerd naar één van 
vier groepen: intramusculaire vaccinatie met een naald en spuit met een volledige dosis 
(IM-NS-0.5), intramusculaire vaccinatie met een jet injector met een volledige dosis 
(IM-JI-0.5), intramusculaire vaccinatie met een naald en spuit met een vijfde van een 
volledige dosis (IM-NS-0.1), intradermale vaccinatie met een jet injector met een vijfde 
van een volledige dosis (ID-JI-0.1).9 Na 28 dagen was de gemiddelde antistoftiter in de ID-
JI-0.1 groep iets lager dan in de referentiegroep (IM-NS-0.5). De verschillen waren niet 
statistisch significant, maar voldeden niet aan de strikte norm voor non-inferioriteit die 
vooraf  was gesteld (i.e. een maximaal verschil van minder dan 1 serum verdunningsstap 
in de microneutralisatie assay). Een jaar later waren de kleine verschillen in antistoftiter 
verdwenen. In tegenstelling tot dit resultaat, was de gemiddelde antistoftiter in de IM-
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NS-0.1 groep statistisch inferieur aan die in de referentiegroep (IM-NS-0.5). In een andere 
studie is recent het adjuvans CAF01 toegevoegd aan IPV en getest op muizen.57 IPV-
CAF01, met 2 D-Units (DU) poliovirus type 1, 2 en 3 werd vergeleken met IPV zonder 
adjuvans met ofwel 2 of  20 DU poliovirus type 1, 2 en 3. De respons op intramusculaire 
toediening van een fractionele-dosis van IPV-CAF01 was even sterk als de respons op 
een volledige dosis IPV en was sterker dan de respons op een fractionele dosis van IPV. 
Bovendien induceerde IPV-CAF01 niet alleen een humorale immuunrespons, maar ook 
een cellulaire respons. 
Het opwekken van een cellulaire Th1 immuunrespons is essentieel om weerstand op te 
wekken tegen Mycobacterium tuberculosis (MTb).58 Om een dergelijke respons op te weken 
met ‘subunit’ vaccins zijn nieuwe hulpstoffen (adjuvans) nodig. De hoofdstukken acht 
en negen betreffen klinische trials waarin twee verschillende nieuwe adjuvans werden 
gecombineerd met een MTb subunit vaccin, H1.59,60 Het subunit vaccin H1 bestaat uit het 
fusie eiwit Ag85B-ESAT6.61-63 Dit zijn twee antigenen die in een vroeg stadium van de 
infectie tot uiting worden gebracht. Het eerste adjuvans dat werd onderzocht is IC31®. 
Dit werd ontwikkeld door Intercell AG (Wenen, Oostenrijk) en bestaat uit het artificiële 
antimicrobiële peptide KLK en de oligodeoxynucleotide ODN1a. KLK fungeert als een 
vehikel om de opname in antigen presenterende cellen (APC) te bevorderen. ODN1a 
stimuleert Toll-like receptor 9 (TLR9) en activeert APC. Dit leidt tot een gemengde Th1 
en Th2 type respons.64-67 Het tweede nieuwe adjuvans dat werd onderzocht is CAF01. Dit 
werd ontwikkeld door het Statens Serum Instituut (Kopenhagen, Denemarken). Het bestaat 
uit liposomen, die gevormd worden door N,N’-dimethyl-N,N’-dioctadecylammonium 
(DDA) en uit de synthetische immunomodulator α,α’-trehalose 6,6’-dibeheneate (TDB), 
die ingevoegd wordt tussen het lipide dubbelmembraan.68-70 DDA liposomen richten 
zich op cel membranen van APC en dit leidt tot toegenomen opname en presentatie 
van antigenen en een zwakke Th1 cel respons.71 TDB is een synthetisch analoog van 
trehalose 6,6’-dimycolate (TDM), een mycobacterieel celmembraan onderdeel, dat vaak 
‘cord factor’ wordt genoemd. TDB stabiliseert DDA liposomen en bevordert een Th1 
en Th17 cel respons.69,70,72-74 Dit wordt gemedieerd door herkenning van TDB door het 
C-type lectin Mincle, hetgeen IL-1 aanmaak stimuleert en een MyD88-afhankelijke Th1/
Th17 cel respons induceert.75-77 
In de klinische trials die worden beschreven in dit proefschrift, veroorzaakte H1-IC31® 
een bestendige Th1 cel respons bij MTb naïeve proefpersonen. Deze respons werd 
gekarakteriseerd door IFN-γ producerende lymfocyten.59 Bij de proefpersonen die in het 
verleden waren gevaccineerd met BCG en bij de proefpersonen die in het verleden een 
MTb infectie hadden doorgemaakt trad de immuunrespons sneller op en was meestal ook 
sterker. H1-CAF01 veroorzaakte eveneens een krachtige en bestendige Th1 cel respons 
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bij MTb naïeve proefpersonen.60 Ondanks deze bemoedigende resultaten, dient een 
kanttekening te worden geplaatst. De surrogaat immunologische eindpunten die in deze 
onderzoeken werden gebruikt kennen geen volledige correlatie met bescherming tegen 
MTb. Zo werd in een recente grote fase 2b onderzoek in Zuid Afrika, waarin een vaccin 
werd onderzocht bestaande uit een recombinant veranderd Vaccinia Ankara virus dat 
Ag85A tot expressie brengt, gezien dat het vaccin een goede immuunrespons opwekte 
maar geen bescherming bood tegen actieve tuberculose.78 Om actieve ziekte te voorkomen 
is het waarschijnlijk ook belangrijk om immuniteit op te wekken tegen latere stadium 
antigenen, die tot expressie worden gebracht gedurende het slapende stadium van de 
bacterie.79 Het vaccin, H56 is gebaseerd op dit concept en combineert Ag85B, ESAT-6 en 
Rv2660c. Rv2660 wordt tot uiting gebracht gedurende het late stadium van infectie.80,81
Mycobacterium tuberculosis kan een latente infectie veroorzaken en in sommige gevallen 
pas decennia later reactiveren. De reactivatie treedt vaker op als de afweer verzwakt 
raakt, zoals kan gebeuren bij veroudering. De leeftijdsafhankelijke veranderingen in het 
immuunsysteem worden samengevat met het begrip ‘immunosenescence’. Dit proces kan 
op verschillende wijzen worden bestudeerd; bijvoorbeeld door de immuunrespons na een 
gestandaardiseerde infectie te vergelijken tussen jongeren en ouderen. Vaccinatie met 
het levend verzwakte gelekoortsvaccin biedt de mogelijkheid om een ‘gestandaardiseerde 
infectie’ te veroorzaken. Het virus uit het vaccin vermenigvuldigt zich in de naïeve gastheer. 
In zeldzame gevallen kan het ernstige ziekte veroorzaken; ofwel gelekoorts geassocieerde 
neurotrope ziekte, hetgeen zich manifesteert als ofwel een encefalitis, ofwel viscerotrope 
ziekte hetgeen de verschijnselen van een wild type infectie nabootst.82,83 Neurotrope ziekte 
treedt met name op bij zuigelingen. Het risico op viscerotrope ziekte daarentegen neem 
toe met de leeftijd. In vergelijking met jong-volwassenen is het risico op deze zeldzame 
bijwerking 4 keer groter bij mensen van 60-69 jaar oud en 13 keer groter bij mensen 
van 70 jaar of  ouder.84 Op grond van deze gegevens is er terughoudendheid met het 
gebruik van het gelekoortsvaccin bij reizigers ouder dan 60 jaar.  Hoofdstuk tien betreft 
een gecontroleerde studie naar de verschillen in de immuunrespons tussen een groep 
van 30 jongeren en een groep van 28 ouderen, na toediening van het gelekoortsvaccin.6 
Bij de oudere personen kwam de humorale respons later op gang. Bovendien ontstond 
bij de groep ouderen vaker een viremie. Aangezien de verschillen in de incidentie en 
de mate van viremie optraden op dag vijf  na vaccinatie, nog voordat het adaptieve 
immuunsysteem voldoende tijd heeft gehad om te reageren, is het aannemelijk dat er een 
leeftijdsafhankelijke afname is van de innate immuunrespons.
Er geldt een contra-indicatie voor het gebruik van levend-verzwakte vaccins bij mensen 
met een immuunstoornis, zoals bij mensen met een HIV infectie en een laag aantal 
CD4 positieve T-cellen. Deze mensen hebben een grotere kans op vaccin-gerelateerde 
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morbiditeit, omdat hun immuunsysteem minder goed werkt, waardoor de virale replicatie 
niet goed wordt geremd. Dit betreft een beperking in het vormen van een adequate 
immuunrespons tegen met name neo-antigenen. Hiermee wordt bedoeld, antigenen die 
het immuunsysteem niet eerder is tegengekomen. In 2009 was er een pandemie met een 
influenza virus dat qua antigenen sterk verschilde met voorgaande jaren en waartegen 
de meeste mensen weinig antistoffen hadden; het zogenaamde 2009 pandemische 
influenza A(H1N1) virus (pH1N1). Het virus verspreidde zich snel over de wereld en 
werd beschouwd als een belangrijk gevaar voor de volksgezondheid. Dit leidde tot een 
snelle ontwikkeling en gebruik van vaccins tegen pH1N1. Hoewel de immuunrespons 
tegen influenza vaccins vrij uitvoerig is onderzocht onder mensen met een HIV-infectie, 
waren de omstandigheden in 2009 om een aantal redenen anders: i) het hemagglutinine 
antigen werd beschouwd als een neo-antigen; ii) het vaccin werd twee keer toegediend 
in plaats van een keer; en iii) de meeste mensen in Nederland waren een maand eerder 
al gevaccineerd met het standaard trivalente geïnactiveerde influenza vaccin (TIV). 
In 2009 verrichtten wij een observationele gecontroleerde studie waarin de humorale 
immuunrespons tegen pH1N1 vaccin werd onderzocht bij mensen met een infectie 
met HIV en bij gezonde controles. Tevens werd onderzocht of  TIV kruisbeschermende 
antistoffen tegen pH1N1 opwekte en of  een tweede vaccinatie  een typische booster 
respons veroorzaakt. Hoofdstuk elf beschrijft het resultaat van dit onderzoek. Bij de 
meeste mensen met een HIV infectie (91%) ontstond seroprotectie. De tweede vaccinatie 
had een klein additioneel effect op de titer en de respons had  niet het typische patroon 
van een boosterrespons met de typerende snelle en hoge titerstijging kort na een tweede 
vaccinatie. Aanvankelijk leek het erop dat TIV al leidde tot kruisreactieve antilichamen 
en een mate van seroprotectie tegen pH1N1. Echter na aanvullend onderzoek, waarin 
een virusneutralisatie werd gebruikt om influenza specifieke antistoffen te meten bleek 
dit niet het geval, zoals wordt beschreven in hoofdstuk twaalf.
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